To amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user-fee programs for prescription drugs and medical devices, to establish user-fee programs for generic drugs and biosimilars, and for other purposes.

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

This Act may be cited as the “Food and Drug Administration Safety and Innovation Act”.

IN THE SENATE OF THE UNITED STATES

MAY 7, 2012

Mr. HARKIN, from the Committee on Health, Education, Labor, and Pensions, reported the following original bill; which was read twice and placed on the calendar
SEC. 2. TABLE OF CONTENTS; REFERENCES IN ACT.

(a) TABLE OF CONTENTS.—The table of contents of this Act is as follows:

Sec. 1. Short title.
Sec. 2. Table of contents; references in Act.

TITLE I—FEES RELATING TO DRUGS

Sec. 101. Short title; finding.
Sec. 102. Definitions.
Sec. 103. Authority to assess and use drug fees.
Sec. 104. Reauthorization; reporting requirements.
Sec. 105. Sunset dates.
Sec. 106. Effective date.
Sec. 107. Savings clause.

TITLE II—FEES RELATING TO DEVICES

Sec. 201. Short title; findings.
Sec. 203. Authority to assess and use device fees.
Sec. 204. Reauthorization; reporting requirements.
Sec. 205. Savings clause.
Sec. 206. Effective date.
Sec. 207. Sunset dates.
Sec. 208. Streamlined hiring authority to support activities related to the process for the review of device applications.

TITLE III—FEES RELATING TO GENERIC DRUGS

Sec. 301. Short title.
Sec. 302. Authority to assess and use human generic drug fees.
Sec. 303. Reauthorization; reporting requirements.
Sec. 304. Sunset dates.
Sec. 305. Effective date.
Sec. 306. Amendment with respect to misbranding.
Sec. 307. Streamlined hiring authority of the Food and Drug Administration to support activities related to human generic drugs.

TITLE IV—FEES RELATING TO BIOSIMILAR BIOLOGICAL PRODUCTS

Sec. 401. Short title; finding.
Sec. 402. Fees relating to biosimilar biological products.
Sec. 403. Reauthorization; reporting requirements.
Sec. 404. Sunset dates.
Sec. 405. Effective date.
Sec. 406. Savings clause.
Sec. 407. Conforming amendment.

TITLE V—PEDIATRIC DRUGS AND DEVICES

Sec. 501. Permanence.
Sec. 502. Written requests.
Sec. 503. Communication with Pediatric Review Committee.
Sec. 504. Access to data.
Sec. 505. Ensuring the completion of pediatric studies.
Sec. 506. Pediatric study plans.
Sec. 507. Reauthorizations.
Sec. 508. Report.
Sec. 509. Technical amendments.
Sec. 510. Relationship Between Pediatric Labeling and New Clinical Investigation Exclusivity.

TITLE VI—MEDICAL DEVICE REGULATORY IMPROVEMENTS

Sec. 601. Reclassification procedures.
Sec. 602. Condition of approval studies.
Sec. 603. Postmarket surveillance.
Sec. 604. Sentinel.
Sec. 605. Recalls.
Sec. 606. Clinical holds on investigational device exemptions.
Sec. 607. Unique device identifier.
Sec. 608. Clarification of least burdensome standard.
Sec. 609. Custom devices.
Sec. 610. Agency documentation and review of certain decisions regarding devices.
Sec. 611. Good guidance practices relating to devices.
Sec. 612. Modification of de novo application process.
Sec. 613. Humanitarian device exemptions.
Sec. 614. Reauthorization of third-party review and inspections.
Sec. 615. 510(k) device modifications.

TITLE VII—DRUG SUPPLY CHAIN

Sec. 701. Registration of domestic drug establishments.
Sec. 702. Registration of foreign establishments.
Sec. 703. Identification of drug excipient information with product listing.
Sec. 704. Electronic system for registration and listing.
Sec. 705. Risk-based inspection frequency.
Sec. 706. Records for inspection.
Sec. 707. Failure to allow foreign inspection.
Sec. 708. Exchange of information.
Sec. 709. Enhancing the safety and quality of the drug supply.
Sec. 710. Accreditation of third-party auditors for drug establishments.
Sec. 711. Standards for admission of imported drugs.
Sec. 712. Notification.
Sec. 713. Protection against intentional adulteration.
Sec. 714. Enhanced criminal penalty for counterfeiting drugs.
Sec. 715. Extraterritorial jurisdiction.
Sec. 716. Compliance with international agreements.

TITLE VIII—GENERATING ANTIBIOTIC INCENTIVES NOW

Sec. 801. Extension of exclusivity period for drugs.
Sec. 802. Priority review.
Sec. 803. Fast track product.
Sec. 804. GAO study.
Sec. 805. Clinical trials.
Sec. 806. Regulatory certainty and predictability.
TITLE IX—DRUG APPROVAL AND PATIENT ACCESS

Sec. 901. Enhancement of accelerated patient access to new medical treatments.
Sec. 902. Breakthrough therapies.
Sec. 903. Consultation with external experts on rare diseases, targeted therapies, and genetic targeting of treatments.
Sec. 904. Accessibility of information on prescription drug container labels by visually-impaired and blind consumers.
Sec. 905. Risk-benefit framework.
Sec. 906. Independent study on medical innovation inducement model.

TITLE X—DRUG SHORTAGES

Sec. 1001. Drug shortages.

TITLE XI—OTHER PROVISIONS

Subtitle A—Reauthorizations

Sec. 1101. Reauthorization of provision relating to exclusivity of certain drugs containing single enantiomers.
Sec. 1102. Reauthorization of the Critical Path Public-Private Partnerships.

Subtitle B—Medical Gas Product Regulation

Sec. 1111. Regulation of medical gas products.
Sec. 1112. Regulations.
Sec. 1113. Applicability.

Subtitle C—Miscellaneous Provisions

Sec. 1121. Advisory committee conflicts of interest.
Sec. 1122. Guidance document regarding product promotion using the Internet.
Sec. 1123. Electronic submission of applications.
Sec. 1124. Combating prescription drug abuse.
Sec. 1125. Tanning bed labeling.
Sec. 1126. Optimizing global clinical trials.
Sec. 1127. Advancing regulatory science to promote public health innovation.
Sec. 1128. Information technology.
Sec. 1129. Reporting requirements.
Sec. 1130. Strategic integrated management plan.
Sec. 1131. Drug development and bioequivalence testing.

(b) REFERENCES IN ACT.—Except as otherwise specified, amendments made by this Act to a section or other provision of law are amendments to such section or other provision of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.).
TITLE I—FEES RELATING TO DRUGS

SEC. 101. SHORT TITLE; FINDING.

(a) SHORT TITLE.—This title may be cited as the “Prescription Drug User Fee Amendments of 2012”.

(b) FINDING.—The Congress finds that the fees authorized by the amendments made in this title will be dedicated toward expediting the drug development process and the process for the review of human drug applications, including postmarket drug safety activities, as set forth in the goals identified for purposes of part 2 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act, in the letters from the Secretary of Health and Human Services to the Chairman of the Committee on Health, Education, Labor, and Pensions of the Senate and the Chairman of the Committee on Energy and Commerce of the House of Representatives, as set forth in the Congressional Record.

SEC. 102. DEFINITIONS.

Paragraph (7) of section 735 (21 U.S.C. 379g) is amended, in the matter preceding subparagraph (A), by striking “incurred”.

SEC. 103. AUTHORITY TO ASSESS AND USE DRUG FEES.

Section 736 (21 U.S.C. 379h) is amended—

(1) in subsection (a)—
(A) in the matter preceding paragraph (1), by striking “fiscal year 2008” and inserting “fiscal year 2013”; 

(B) in paragraph (1), in clauses (i) and (ii) of subparagraph (A), by striking “subsection (c)(5)” each place such term appears and inserting “subsection (c)(4)”;

(C) in the matter following clause (ii) in paragraph (2)(A)—

(i) by striking “subsection (c)(5)” and inserting “subsection (c)(4)”; and

(ii) by striking “payable on or before October 1 of each year” and inserting “due on the later of the first business day on or after October 1 of each fiscal year or the first business day after the enactment of an appropriations Act providing for the collection and obligation of fees for such fiscal year under this section”; and

(D) in paragraph (3)—

(i) in subparagraph (A)—

(I) by striking “subsection (c)(5)” and inserting “subsection (c)(4)”; and
(II) by striking “payable on or before October 1 of each year.” and inserting “due on the later of the first business day on or after October 1 of each fiscal year or the first business day after the enactment of an appropriations Act providing for the collection and obligation of fees for such fiscal year under this section.”; and

(ii) by amending subparagraph (B) to read as follows:

“(B) EXCEPTION.—A prescription drug product shall not be assessed a fee under subparagraph (A) if such product is—

“(i) identified on the list compiled under section 505(j)(7) with a potency described in terms of per 100 mL;

“(ii) the same product as another product that—

“(I) was approved under an application filed under section 505(b) or 505(j); and

“(II) is not in the list of discontinued products compiled under section 505(j)(7);
“(iii) the same product as another product that was approved under an abbreviated application filed under section 507 (as in effect on the day before the date of enactment of the Food and Drug Administration Modernization Act of 1997); or

“(iv) the same product as another product that was approved under an abbreviated new drug application pursuant to regulations in effect prior to the implementation of the Drug Price Competition and Patent Term Restoration Act of 1984.”;

(2) in subsection (b)—

(A) in paragraph (1)—

(i) in the matter preceding subparagraph (A), by striking “fiscal years 2008 through 2012” and inserting “fiscal years 2013 through 2017”;

(ii) in subparagraph (A), by striking “$392,783,000; and” and inserting “$693,099,000;”; and

(iii) by striking subparagraph (B) and inserting the following:
“(B) the dollar amount equal to the inflation adjustment for fiscal year 2013 (as determined under paragraph (3)(A)); and

“(C) the dollar amount equal to the workload adjustment for fiscal year 2013 (as determined under paragraph (3)(B)).”; and

(B) by striking paragraphs (3) and (4) and inserting the following:

“(3) FISCAL YEAR 2013 INFLATION AND WORKLOAD ADJUSTMENTS.—For purposes of paragraph (1), the dollar amount of the inflation and workload adjustments for fiscal year 2013 shall be determined as follows:

“(A) INFLATION ADJUSTMENT.—The inflation adjustment for fiscal year 2013 shall be the sum of—

“(i) $652,709,000 multiplied by the result of an inflation adjustment calculation determined using the methodology described in subsection (c)(1)(B); and

“(ii) $652,709,000 multiplied by the result of an inflation adjustment calculation determined using the methodology described in subsection (c)(1)(C).
“(B) WORKLOAD ADJUSTMENT.—Subject to subparagraph (C), the workload adjustment for fiscal 2013 shall be—

“(i) $652,709,000 plus the amount of the inflation adjustment calculated under subparagraph (A); multiplied by

“(ii) the amount (if any) by which a percentage workload adjustment for fiscal year 2013, as determined using the methodology described in subsection (c)(2)(A), would exceed the percentage workload adjustment (as so determined) for fiscal year 2012, if both such adjustment percentages were calculated using the 5-year base period consisting of fiscal years 2003 through 2007.

“(C) LIMITATION.—Under no circumstances shall the adjustment under subparagraph (B) result in fee revenues for fiscal year 2013 that are less than the sum of the amount under paragraph (1)(A) and the amount under paragraph (1)(B).”;

(3) by striking subsection (e) and inserting the following:

“(e) ADJUSTMENTS.—
“(1) INFLATION ADJUSTMENT.—For fiscal year 2014 and subsequent fiscal years, the revenues established in subsection (b) shall be adjusted by the Secretary by notice, published in the Federal Register, for a fiscal year by the amount equal to the sum of—

“(A) one;

“(B) the average annual percent change in the cost, per full-time equivalent position of the Food and Drug Administration, of all personnel compensation and benefits paid with respect to such positions for the first 3 years of the preceding 4 fiscal years, multiplied by the proportion of personnel compensation and benefits costs to total costs of the process for the review of human drug applications (as defined in section 735(6)) for the first 3 years of the preceding 4 fiscal years; and

“(C) the average annual percent change that occurred in the Consumer Price Index for urban consumers (Washington-Baltimore, DC–MD–VA–WV; Not Seasonally Adjusted; All items; Annual Index) for the first 3 years of the preceding 4 years of available data, multiplied by the proportion of all costs other than per-
sonnel compensation and benefits costs to total
costs of the process for the review of human
drug applications (as defined in section 735(6))
for the first 3 years of the preceding 4 fiscal
years.
The adjustment made each fiscal year under this
paragraph shall be added on a compounded basis to
the sum of all adjustments made each fiscal year
after fiscal year 2013 under this paragraph.

“(2) WORKLOAD ADJUSTMENT.—For fiscal
year 2014 and subsequent fiscal years, after the fee
revenues established in subsection (b) are adjusted
for a fiscal year for inflation in accordance with
paragraph (1), the fee revenues shall be adjusted
further for such fiscal year to reflect changes in the
workload of the Secretary for the process for the re-
view of human drug applications. With respect to
such adjustment:

“(A) The adjustment shall be determined
by the Secretary based on a weighted average
of the change in the total number of human
drug applications (adjusted for changes in re-
view activities, as described in the notice that
the Secretary is required to publish in the Fed-
eral Register under this subparagraph), efficacy
supplements, and manufacturing supplements submitted to the Secretary, and the change in the total number of active commercial investigational new drug applications (adjusted for changes in review activities, as so described) during the most recent 12-month period for which data on such submissions is available. The Secretary shall publish in the Federal Register the fee revenues and fees resulting from the adjustment and the supporting methodologies.

“(B) Under no circumstances shall the adjustment result in fee revenues for a fiscal year that are less than the sum of the amount under subsection (b)(1)(A) and the amount under subsection (b)(1)(B), as adjusted for inflation under paragraph (1).

“(C) The Secretary shall contract with an independent accounting or consulting firm to periodically review the adequacy of the adjustment and publish the results of those reviews. The first review shall be conducted and published by the end of fiscal year 2013 (to examine the performance of the adjustment since fiscal year 2009), and the second review shall be
conducted and published by the end of fiscal year 2015 (to examine the continued performance of the adjustment). The reports shall evaluate whether the adjustment reasonably represents actual changes in workload volume and complexity and present options to discontinue, retain, or modify any elements of the adjustment. The reports shall be published for public comment. After review of the reports and receipt of public comments, the Secretary shall, if warranted, adopt appropriate changes to the methodology. If the Secretary adopts changes to the methodology based on the first report, the changes shall be effective for the first fiscal year for which fees are set after the Secretary adopts such changes and each subsequent fiscal year.

“(3) Final year adjustment.—For fiscal year 2017, the Secretary may, in addition to adjustments under this paragraph and paragraphs (1) and (2), further increase the fee revenues and fees established in subsection (b) if such an adjustment is necessary to provide for not more than 3 months of operating reserves of carryover user fees for the process for the review of human drug applications for
the first 3 months of fiscal year 2018. If such an adjustment is necessary, the rationale for the amount of the increase shall be contained in the annual notice establishing fee revenues and fees for fiscal year 2017. If the Secretary has carryover balances for such process in excess of 3 months of such operating reserves, the adjustment under this paragraph shall not be made.

“(4) Annual Fee Setting.—The Secretary shall, not later than 60 days before the start of each fiscal year that begins after September 30, 2012, establish, for the next fiscal year, application, product, and establishment fees under subsection (a), based on the revenue amounts established under subsection (b) and the adjustments provided under this subsection.

“(5) Limit.—The total amount of fees charged, as adjusted under this subsection, for a fiscal year may not exceed the total costs for such fiscal year for the resources allocated for the process for the review of human drug applications.”; and

(4) in subsection (g)—

(A) in paragraph (1), by striking “Fees authorized” and inserting “Subject to paragraph (2)(C), fees authorized”;
(B) in paragraph (2)—

(i) in subparagraph (A)—

(I) in clause (i), by striking “shall be retained” and inserting “subject to subparagraph (C), shall be collected and available”; and

(II) in clause (ii), by striking “shall only be collected and available” and inserting “shall be available”; and

(ii) by adding at the end the following new subparagraph:

“(C) Provision for early payments.—Payment of fees authorized under this section for a fiscal year, prior to the due date for such fees, may be accepted by the Secretary in accordance with authority provided in advance in a prior year appropriations Act.”;

(C) in paragraph (3), by striking “fiscal years 2008 through 2012” and inserting “fiscal years 2013 through 2017”; and

(D) in paragraph (4)—

(i) by striking “fiscal years 2008 through 2010” and inserting “fiscal years 2013 through 2015”;
(ii) by striking “fiscal year 2011” and inserting “fiscal year 2016”;

(iii) by striking “fiscal years 2008 though 2011” and inserting “fiscal years 2013 through 2016”; and

(iv) by striking “fiscal year 2012” and inserting “fiscal year 2017”.

SEC. 104. REAUTHORIZATION; REPORTING REQUIREMENTS.

Section 736B (21 U.S.C. 379h–2) is amended—

(1) by amending subsection (a) to read as follows:

“(a) PERFORMANCE REPORT.—Beginning with fiscal year 2013, not later than 120 days after the end of each fiscal year for which fees are collected under this part, the Secretary shall prepare and submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate a report concerning the progress of the Food and Drug Administration in achieving the goals identified in the letters described in section 101(b) of the Prescription Drug User Fee Amendments of 2012 during such fiscal year and the future plans of the Food and Drug Administration for meeting the goals. The report under this subsection for a fiscal year shall include information on all previous cohorts for which the Sec-
retary has not given a complete response on all human
drug applications and supplements in the cohort.”;

(2) in subsection (b), by striking “2008” and
inserting “2013”; and

(3) in subsection (d), by striking “2012” each
place it appears and inserting “2017”.

SEC. 105. SUNSET DATES.

(a) AUTHORIZATION.—Sections 735 and 736 of the
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379g;
379h) shall cease to be effective October 1, 2017.

(b) REPORTING REQUIREMENTS.—Section 736B of
379h–2) shall cease to be effective January 31, 2018.

(c) PREVIOUS SUNSET PROVISION.—The Prescrip-
tion Drug User Fee Amendments of 2007 is amended by
striking section 106.

SEC. 106. EFFECTIVE DATE.

The amendments made by this title shall take effect
on October 1, 2012, or the date of the enactment of this
Act, whichever is later, except that fees under part 2 of
subchapter C of chapter VII of the Federal Food, Drug,
and Cosmetic Act shall be assessed for all human drug
applications received on or after October 1, 2012, regard-
less of the date of the enactment of this Act.
SEC. 107. SAVINGS CLAUSE.

Notwithstanding the amendments made by this title, part 2 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act, as in effect on the day before the date of the enactment of this title, shall continue to be in effect with respect to human drug applications and supplements (as defined in such part as of such day) that on or after October 1, 2007, but before October 1, 2012, were accepted by the Food and Drug Administration for filing with respect to assessing and collecting any fee required by such part for a fiscal year prior to fiscal year 2012.

TITLE II—FEES RELATING TO DEVICES

SEC. 201. SHORT TITLE; FINDINGS.

(a) Short Title.—This title may be cited as the “Medical Device User Fee Amendments of 2012”.

(b) Findings.—The Congress finds that the fees authorized under the amendments made by this title will be dedicated toward expediting the process for the review of device applications and for assuring the safety and effectiveness of devices, as set forth in the goals identified for purposes of part 3 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act in the letters from the Secretary of Health and Human Services to the Chairman of the Committee on Health, Education, Labor, and
Pensions of the Senate and the Chairman of the Committee on Energy and Commerce of the House of Representatives, as set forth in the Congressional Record.

SEC. 202. DEFINITIONS.

Section 737 (21 U.S.C. 379i) is amended—

(1) in paragraph (9), by striking “incurred” after “expenses”;

(2) in paragraph (10), by striking “October 2001” and inserting “October 2011”; and

(3) in paragraph (13), by striking “is required to register” and all that follows through the end of paragraph (13) and inserting the following: “is registered (or is required to register) with the Secretary under section 510 because such establishment is engaged in the manufacture, preparation, propagation, compounding, or processing of a device.”.

SEC. 203. AUTHORITY TO ASSESS AND USE DEVICE FEES.

(a) TYPES OF FEES.—Section 738(a) (21 U.S.C. 379j(a)) is amended—

(1) in paragraph (1), by striking “fiscal year 2008” and inserting “fiscal year 2013”;
(i) by striking “subsections (d) and (e)” and inserting “subsections (d), (e), and (f)”;

(ii) by striking “October 1, 2002” and inserting “October 1, 2012”; and

(iii) by striking “subsection (c)(1)” and inserting “subsection (e)”;

(B) in clause (viii), by striking “1.84” and inserting “2”; and

(3) in paragraph (3)—

(A) in subparagraph (A)—

(i) by inserting “and subsection (f)” after “subparagraph (B)”;

(ii) by striking “2008” and inserting “2013”; and

(B) in subparagraph (C), by striking “initial registration” and all that follows through “section 510.” and inserting “later of—

“(i) the initial or annual registration (as applicable) of the establishment under section 510; or

“(ii) the first business day after the date of enactment of an appropriations Act providing for the collection and obligation of fees for such year under this section.”.
(b) Fee Amounts.—Section 738(b) (21 U.S.C. 379j(b)) is amended to read as follows:

“(b) Fee Amounts.—

“(1) In general.—Subject to subsections (c), (d), (e), (f), and (i), for each of fiscal years 2013 through 2017, fees under subsection (a) shall be derived from the base fee amounts specified in paragraph (2), to generate the total revenue amounts specified in paragraph (3).

“(2) Base fee amounts.—For purposes of paragraph (1), the base fee amounts specified in this paragraph are as follows:

<table>
<thead>
<tr>
<th>Fee Type</th>
<th>Fiscal Year 2013</th>
<th>Fiscal Year 2014</th>
<th>Fiscal Year 2015</th>
<th>Fiscal Year 2016</th>
<th>Fiscal Year 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Premarket Application</td>
<td>$248,000</td>
<td>$252,960</td>
<td>$258,019</td>
<td>$263,180</td>
<td>$268,443</td>
</tr>
<tr>
<td>Establishment Registration</td>
<td>$2,575</td>
<td>$3,200</td>
<td>$3,750</td>
<td>$3,872</td>
<td>$3,872</td>
</tr>
</tbody>
</table>

“(3) Total revenue amounts.—For purposes of paragraph (1), the total revenue amounts specified in this paragraph are as follows:

“(A) $97,722,301 for fiscal year 2013.

“(B) $112,580,497 for fiscal year 2014.

“(C) $125,767,107 for fiscal year 2015.

“(D) $129,339,949 for fiscal year 2016.

“(E) $130,184,348 for fiscal year 2017.”.

(c) Annual Fee Setting; Adjustments.—Section 738(c) (21 U.S.C. 379j(c)) is amended—
(1) in the subsection heading, by inserting “;
ADJUSTMENTS” after “SETTING”;

(2) by striking paragraphs (1) and (2);

(3) by redesignating paragraphs (3) and (4) as
paragraphs (4) and (5), respectively; and

(4) by inserting before paragraph (4), as so re-
designated, the following:

“(1) IN GENERAL.—The Secretary shall, 60
days before the start of each fiscal year after Sep-
tember 30, 2012, establish fees under subsection (a),
based on amounts specified under subsection (b) and
the adjustments provided under this subsection, and
publish such fees, and the rationale for any adjust-
ments to such fees, in the Federal Register.

“(2) INFLATION ADJUSTMENTS.—

“(A) ADJUSTMENT TO TOTAL REVENUE
AMOUNTS.—For fiscal year 2014 and each sub-
sequent fiscal year, the Secretary shall adjust
the total revenue amount specified in subsection
(b)(3) for such fiscal year by multiplying such
amount by the applicable inflation adjustment
under subparagraph (B) for such year.

“(B) APPLICABLE INFLATION ADJUST-
MENT TO TOTAL REVENUE AMOUNTS.—The ap-
Aplicable inflation adjustment for a fiscal year is—

“(i) for fiscal year 2014, the base inflation adjustment under subparagraph (C) for such fiscal year; and

“(ii) for fiscal year 2015 and each subsequent fiscal year, the product of—

“(I) the base inflation adjustment under subparagraph (C) for such fiscal year; and

“(II) the product of the base inflation adjustment under subparagraph (C) for each of the fiscal years preceding such fiscal year, beginning with fiscal year 2014.

“(C) Base inflation adjustment to total revenue amounts.—

“(i) In general.—Subject to further adjustment under clause (ii), the base inflation adjustment for a fiscal year is the sum of one plus—

“(I) the average annual percent change in the cost, per full-time equivalent position of the Food and Drug Administration, of all personnel com-
pensation and benefits paid with re-
spect to such positions for the first 3
years of the preceding 4 fiscal years,
multiplied by 0.60; and

“(II) the average annual percent
change that occurred in the Consumer
Price Index for urban consumers
(Washington-Baltimore, DC–MD–VA–
WV; Not Seasonally Adjusted; All
items; Annual Index) for the first 3
years of the preceding 4 years of
available data multiplied by 0.40.

“(ii) LIMITATIONS.—For purposes of
subparagraph (B), if the base inflation ad-
justment for a fiscal year under clause
(i)—

“(I) is less than 1, such adjust-
ment shall be considered to be equal
to 1; or

“(II) is greater than 1.04, such
adjustment shall be considered to be
equal to 1.04.

“(D) ADJUSTMENT TO BASE FEE
AMOUNTS.—For each of fiscal years 2014
through 2017, the base fee amounts specified in
subsection (b)(2) shall be adjusted as needed, on a uniform proportionate basis, to generate the total revenue amounts under subsection (b)(3), as adjusted for inflation under subparagraph (A).

“(3) Volume-based adjustments to establishment registration base fees.—For each of fiscal years 2014 through 2017, after the base fee amounts specified in subsection (b)(2) are adjusted under paragraph (2)(D), the base establishment registration fee amounts specified in such subsection shall be further adjusted, as the Secretary estimates is necessary in order for total fee collections for such fiscal year to generate the total revenue amounts, as adjusted under paragraph (2).”.

(d) Fee Waiver or Reduction.—Section 738 (21 U.S.C. 379j) is amended by—

(1) redesignating subsections (f) through (k) as subsections (g) through (l), respectively; and

(2) by inserting after subsection (e) the following new subsection:

“(f) Fee Waiver or Reduction.—

“(1) In General.—The Secretary may, at the Secretary’s sole discretion, grant a waiver or reduction of fees under subsection (a)(2) or (a)(3) if the
Secretary finds that such waiver or reduction is in the interest of public health.

“(2) LIMITATION.—The sum of all fee waivers or reductions granted by the Secretary in any fiscal year under paragraph (1) shall not exceed 2 percent of the total fee revenue amounts established for such year under subsection (e).

“(3) DURATION.—The authority provided by this subsection terminates October 1, 2017.”.

(e) CONDITIONS.—Section 738(h)(1)(A) (21 U.S.C. 379j(h)(1)(A)), as redesignated by subsection (d)(1), is amended by striking “$205,720,000” and inserting “$280,587,000”.

(f) CREDITING AND AVAILABILITY OF FEES.—Section 738(i) (21 U.S.C. 379j(i)), as redesignated by subsection (d)(1), is amended—

(1) in paragraph (1), by striking “Fees authorized” and inserting “Subject to paragraph (2)(C), fees authorized”;

(2) in paragraph (2)—

(A) in subparagraph (A)—

(i) in clause (i), by striking “shall be retained” and inserting “subject to subparagraph (C), shall be collected and available”; and
(ii) in clause (ii)—

(I) by striking “collected and” after “shall only be”; and

(II) by striking “fiscal year 2002” and inserting “fiscal year 2009”; and

(B) by adding at the end, the following:

“(C) Provision for Early Payments.—

Payment of fees authorized under this section for a fiscal year, prior to the due date for such fees, may be accepted by the Secretary in accordance with authority provided in advance in a prior year appropriations Act.”;

(3) by amending paragraph (3) to read as follows:

“(3) Authorizations of Appropriations.—

For each of the fiscal years 2013 through 2017, there is authorized to be appropriated for fees under this section an amount equal to the total revenue amount specified under subsection (b)(3) for the fiscal year, as adjusted under subsection (c) and, for fiscal year 2017 only, as further adjusted under paragraph (4).”; and

(4) in paragraph (4)—
(A) by striking “fiscal years 2008, 2009, and 2010” and inserting “fiscal years 2013, 2014, and 2015”;

(B) by striking “fiscal year 2011” and inserting “fiscal year 2016”;

(C) by striking “June 30, 2011” and inserting “June 30, 2016”;

(D) by striking “the amount of fees specified in aggregate in” and inserting “the cumulative amount appropriated pursuant to”;

(E) by striking “aggregate amount in” before “excess shall be credited”; and

(F) by striking “fiscal year 2012” and inserting “fiscal year 2017”.

(g) CONFORMING AMENDMENT.—Section 515(c)(4)(A) (21 U.S.C. 360e(c)(4)(A)) is amended by striking “738(g)” and inserting “738(h)”.

SEC. 204. REAUTHORIZATION; REPORTING REQUIREMENTS.

(a) REAUTHORIZATION.—Section 738A(b) (21 U.S.C. 379j–1(b)) is amended—

(1) in paragraph (1), by striking “2012” and inserting “2017”; and

(2) in paragraph (5), by striking “2012” and inserting “2017”.
(b) REPORTS.—Section 738A(a) (21 U.S.C. 379j–1(a)) is amended—

(1) by striking “2008 through 2012” each place it appears and inserting “2013 through 2017”; and

(2) by striking “section 201(c) of the Food and Drug Administration Amendments Act of 2007” and inserting “section 201(b) of the Medical Device User Fee Amendments of 2012”.

SEC. 205. SAVINGS CLAUSE.

Notwithstanding the amendments made by this title, part 3 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379i et seq.), as in effect on the day before the date of the enactment of this title, shall continue to be in effect with respect to submissions described in section 738(a)(2)(A) of the Federal Food, Drug, and Cosmetic Act (as in effect as of such day) that on or after October 1, 2007, but before October 1, 2012, were accepted by the Food and Drug Administration for filing with respect to assessing and collecting any fee required by such part for a fiscal year prior to fiscal year 2013.

SEC. 206. EFFECTIVE DATE.

The amendments made by this title shall take effect on October 1, 2012, or the date of the enactment of this Act, whichever is later, except that fees under part 3 of
subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act shall be assessed for submissions described in section 738(a)(2)(A) of the Federal Food, Drug, and Cosmetic Act received on or after October 1, 2012, regardless of the date of the enactment of this Act.

SEC. 207. SUNSET DATES.

(a) Authorizations.—Sections 737 and 738 (21 U.S.C. 739i; 739j) shall cease to be effective October 1, 2017.

(b) Reporting Requirements.—Section 738A (21 U.S.C. 739j–1) shall cease to be effective January 31, 2018.

(c) Previous Sunset Provision.—The Food and Drug Administration Amendments Act of 2007 is amended by striking section 217.

SEC. 208. STREAMLINED HIRING AUTHORITY TO SUPPORT ACTIVITIES RELATED TO THE PROCESS FOR THE REVIEW OF DEVICE APPLICATIONS.

Subchapter A of chapter VII (21 U.S.C. 371 et seq.) is amended by inserting after section 713 the following new section:

“SEC. 714. STREAMLINED HIRING AUTHORITY.

“(a) In General.—In addition to any other personnel authorities under other provisions of law, the Secretary may, without regard to the provisions of title 5,
United States Code, governing appointments in the competitive service, appoint employees to positions in the Food and Drug Administration to perform, administer, or support activities described in subsection (b), if the Secretary determines that such appointments are needed to achieve the objectives specified in subsection (c).

“(b) Activities Described.—The activities described in this subsection are activities under this Act related to the process for the review of device applications (as defined in section 737(8)).

“(c) Objectives Specified.—The objectives specified in this subsection are with respect to the activities under subsection (b), the goals referred to in section 738A(a)(1).

“(d) Internal Controls.—The Secretary shall institute appropriate internal controls for appointments under this section.

“(e) Sunset.—The authority to appoint employees under this section shall terminate on the date that is three years after the date of enactment of this section.”.

**TITLE III—FEES RELATING TO GENERIC DRUGS**

**SEC. 301. SHORT TITLE.**

(a) Short Title.—This title may be cited as the “Generic Drug User Fee Amendments of 2012”.
(b) FINDING.—The Congress finds that the fees authorized by the amendments made in this title will be dedicated to human generic drug activities, as set forth in the goals identified for purposes of part 7 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act, in the letters from the Secretary of Health and Human Services to the Chairman of the Committee on Health, Education, Labor, and Pensions of the Senate and the Chairman of the Committee on Energy and Commerce of the House of Representatives, as set forth in the Congressional Record.

SEC. 302. AUTHORITY TO ASSESS AND USE HUMAN GENERIC DRUG FEES.

Subchapter C of chapter VII (21 U.S.C. 379f et seq.) is amended by adding at the end the following:

“PART 7—FEES RELATING TO GENERIC DRUGS

“SEC. 744A. DEFINITIONS.

“For purposes of this part:

“(1) The term ‘abbreviated new drug application’—

“(A) means an application submitted under section 505(j), an abbreviated application submitted under section 507 (as in effect on the day before the date of enactment of the Food and Drug Administration Modernization Act of
1997), or an abbreviated new drug application submitted pursuant to regulations in effect prior to the implementation of the Drug Price Competition and Patent Term Restoration Act of 1984; and

“(B) does not include an application for a positron emission tomography drug.

“(2) The term ‘active pharmaceutical ingredient’ means—

“(A) a substance, or a mixture when the substance is unstable or cannot be transported on its own, intended—

“(i) to be used as a component of a drug; and

“(ii) to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the human body; or

“(B) a substance intended for final crystallization, purification, or salt formation, or any combination of those activities, to become a substance or mixture described in subparagraph (A).
“(3) The term ‘adjustment factor’ means a factor applicable to a fiscal year that is the Consumer Price Index for all urban consumers (all items; United States city average) for October of the preceding fiscal year divided by such Index for October 2011.

“(4) The term ‘affiliate’ means a business entity that has a relationship with a second business entity if, directly or indirectly—

“(A) one business entity controls, or has the power to control, the other business entity; or

“(B) a third party controls, or has power to control, both of the business entities.

“(5)(A) The term ‘facility’—

“(i) means a business or other entity—

“(I) under one management, either direct or indirect; and

“(II) at one geographic location or address engaged in manufacturing or processing an active pharmaceutical ingredient or a finished dosage form; and

“(ii) does not include a business or other entity whose only manufacturing or processing
activities are one or more of the following: re-
packaging, relabeling, or testing.

“(B) For purposes of subparagraph (A), sepa-
rate buildings within close proximity are considered
to be at one geographic location or address if the ac-
tivities in them are—

“(i) closely related to the same business
enterprise;

“(ii) under the supervision of the same
local management; and

“(iii) capable of being inspected by the
Food and Drug Administration during a single
inspection.

“(C) If a business or other entity would meet
the definition of a facility under this paragraph but
for being under multiple management, the business
or other entity is deemed to constitute multiple fa-
cilities, one per management entity, for purposes of
this paragraph.

“(6) The term ‘finished dosage form’ means—

“(A) a drug product in the form in which
it will be administered to a patient, such as a
tablet, capsule, solution, or topical application;

“(B) a drug product in a form in which re-
constitution is necessary prior to administration
to a patient, such as oral suspensions or
lyophilized powders; or

“(C) any combination of an active pharma-
ceutical ingredient with another component of a
drug product for purposes of production of a
drug product described in subparagraph (A) or
(B).

“(7) The term ‘generic drug submission’ means
an abbreviated new drug application, an amendment
to an abbreviated new drug application, or a prior
approval supplement to an abbreviated new drug ap-
lication.

“(8) The term ‘human generic drug activities’
means the following activities of the Secretary asso-
ciated with generic drugs and inspection of facilities
associated with generic drugs:

“(A) The activities necessary for the re-
view of generic drug submissions, including re-
view of drug master files referenced in such
submissions.

“(B) The issuance of—

“(i) approval letters which approve
abbreviated new drug applications or sup-
plements to such applications; or
“(ii) complete response letters which set forth in detail the specific deficiencies in such applications and, where appropriate, the actions necessary to place such applications in condition for approval.

“(C) The issuance of letters related to Type II active pharmaceutical drug master files which—

“(i) set forth in detail the specific deficiencies in such submissions, and where appropriate, the actions necessary to resolve those deficiencies; or

“(ii) document that no deficiencies need to be addressed.

“(D) Inspections related to generic drugs.

“(E) Monitoring of research conducted in connection with the review of generic drug submissions and drug master files.

“(F) Postmarket safety activities with respect to drugs approved under abbreviated new drug applications or supplements, including the following activities:

“(i) Collecting, developing, and reviewing safety information on approved drugs, including adverse event reports.
“(ii) Developing and using improved adverse-event data-collection systems, including information technology systems.

“(iii) Developing and using improved analytical tools to assess potential safety problems, including access to external data bases.

“(iv) Implementing and enforcing section 505(o) (relating to postapproval studies and clinical trials and labeling changes) and section 505(p) (relating to risk evaluation and mitigation strategies) insofar as those activities relate to abbreviated new drug applications.

“(v) Carrying out section 505(k)(5) (relating to adverse-event reports and postmarket safety activities).

“(G) Regulatory science activities related to generic drugs.

“(9) The term ‘positron emission tomography drug’ has the meaning given to the term ‘compounded positron emission tomography drug’ in section 201(ii), except that paragraph (1)(B) of such section shall not apply.
“(10) The term ‘prior approval supplement’ means a request to the Secretary to approve a change in the drug substance, drug product, production process, quality controls, equipment, or facilities covered by an approved abbreviated new drug application when that change has a substantial potential to have an adverse effect on the identity, strength, quality, purity, or potency of the drug product as these factors may relate to the safety or effectiveness of the drug product.

“(11) The term ‘resources allocated for human generic drug activities’ means the expenses for—

“(A) officers and employees of the Food and Drug Administration, contractors of the Food and Drug Administration, advisory committees, and costs related to such officers and employees and to contracts with such contractors;

“(B) management of information, and the acquisition, maintenance, and repair of computer resources;

“(C) leasing, maintenance, renovation, and repair of facilities and acquisition, maintenance, and repair of fixtures, furniture, scientific
equipment, and other necessary materials and
supplies; and

“(D) collecting fees under subsection (a)
and accounting for resources allocated for the
review of abbreviated new drug applications and
supplements and inspection related to generic
drugs.

“(12) The term ‘Type II active pharmaceutical
ingredient drug master file’ means a submission of
information to the Secretary by a person that in-
tends to authorize the Food and Drug Administra-
tion to reference the information to support approval
of a generic drug submission without the submitter
having to disclose the information to the generic
drug submission applicant.

“SEC. 744B. AUTHORITY TO ASSESS AND USE HUMAN GE-
NERIC DRUG FEES.

“(a) Types of Fees.—Beginning in fiscal year
2013, the Secretary shall assess and collect fees in accord-
ance with this section as follows:

“(1) One-time backlog fee for abbrevi-
ated new drug applications pending on oc-
tober 1, 2012.—

“(A) In general.—Each person that
owns an abbreviated new drug application that
is pending on October 1, 2012, and that has not received a tentative approval prior to that date, shall be subject to a fee for each such application, as calculated under subparagraph (B).

“(B) Method of Fee Amount Calculation.—The amount of each one-time backlog fee shall be calculated by dividing $50,000,000 by the total number of abbreviated new drug applications pending on October 1, 2012, that have not received a tentative approval as of that date.

“(C) Notice.—Not later than October 31, 2012, the Secretary shall publish in the Federal Register a notice announcing the amount of the fee required by subparagraph (A).

“(D) Fee Due Date.—The fee required by subparagraph (A) shall be due no later than 30 calendar days after the date of the publication of the notice specified in subparagraph (C).

“(2) Drug Master File Fee.—

“(A) In General.—Each person that owns a Type II active pharmaceutical ingredient drug master file that is referenced on or after October 1, 2012, in a generic drug sub-
mission by any initial letter of authorization shall be subject to a drug master file fee.

“(B) One-time payment.—If a person has paid a drug master file fee for a Type II active pharmaceutical ingredient drug master file, the person shall not be required to pay a subsequent drug master file fee when that Type II active pharmaceutical ingredient drug master file is subsequently referenced in generic drug submissions.

“(C) Notice.—

“(i) Fiscal year 2013.—Not later than October 31, 2012, the Secretary shall publish in the Federal Register a notice announcing the amount of the drug master file fee for fiscal year 2013.

“(ii) Fiscal year 2014 through 2017.—Not later than 60 days before the start of each of fiscal years 2014 through 2017, the Secretary shall publish in the Federal Register the amount of the drug master file fee established by this paragraph for such fiscal year.

“(D) Availability for reference.—
“(i) IN GENERAL.—Subject to subsection (g)(2)(C), for a generic drug submission to reference a Type II active pharmaceutical ingredient drug master file, the drug master file must be deemed available for reference by the Secretary.

“(ii) CONDITIONS.—A drug master file shall be deemed available for reference by the Secretary if—

“(I) the person that owns a Type II active pharmaceutical ingredient drug master file has paid the fee required under subparagraph (A) within 20 calendar days after the applicable due date under subparagraph (E); and

“(II) the drug master file has not failed an initial completeness assessment by the Secretary, in accordance with criteria to be published by the Secretary.

“(iii) LIST.—The Secretary shall make publicly available on the Internet Web site of the Food and Drug Administration a list of the drug master file num-
bers that correspond to drug master files
that have successfully undergone an initial
completeness assessment, in accordance
with criteria to be published by the Sec-
retary, and are available for reference.

“(E) Fee due date.—

“(i) In general.—Subject to clause
(ii), a drug master file fee shall be due no
later than the date on which the first ge-
neric drug submission is submitted that
references the associated Type II active
pharmaceutical ingredient drug master file.

“(ii) Limitation.—No fee shall be
due under subparagraph (A) for a fiscal
year until the later of—

“(I) 30 calendar days after publi-
cation of the notice provided for in
clause (i) or (ii) of subparagraph (C),
as applicable; or

“(II) 30 calendar days after the
date of enactment of an appropria-
tions Act providing for the collection
and obligation of fees under this sec-
tion.
“(3) Abbreviated new drug application and prior approval supplement filing fee.—

“(A) In general.—Each applicant that submits, on or after October 1, 2012, an abbreviated new drug application or a prior approval supplement to an abbreviated new drug application shall be subject to a fee for each such submission in the amount established under subsection (d).

“(B) Notice.—

“(i) Fiscal year 2013.—Not later than October 31, 2012, the Secretary shall publish in the Federal Register a notice announcing the amount of the fees under subparagraph (A) for fiscal year 2013.

“(ii) Fiscal years 2014 through 2017.—Not later than 60 days before the start of each of fiscal years 2014 through 2017, the Secretary shall publish in the Federal Register the amount of the fees under subparagraph (A) for such fiscal year.

“(C) Fee due date.—

“(i) In general.—Except as provided in clause (ii), the fees required by
subparagraphs (A) and (F) shall be due no later than the date of submission of the abbreviated new drug application or prior approval supplement for which such fee applies.

“(ii) Special rule for 2013.—For fiscal year 2013, such fees shall be due on the later of—

“(I) the date on which the fee is due under clause (i);

“(II) 30 calendar days after publication of the notice referred to in subparagraph (B)(i); or

“(III) if an appropriations Act is not enacted providing for the collection and obligation of fees under this section by the date of submission of the application or prior approval supplement for which the fees under subparagraphs (A) and (F) apply, 30 calendar days after the date that such an appropriations Act is enacted.

“(D) Refund of fee if abbreviated new drug application is not considered to have been received.—The Secretary
shall refund 75 percent of the fee paid under
subparagraph (A) for any abbreviated new drug
application or prior approval supplement to an
abbreviated new drug application that the Sec-
retary considers not to have been received with-
in the meaning of section 505(j)(5)(A) for a
cause other than failure to pay fees.

“(E) Fee for an application the Sec-
retary considers not to have been re-
ceived, or that has been withdrawn.—An
abbreviated new drug application or prior ap-
proval supplement that was submitted on or
after October 1, 2012, and that the Secretary
considers not to have been received, or that has
been withdrawn, shall, upon resubmission of the
application or a subsequent new submission fol-
lowing the applicant’s withdrawal of the appli-
cation, be subject to a full fee under subpara-
graph (A).

“(F) Additional fee for active phar-
aceutical ingredient information not
included by reference to type II active
pharmaceutical ingredient drug master
file.—An applicant that submits a generic
drug submission on or after October 1, 2012,
shall pay a fee, in the amount determined under subsection (d)(3), in addition to the fee required under subparagraph (A), if—

“(i) such submission contains information concerning the manufacture of an active pharmaceutical ingredient at a facility by means other than reference by a letter of authorization to a Type II active pharmaceutical drug master file; and

“(ii) a fee in the amount equal to the drug master file fee established in paragraph (2) has not been previously paid with respect to such information.

“(4) GENERIC DRUG FACILITY FEE AND ACTIVE PHARMACEUTICAL INGREDIENT FACILITY FEE.—

“(A) IN GENERAL.—Facilities identified, or intended to be identified, in at least one generic drug submission that is pending or approved to produce a finished dosage form of a human generic drug or an active pharmaceutical ingredient contained in a human generic drug shall be subject to fees as follows:

“(i) GENERIC DRUG FACILITY.—Each person that owns a facility which is identified or intended to be identified in at least
one generic drug submission that is pending or approved to produce one or more finished dosage forms of a human generic drug shall be assessed an annual fee for each such facility.

“(ii) Active Pharmaceutical Ingredient Facility.—Each person that owns a facility which produces, or which is pending review to produce, one or more active pharmaceutical ingredients identified, or intended to be identified, in at least one generic drug submission that is pending or approved or in a Type II active pharmaceutical ingredient drug master file referenced in such a generic drug submission, shall be assessed an annual fee for each such facility.

“(iii) Facilities Producing Both Active Pharmaceutical Ingredients and Finished Dosage Forms.—Each person that owns a facility identified, or intended to be identified, in at least one generic drug submission that is pending or approved to produce both one or more finished dosage forms subject to clause (i)
and one or more active pharmaceutical ingredi-
ents subject to clause (ii) shall be
subject to fees under both such clauses for
that facility.

“(B) AMOUNT.—The amount of fees estab-
lished under subparagraph (A) shall be estab-
lished under subsection (d).

“(C) NOTICE.—

“(i) FISCAL YEAR 2013.—For fiscal
year 2013, the Secretary shall publish in
the Federal Register a notice announcing
the amount of the fees provided for in sub-
paragraph (A) within the timeframe speci-
fied in subsection (d)(1)(B).

“(ii) FISCAL YEARS 2014 THROUGH
2017.—Within the timeframe specified in
subsection (d)(2), the Secretary shall pub-
lish in the Federal Register the amount of
the fees under subparagraph (A) for such
fiscal year.

“(D) FEE DUE DATE.—

“(i) FISCAL YEAR 2013.—For fiscal
year 2013, the fees under subparagraph
(A) shall be due on the later of—
“(I) not later than 45 days after
the publication of the notice under
subparagraph (B); or
“(II) if an appropriations Act is
not enacted providing for the collect-
ion and obligation of fees under this
section by the date of the publication
of such notice, 30 days after the date
that such an appropriations Act is en-
acted.
“(ii) Fiscal Years 2014 through
2017.—For each of fiscal years 2014
through 2017, the fees under subpara-
graph (A) for such fiscal year shall be due
on the later of—
“(I) the first business day on or
after October 1 of each such year; or
“(II) the first business day after
the enactment of an appropriations
Act providing for the collection and
obligation of fees under this section
for such year.
“(5) Date of Submission.—For purposes of
this Act, a generic drug submission or Type II phar-
maceutical master file is deemed to be ‘submitted’ to
the Food and Drug Administration—

“(A) if it is submitted via a Food and
Drug Administration electronic gateway, on the
day when transmission to that electronic gate-
way is completed, except that a submission or
master file that arrives on a weekend, Federal
holiday, or day when the Food and Drug Ad-
ministration office that will review that submis-
sion is not otherwise open for business shall be
deemed to be submitted on the next day when
that office is open for business; or

“(B) if it is submitted in physical media
form, on the day it arrives at the appropriate
designated document room of the Food and
Drug Administration.

“(b) Fee Revenue Amounts.—

“(1) In general.—

“(A) Fiscal year 2013.—For fiscal year
2013, fees under subsection (a) except as pro-
vided in subsection (o) (relating to waivers)
shall be established to generate a total esti-
mated revenue amount under such subsection of
$299,000,000. Of that amount—
“(i) $50,000,000 shall be generated by the one-time backlog fee for generic drug applications pending on October 1, 2012, established in subsection (a)(1); and “(ii) $249,000,000 shall be generated by the fees under paragraphs (2) through (4) of subsection (a).

“(B) Fiscal years 2014 through 2017.—For each of the fiscal years 2014 through 2017, fees under paragraphs (2) through (4) of subsection (a) shall be established to generate a total estimated revenue amount under such subsection that is equal to $299,000,000, as adjusted pursuant to subsection (c).

“(2) Types of fees.—In establishing fees under paragraph (1) to generate the revenue amounts specified in paragraph (1)(A)(ii) for fiscal year 2013 and paragraph (1)(B) for each of fiscal years 2014 through 2017, such fees shall be derived from the fees under paragraphs (2) through (4) of subsection (a) as follows:

“(A) 6 percent shall be derived from fees under subsection (a)(2) (relating to drug master files).
“(B) 24 percent shall be derived from fees under subsection (a)(3) (relating to abbreviated new drug applications and supplements). The amount of a fee for a prior approval supplement shall be half the amount of the fee for an abbreviated new drug application.

“(C) 56 percent shall be derived from fees under subsection (a)(4)(A)(i) (relating to generic drug facilities). The amount of the fee for a facility located outside the United States and its territories and possessions shall be not less than $15,000 and not more than $30,000 higher than the amount of the fee for a facility located in the United States and its territories and possessions, as determined by the Secretary on the basis of data concerning the difference in cost between inspections of facilities located in the United States, including its territories and possessions, and those located outside of the United States and its territories and possessions.

“(D) 14 percent shall be derived from fees under subsection (a)(4)(A)(ii) (relating to active pharmaceutical ingredient facilities). The amount of the fee for a facility located outside
the United States and its territories and possess-
sions shall be not less than $15,000 and not
more than $30,000 higher than the amount of
the fee for a facility located in the United
States, including its territories and possessions,
as determined by the Secretary on the basis of
data concerning the difference in cost between
inspections of facilities located in the United
States and its territories and possessions and
those located outside of the United States and
its territories and possessions.

“(c) ADJUSTMENTS.—

“(1) INFLATION ADJUSTMENT.—For fiscal year
2014 and subsequent fiscal years, the revenues es-
established in subsection (b) shall be adjusted by the
Secretary by notice, published in the Federal Reg-
ister, for a fiscal year, by an amount equal to the
sum of—

“(A) one;

“(B) the average annual percent change in
the cost, per full-time equivalent position of the
Food and Drug Administration, of all personnel
compensation and benefits paid with respect to
such positions for the first 3 years of the pre-
ceding 4 fiscal years multiplied by the propor-
tion of personnel compensation and benefits costs to total costs of human generic drug activities for the first 3 years of the preceding 4 fiscal years; and

“(C) the average annual percent change that occurred in the Consumer Price Index for urban consumers (Washington-Baltimore, DC–MD–VA–WV; Not Seasonally Adjusted; All items; Annual Index) for the first 3 years of the preceding 4 years of available data multiplied by the proportion of all costs other than personnel compensation and benefits costs to total costs of human generic drug activities for the first 3 years of the preceding 4 fiscal years.

The adjustment made each fiscal year under this subsection shall be added on a compounded basis to the sum of all adjustments made each fiscal year after fiscal year 2013 under this subsection.

“(2) Final year adjustment.—For fiscal year 2017, the Secretary may, in addition to adjustments under paragraph (1), further increase the fee revenues and fees established in subsection (b) if such an adjustment is necessary to provide for not more than 3 months of operating reserves of carry-over user fees for human generic drug activities for
the first 3 months of fiscal year 2018. Such fees may only be used in fiscal year 2018. If such an adjustment is necessary, the rationale for the amount of the increase shall be contained in the annual notice establishing fee revenues and fees for fiscal year 2017. If the Secretary has carryover balances for such activities in excess of 3 months of such operating reserves, the adjustment under this subparagraph shall not be made.

“(d) ANNUAL FEE SETTING.—

“(1) FISCAL YEAR 2013.—For fiscal year 2013—

“(A) the Secretary shall establish, by October 31, 2012, the one-time generic drug backlog fee for generic drug applications pending on October 1, 2012, the drug master file fee, the abbreviated new drug application fee, and the prior approval supplement fee under subsection (a), based on the revenue amounts established under subsection (b); and

“(B) the Secretary shall establish, not later than 45 days after the date to comply with the requirement for identification of facilities in subsection (f)(2), the generic drug facility fee and active pharmaceutical ingredient fa-
ility fee under subsection (a) based on the revenue amounts established under subsection (b).

“(2) Fiscal years 2014 through 2017.—Not more than 60 days before the first day of each of fiscal years 2014 through 2017, the Secretary shall establish the drug master file fee, the abbreviated new drug application fee, the prior approval supplement fee, the generic drug facility fee, and the active pharmaceutical ingredient facility fee under subsection (a) for such fiscal year, based on the revenue amounts established under subsection (b) and the adjustments provided under subsection (c).

“(3) Fee for active pharmaceutical ingredient information not included by reference to type II active pharmaceutical ingredient drug master file.—In establishing the fees under paragraphs (1) and (2), the amount of the fee under subsection (a)(3)(F) shall be determined by multiplying—

“(A) the sum of—

“(i) the total number of such active pharmaceutical ingredients in such submission; and

“(ii) for each such ingredient that is manufactured at more than one such facil-
ity, the total number of such additional fa-
cilities; and

“(B) the amount equal to the drug master
file fee established in subsection (a)(2) for such
submission.

“(e) Limit.—The total amount of fees charged, as
adjusted under subsection (c), for a fiscal year may not
exceed the total costs for such fiscal year for the resources
allocated for human generic drug activities.

“(f) Identification of Facilities.—

“(1) Publication of notice; deadline for
compliance.—Not later than October 1, 2012, the
Secretary shall publish in the Federal Register a no-
tice requiring each person that owns a facility de-
scribed in subsection (a)(4)(A), or a site or organi-
ization required to be identified by paragraph (4), to
submit to the Secretary information on the identity
of each such facility, site, or organization. The no-
tice required by this paragraph shall specify the type
of information to be submitted and the means and
format for submission of such information.

“(2) Required submission of facility
identification.—Each person that owns a facility
described in subsection (a)(4)(A) or a site or organi-
ization required to be identified by paragraph (4)
shall submit to the Secretary the information re-
quired under this subsection each year. Such infor-
mation shall—

“(A) for fiscal year 2013, be submitted not
later than 60 days after the publication of the
notice under paragraph (1); and

“(B) for each subsequent fiscal year, be
submitted, updated, or reconfirmed on or before
June 1 of the previous year.

“(3) CONTENTS OF NOTICE.—At a minimum,
the submission required by paragraph (2) shall in-
clude for each such facility—

“(A) identification of a facility identified or
intended to be identified in an approved or
pending generic drug submission;

“(B) whether the facility manufactures ac-
tive pharmaceutical ingredients or finished dos-
age forms, or both;

“(C) whether or not the facility is located
within the United States and its territories and
possessions;

“(D) whether the facility manufactures
positron emission tomography drugs solely, or
in addition to other drugs; and
“(E) whether the facility manufactures drugs that are not generic drugs.

“(4) CERTAIN SITES AND ORGANIZATIONS.—

“(A) IN GENERAL.—Any person that owns or operates a site or organization described in subparagraph (B) shall submit to the Secretary information concerning the ownership, name, and address of the site or organization.

“(B) SITES AND ORGANIZATIONS.—A site or organization is described in this subparagraph if it is identified in a generic drug submission and is—

“(i) a site in which a bioanalytical study is conducted;

“(ii) a clinical research organization;

“(iii) a contract analytical testing site;

or

“(iv) a contract repackager site.

“(C) NOTICE.—The Secretary may, by notice published in the Federal Register, specify the means and format for submission of the information under subparagraph (A) and may specify, as necessary for purposes of this section, any additional information to be submitted.
“(D) Inspection Authority.—The Secretary’s inspection authority under section 704(a)(1) shall extend to all such sites and organizations.

“(g) Effect of Failure To Pay Fees.—

“(1) Generic Drug Backlog Fee.—Failure to pay the fee under subsection (a)(1) shall result in the Secretary placing the person that owns the abbreviated new drug application subject to that fee on an arrears list, such that no new abbreviated new drug applications or supplement submitted on or after October 1, 2012, from that person, or any affiliate of that person, will be received within the meaning of section 505(j)(5)(A) until such outstanding fee is paid.

“(2) Drug Master File Fee.—

“(A) Failure to pay the fee under subsection (a)(2) within 20 calendar days after the applicable due date under subparagraph (E) of such subsection (as described in subsection (a)(2)(D)(ii)(I)) shall result in the Type II active pharmaceutical ingredient drug master file not being deemed available for reference.

“(B)(i) Any generic drug submission submitted on or after October 1, 2012, that ref-
erences, by a letter of authorization, a Type II active pharmaceutical ingredient drug master file that has not been deemed available for reference shall not be received within the meaning of section 505(j)(5)(A) unless the condition specified in clause (ii) is met.

“(ii) The condition specified in this clause is that the fee established under subsection (a)(2) has been paid within 20 calendar days of the Secretary providing the notification to the sponsor of the abbreviated new drug application or supplement of the failure of the owner of the Type II active pharmaceutical ingredient drug master file to pay the drug master file fee as specified in subparagraph (C).

“(C)(i) If an abbreviated new drug application or supplement to an abbreviated new drug application references a Type II active pharmaceutical ingredient drug master file for which a fee under subsection (a)(2)(A) has not been paid by the applicable date under subsection (a)(2)(E), the Secretary shall notify the sponsor of the failure of the owner of the Type
II active pharmaceutical ingredient drug master file to pay the applicable fee.

“(ii) If such fee is not paid within 20 calendar days of the Secretary providing the notification, the abbreviated new drug application or supplement to an abbreviated new drug application shall not be received within the meaning of 505(j)(5)(A).

“(3) ABBREVIATED NEW DRUG APPLICATION FEE AND PRIOR APPROVAL SUPPLEMENT FEE.— Failure to pay a fee under subparagraph (A) or (F) of subsection (a)(3) within 20 calendar days of the applicable due date under subparagraph (C) of such subsection shall result in the abbreviated new drug application or the prior approval supplement to an abbreviated new drug application not being received within the meaning of section 505(j)(5)(A) until such outstanding fee is paid.

“(4) GENERIC DRUG FACILITY FEE AND ACTIVE PHARMACEUTICAL INGREDIENT FACILITY FEE.—

“(A) IN GENERAL.—Failure to pay the fee under subsection (a)(4) within 20 calendar days of the due date as specified in subparagraph (D) of such subsection shall result in the following:
“(i) The Secretary shall place the facility on a publicly available arrears list, such that no new abbreviated new drug application or supplement submitted on or after October 1, 2012, from the person that is responsible for paying such fee, or any affiliate of that person, will be received within the meaning of section 505(j)(5)(A).

“(ii) Any new generic drug submission submitted on or after October 1, 2012, that references such a facility shall not be received, within the meaning of section 505(j)(5)(A) if the outstanding facility fee is not paid within 20 calendar days of the Secretary providing the notification to the sponsor of the failure of the owner of the facility to pay the facility fee under subsection (a)(4)(C).

“(iii) All drugs or active pharmaceutical ingredients manufactured in such a facility or containing an ingredient manufactured in such a facility shall be deemed misbranded under section 502(aa).

“(B) Application of penalties.—The penalties under this paragraph shall apply until
the fee established by subsection (a)(4) is paid or the facility is removed from all generic drug submissions that refer to the facility.

“(C) NONRECEIVAL FOR NONPAYMENT.—

“(i) NOTICE.—If an abbreviated new drug application or supplement to an abbreviated new drug application submitted on or after October 1, 2012, references a facility for which a facility fee has not been paid by the applicable date under subsection (a)(4)(C), the Secretary shall notify the sponsor of the generic drug submission of the failure of the owner of the facility to pay the facility fee.

“(ii) NONRECEIVAL.—If the facility fee is not paid within 20 calendar days of the Secretary providing the notification under clause (i), the abbreviated new drug application or supplement to an abbreviated new drug application shall not be received within the meaning of section 505(j)(5)(A).

“(h) LIMITATIONS.—

“(1) IN GENERAL.—Fees under subsection (a) shall be refunded for a fiscal year beginning after
fiscal year 2012, unless appropriations for salaries
and expenses of the Food and Drug Administration
for such fiscal year (excluding the amount of fees
appropriated for such fiscal year) are equal to or
greater than the amount of appropriations for the
salaries and expenses of the Food and Drug Admin-
istration for the fiscal year 2009 (excluding the
amount of fees appropriated for such fiscal year)
multiplied by the adjustment factor (as defined in
section 744A) applicable to the fiscal year involved.

“(2) Authority.—If the Secretary does not
assess fees under subsection (a) during any portion
of a fiscal year and if at a later date in such fiscal
year the Secretary may assess such fees, the Sec-
retary may assess and collect such fees, without any
modification in the rate, for Type II active pharma-
ceutical ingredient drug master files, abbreviated
new drug applications and prior approval supple-
ments, and generic drug facilities and active phar-
maceutical ingredient facilities at any time in such
fiscal year notwithstanding the provisions of sub-
section (a) relating to the date fees are to be paid.

“(i) Crediting and Availability of Fees.—

“(1) In General.—Fees authorized under sub-
section (a) shall be collected and available for obliga-
tion only to the extent and in the amount provided
in advance in appropriations Acts, subject to para-
graph (2). Such fees are authorized to remain avail-
able until expended. Such sums as may be necessary
may be transferred from the Food and Drug Admin-
istration salaries and expenses appropriation account
without fiscal year limitation to such appropriation
account for salaries and expenses with such fiscal
year limitation. The sums transferred shall be avail-
able solely for human generic drug activities.

“(2) COLLECTIONS AND APPROPRIATION
ACTS.—

“(A) IN GENERAL.—The fees authorized
by this section—

“(i) subject to subparagraphs (C) and
(D), shall be collected and available in each
fiscal year in an amount not to exceed the
amount specified in appropriation Acts, or
otherwise made available for obligation for
such fiscal year; and

“(ii) shall be available for a fiscal year
beginning after fiscal year 2012 to defray
the costs of human generic drug activities
(including such costs for an additional
number of full-time equivalent positions in
the Department of Health and Human Services to be engaged in such activities), only if the Secretary allocates for such purpose an amount for such fiscal year (excluding amounts from fees collected under this section) no less than $97,000,000 multiplied by the adjustment factor, as defined in section 744A(3), applicable to the fiscal year involved.

“(B) COMPLIANCE.—The Secretary shall be considered to have met the requirements of subparagraph (A)(ii) in any fiscal year if the costs funded by appropriations and allocated for human generic activities are not more than 10 percent below the level specified in such subparagraph.

“(C) FEE COLLECTION DURING FIRST PROGRAM YEAR.—Until the date of enactment of an Act making appropriations through September 30, 2013 for the salaries and expenses account of the Food and Drug Administration, fees authorized by this section for fiscal year 2013, may be collected and shall be credited to such account and remain available until expended.
“(D) Provision for early payments in subsequent years.—Payment of fees authorized under this section for a fiscal year (after fiscal year 2013), prior to the due date for such fees, may be accepted by the Secretary in accordance with authority provided in advance in a prior year appropriations Act.

“(3) Authorization of appropriations.—For each of the fiscal years 2013 through 2017, there is authorized to be appropriated for fees under this section an amount equivalent to the total revenue amount determined under subsection (b) for the fiscal year, as adjusted under subsection (c), if applicable, or as otherwise affected under paragraph (2) of this subsection.

“(j) Collection of unpaid fees.—In any case where the Secretary does not receive payment of a fee assessed under subsection (a) within 30 calendar days after it is due, such fee shall be treated as a claim of the United States Government subject to subchapter II of chapter 37 of title 31, United States Code.

“(k) Construction.—This section may not be construed to require that the number of full-time equivalent positions in the Department of Health and Human Services, for officers, employees, and advisory committees not
engaged in human generic drug activities, be reduced to
offset the number of officers, employees, and advisory
committees so engaged.

“(l) Positron Emission Tomography Drugs.—

“(1) Exemption from Fees.—Submission of
an application for a positron emission tomography
drug or active pharmaceutical ingredient for a
positron emission tomography drug shall not require
the payment of any fee under this section. Facilities
that solely produce positron emission tomography
drugs shall not be required to pay a facility fee as
established in subsection (a)(4).

“(2) Identification Requirement.—Facili-
ties that produce positron emission tomography
drugs or active pharmaceutical ingredients of such
drugs are required to be identified pursuant to sub-
section (f).

“(m) Disputes Concerning Fees.—To qualify for
the return of a fee claimed to have been paid in error
under this section, a person shall submit to the Secretary
a written request justifying such return within 180 cal-
endar days after such fee was paid.

“(n) Substantially Complete Applications.—
An abbreviated new drug application that is not consid-
ered to be received within the meaning of section
505(j)(5)(A) because of failure to pay an applicable fee under this provision within the time period specified in subsection (g) shall be deemed not to have been ‘substantially complete’ on the date of its submission within the meaning of section 505(j)(5)(B)(iv)(II)(cc). An abbreviated new drug application that is not substantially complete on the date of its submission solely because of failure to pay an applicable fee under the preceding sentence shall be deemed substantially complete and received within the meaning of section 505(j)(5)(A) as of the date such applicable fee is received.”.

SEC. 303. REAUTHORIZATION; REPORTING REQUIREMENTS.

Part 7 of subchapter C of chapter VII, as added by section 302 of this Act, is amended by inserting after section 744B the following:

"SEC. 744C. REAUTHORIZATION; REPORTING REQUIREMENTS.

“(a) Performance Report.—Beginning with fiscal year 2013, not later than 120 days after the end of each fiscal year for which fees are collected under this part, the Secretary shall prepare and submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate a report concerning the progress of the Food and Drug Administration in achieving the
goals identified in the letters described in section 301(b) of the Generic Drug User Fee Amendments of 2012 during such fiscal year and the future plans of the Food and Drug Administration for meeting the goals.

“(b) Fiscal Report.—Beginning with fiscal year 2013, not later than 120 days after the end of each fiscal year for which fees are collected under this part, the Secretary shall prepare and submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate a report on the implementation of the authority for such fees during such fiscal year and the use, by the Food and Drug Administration, of the fees collected for such fiscal year.

“(c) Public Availability.—The Secretary shall make the reports required under subsections (a) and (b) available to the public on the Internet Web site of the Food and Drug Administration.

“(d) Reauthorization.—

“(1) Consultation.—In developing recommendations to present to the Congress with respect to the goals, and plans for meeting the goals, for human generic drug activities for the first 5 fiscal years after fiscal year 2017, and for the reau-
authorization of this part for such fiscal years, the Sec-
retary shall consult with—

“(A) the Committee on Energy and Com-
merce of the House of Representatives;
“(B) the Committee on Health, Education,
Labor, and Pensions of the Senate;
“(C) scientific and academic experts;
“(D) health care professionals;
“(E) representatives of patient and con-
sumer advocacy groups; and
“(F) the generic drug industry.
“(2) PRIOR PUBLIC INPUT.—Prior to beginning
negotiations with the generic drug industry on the
reauthorization of this part, the Secretary shall—
“(A) publish a notice in the Federal Reg-
ister requesting public input on the reauthoriza-
tion;
“(B) hold a public meeting at which the
public may present its views on the reauthoriza-
tion, including specific suggestions for changes
to the goals referred to in subsection (a);
“(C) provide a period of 30 days after the
public meeting to obtain written comments from
the public suggesting changes to this part; and
“(D) publish the comments on the Food and Drug Administration’s Internet Web site.

“(3) Periodic Consultation.—Not less frequently than once every month during negotiations with the generic drug industry, the Secretary shall hold discussions with representatives of patient and consumer advocacy groups to continue discussions of their views on the reauthorization and their suggestions for changes to this part as expressed under paragraph (2).

“(4) Public Review of Recommendations.—After negotiations with the generic drug industry, the Secretary shall—

“(A) present the recommendations developed under paragraph (1) to the congressional committees specified in such paragraph;

“(B) publish such recommendations in the Federal Register;

“(C) provide for a period of 30 days for the public to provide written comments on such recommendations;

“(D) hold a meeting at which the public may present its views on such recommendations; and
(E) after consideration of such public views and comments, revise such recommen-
dations as necessary.

(5) TRANSMITTAL OF RECOMMENDATIONS.— Not later than January 15, 2017, the Secretary shall transmit to the Congress the revised recom-
ommendations under paragraph (4), a summary of the views and comments received under such para-
graph, and any changes made to the recommenda-
tions in response to such views and comments.

(6) MINUTES OF NEGOTIATION MEETINGS.—

(A) PUBLIC AVAILABILITY.—Before pre-
senting the recommendations developed under paragraphs (1) through (5) to the Congress, the Secretary shall make publicly available, on the Internet Web site of the Food and Drug Ad-
ministration, minutes of all negotiation meet-
ings conducted under this subsection between the Food and Drug Administration and the ge-
neric drug industry.

(B) CONTENT.—The minutes described under subparagraph (A) shall summarize any substantive proposal made by any party to the negotiations as well as significant controversies
SEC. 304. SUNSET DATES.

(a) Authorization.—The amendments made by section 302 cease to be effective October 1, 2017.

(b) Reporting Requirements.—The amendments made by section 303 cease to be effective January 31, 2018.

SEC. 305. EFFECTIVE DATE.

The amendments made by this title shall take effect on October 1, 2012, or the date of the enactment of this title, whichever is later, except that fees under section 302 shall be assessed for all human generic drug submissions and Type II active pharmaceutical drug master files received on or after October 1, 2012, regardless of the date of enactment of this title.

SEC. 306. AMENDMENT WITH RESPECT TO MISBRANDING.

Section 502 (21 U.S.C. 352) is amended by adding at the end the following:

“(aa) If it is a drug, or an active pharmaceutical ingredient, and it was manufactured, prepared, propagated, compounded, or processed in a facility for which fees have not been paid as required by section 744A(a)(4) or for which identifying information required by section 744B(f) has not been submitted, or it contains an active pharma-
ceutical ingredient that was manufactured, prepared, propagated, compounded, or processed in such a facility.”.

SEC. 307. STREAMLINED HIRING AUTHORITY OF THE FOOD AND DRUG ADMINISTRATION TO SUPPORT ACTIVITIES RELATED TO HUMAN GENERIC DRUGS.

Section 714 of the Federal Food, Drug, and Cosmetic Act, as added by section 208, is amended—

(1) in subsection (b)—

(A) by striking “are activities” and inserting “are—

“(1) activities”;

(B) by striking the period at the end and inserting “; and”; and

(C) by adding at the end the following:

“(2) activities under this Act related to human generic drug activities (as defined in section 744A).”; and

(2) by amending subsection (c) to read as follows:

“(c) OBJECTIVES SPECIFIED.—The objectives specified in this subsection are—

“(1) with respect to the activities under subsection (b)(1), the goals referred to in section 738A(a)(1); and
“(2) with respect to the activities under subsection (b)(2), the performance goals with respect to section 744A (regarding assessment and use of human generic drug fees), as set forth in the letters described in section 301(b) of the Generic Drug User Fee Amendments of 2012.”.

TITLE IV—FEES RELATING TO BIOSIMILAR BIOLOGICAL PRODUCTS

SEC. 401. SHORT TITLE; FINDING.

(a) Short Title.—This title may be cited as the “Biosimilar User Fee Act of 2012”.

(b) Finding.—The Congress finds that the fees authorized by the amendments made in this title will be dedicated to expediting the process for the review of biosimilar biological product applications, including postmarket safety activities, as set forth in the goals identified for purposes of part 8 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act, in the letters from the Secretary of Health and Human Services to the Chairman of the Committee on Health, Education, Labor, and Pensions of the Senate and the Chairman of the Committee on Energy and Commerce of the House of Representatives, as set forth in the Congressional Record.
SEC. 402. FEES RELATING TO BIOSIMILAR BIOLOGICAL PRODUCTS.

Subchapter C of chapter VII (21 U.S.C. 379f et seq.) is amended by inserting after part 7, as added by title III of this Act, the following:

“PART 8—FEES RELATING TO BIOSIMILAR BIOLOGICAL PRODUCTS

SEC. 744G. DEFINITIONS.

“For purposes of this part:

“(1) The term ‘adjustment factor’ applicable to a fiscal year that is the Consumer Price Index for all urban consumers (Washington-Baltimore, DC–MD–VA–WV; Not Seasonally Adjusted; All items) of the preceding fiscal year divided by such Index for September 2011.

“(2) The term ‘affiliate’ means a business entity that has a relationship with a second business entity if, directly or indirectly—

“(A) one business entity controls, or has the power to control, the other business entity;

or

“(B) a third party controls, or has power to control, both of the business entities.

“(3) The term ‘biosimilar biological product’ means a product for which a biosimilar biological product application has been approved.
“(4)(A) Subject to subparagraph (B), the term ‘biosimilar biological product application’ means an application for licensure of a biological product under section 351(k) of the Public Health Service Act.

“(B) Such term does not include—

“(i) a supplement to such an application;

“(ii) an application filed under section 351(k) of the Public Health Service Act that cites as the reference product a bovine blood product for topical application licensed before September 1, 1992, or a large volume parenteral drug product approved before such date;

“(iii) an application filed under section 351(k) of the Public Health Service Act with respect to—

“(I) whole blood or a blood component for transfusion;

“(II) an allergenic extract product;

“(III) an in vitro diagnostic biological product; or

“(IV) a biological product for further manufacturing use only; or

“(iv) an application for licensure under section 351(k) of the Public Health Service Act.
that is submitted by a State or Federal Government entity for a product that is not distributed commercially.

“(5) The term ‘biosimilar biological product development meeting’ means any meeting, other than a biosimilar initial advisory meeting, regarding the content of a development program, including a proposed design for, or data from, a study intended to support a biosimilar biological product application.

“(6) The term ‘biosimilar biological product development program’ means the program under this part for expediting the process for the review of submissions in connection with biosimilar biological product development.

“(7)(A) The term ‘biosimilar biological product establishment’ means a foreign or domestic place of business—

“(i) that is at one general physical location consisting of one or more buildings, all of which are within five miles of each other; and

“(ii) at which one or more biosimilar biological products are manufactured in final dosage form.

“(B) For purposes of subparagraph (A)(ii), the term ‘manufactured’ does not include packaging.
“(8) The term ‘biosimilar initial advisory meeting’—

“(A) means a meeting, if requested, that is limited to—

“(i) a general discussion regarding whether licensure under section 351(k) of the Public Health Service Act may be feasible for a particular product; and

“(ii) if so, general advice on the expected content of the development program; and

“(B) does not include any meeting that involves substantive review of summary data or full study reports.

“(9) The term ‘costs of resources allocated for the process for the review of biosimilar biological product applications’ means the expenses in connection with the process for the review of biosimilar biological product applications for—

“(A) officers and employees of the Food and Drug Administration, contractors of the Food and Drug Administration, advisory committees, and costs related to such officers employees and committees and to contracts with such contractors;
“(B) management of information, and the
acquisition, maintenance, and repair of com-
puter resources;

“(C) leasing, maintenance, renovation, and
repair of facilities and acquisition, maintenance,
and repair of fixtures, furniture, scientific
equipment, and other necessary materials and
supplies; and

“(D) collecting fees under section 744H
and accounting for resources allocated for the
review of submissions in connection with bio-
similar biological product development, bio-
similar biological product applications, and sup-
plements.

“(10) The term ‘final dosage form’ means, with
respect to a biosimilar biological product, a finished
dosage form which is approved for administration to
a patient without substantial further manufacturing
(such as lyophilized products before reconstitution).

“(11) The term ‘financial hold’—

“(A) means an order issued by the Sec-
retary to prohibit the sponsor of a clinical in-
vestigation from continuing the investigation if
the Secretary determines that the investigation
is intended to support a biosimilar biological
product application and the sponsor has failed to pay any fee for the product required under subparagraph (A), (B), or (D) of section 744H(a)(1); and

“(B) does not mean that any of the bases for a ‘clinical hold’ under section 505(i)(3) have been determined by the Secretary to exist concerning the investigation.

“(12) The term ‘person’ includes an affiliate of such person.

“(13) The term ‘process for the review of biosimilar biological product applications’ means the following activities of the Secretary with respect to the review of submissions in connection with biosimilar biological product development, biosimilar biological product applications, and supplements:

“(A) The activities necessary for the review of submissions in connection with biosimilar biological product development, biosimilar biological product applications, and supplements.

“(B) Actions related to submissions in connection with biosimilar biological product development, the issuance of action letters which approve biosimilar biological product applications
or which set forth in detail the specific defi-
iciencies in such applications, and where appro-
priate, the actions necessary to place such ap-
plications in condition for approval.

“(C) The inspection of biosimilar biological
product establishments and other facilities un-
dertaken as part of the Secretary’s review of
pending biosimilar biological product applica-
tions and supplements.

“(D) Activities necessary for the release of
lots of biosimilar biological products under sec-
tion 351(k) of the Public Health Service Act.

“(E) Monitoring of research conducted in
connection with the review of biosimilar biologi-
cal product applications.

“(F) Postmarket safety activities with re-
pect to biologics approved under biosimilar bio-
logical product applications or supplements, in-
cluding the following activities:

“(i) Collecting, developing, and re-
viewing safety information on biosimilar bi-
ological products, including adverse-event
reports.
“(ii) Developing and using improved adverse-event data-collection systems, including information technology systems.

“(iii) Developing and using improved analytical tools to assess potential safety problems, including access to external databases.

“(iv) Implementing and enforcing section 505(o) (relating to postapproval studies and clinical trials and labeling changes) and section 505(p) (relating to risk evaluation and mitigation strategies).

“(v) Carrying out section 505(k)(5) (relating to adverse-event reports and postmarket safety activities).

“(14) The term ‘supplement’ means a request to the Secretary to approve a change in a biosimilar biological product application which has been approved, including a supplement requesting that the Secretary determine that the biosimilar biological product meets the standards for interchangeability described in section 351(k)(4) of the Public Health Service Act.
SEC. 744H. AUTHORITY TO ASSESS AND USE BIOSIMILAR BIOLOGICAL PRODUCT FEES.

“(a) Types of Fees.—Beginning in fiscal year 2013, the Secretary shall assess and collect fees in accordance with this section as follows:

“(1) Biosimilar development program fees.—

“(A) Initial biosimilar biological product development fee.—

“(i) In general.—Each person that submits to the Secretary a meeting request described under clause (ii) or a clinical protocol for an investigational new drug protocol described under clause (iii) shall pay for the product named in the meeting request or the investigational new drug application the initial biosimilar biological product development fee established under subsection (b)(1)(A).

“(ii) Meeting request.—The meeting request described in this clause is a request for a biosimilar biological product development meeting for a product.

“(iii) Clinical protocol for IND.—A clinical protocol for an investigational new drug protocol described in this clause
is a clinical protocol consistent with the provisions of section 505(i), including any regulations promulgated under section 505(i), (referred to in this section as ‘investigational new drug application’) describing an investigation that the Secretary determines is intended to support a biosimilar biological product application for a product.

“(iv) DUE DATE.—The initial biosimilar biological product development fee shall be due by the earlier of the following:

“(I) Not later than 5 days after the Secretary grants a request for a biosimilar biological product development meeting.

“(II) The date of submission of an investigational new drug application describing an investigation that the Secretary determines is intended to support a biosimilar biological product application.

“(v) TRANSITION RULE.—Each person that has submitted an investigational new drug application prior to the date of
enactment of the Biosimilars User Fee Act of 2012 shall pay the initial biosimilar biological product development fee by the earlier of the following:

“(I) Not later than 60 days after the date of the enactment of the Biosimilars User Fee Act of 2012, if the Secretary determines that the investigational new drug application describes an investigation that is intended to support a biosimilar biological product application.

“(II) Not later than 5 days after the Secretary grants a request for a biosimilar biological product development meeting.

“(B) ANNUAL BIOSIMILAR BIOLOGICAL PRODUCT DEVELOPMENT FEE.—

“(i) IN GENERAL.—A person that pays an initial biosimilar biological product development fee for a product shall pay for such product, beginning in the fiscal year following the fiscal year in which the initial biosimilar biological product development fee was paid, an annual fee established
under subsection (b)(1)(B) for biosimilar biological product development (referred to in this section as ‘annual biosimilar biological product development fee’).

“(ii) DUE DATE.—The annual biosimilar biological product development program fee for each fiscal year will be due on the later of—

“(I) the first business day on or after October 1 of each such year; or

“(II) the first business day after the enactment of an appropriations Act providing for the collection and obligation of fees for such year under this section.

“(iii) EXCEPTION.—The annual biosimilar development program fee for each fiscal year will be due on the date specified in clause (ii), unless the person has—

“(I) submitted a marketing application for the biological product that was accepted for filing; or

“(II) discontinued participation in the biosimilar biological product de-
velopment program for the product under subparagraph (C).

“(C) DISCONTINUATION OF FEE OBLIGA-
tion.—A person may discontinue participation in the biosimilar biological product development program for a product effective October 1 of a fiscal year by, not later than August 1 of the preceding fiscal year—

“(i) if no investigational new drug application concerning the product has been submitted, submitting to the Secretary a written declaration that the person has no present intention of further developing the product as a biosimilar biological product; or

“(ii) if an investigational new drug application concerning the product has been submitted, by withdrawing the investigational new drug application in accordance with part 312 of title 21, Code of Federal Regulations (or any successor regulations).

“(D) REACTIVATION FEE.—

“(i) IN GENERAL.—A person that has discontinued participation in the biosimilar
biological product development program for
a product under subparagraph (C) shall
pay a fee (referred to in this section as ‘re-
activation fee’) by the earlier of the fol-
lowing:

“(I) Not later than 5 days after
the Secretary grants a request for a
biosimilar biological product develop-
ment meeting for the product (after
the date on which such participation
was discontinued).

“(II) Upon the date of submis-
ion (after the date on which such
participation was discontinued) of an
investigational new drug application
describing an investigation that the
Secretary determines is intended to
support a biosimilar biological product
application for that product.

“(ii) Application of annual
fee.—A person that pays a reactivation
fee for a product shall pay for such prod-
uct, beginning in the next fiscal year, the
annual biosimilar biological product devel-
opment fee under subparagraph (B).
“(E) Effect of failure to pay biosimilar development program fees.—

“(i) No biosimilar biological product development meetings.—If a person has failed to pay an initial or annual biosimilar biological product development fee as required under subparagraph (A) or (B), or a reactivation fee as required under subparagraph (D), the Secretary shall not provide a biosimilar biological product development meeting relating to the product for which fees are owed.

“(ii) No receipt of investigational new drug applications.—Except in extraordinary circumstances, the Secretary shall not consider an investigational new drug application to have been received under section 505(i)(2) if—

“(I) the Secretary determines that the investigation is intended to support a biosimilar biological product application; and

“(II) the sponsor has failed to pay an initial or annual biosimilar biological product development fee for
the product as required under sub-
paragraph (A) or (B), or a reactiva-
tion fee as required under subpara-
graph (D).

“(iii) FINANCIAL HOLD.—Notwith-
standing section 505(i)(2), except in ex-
traordinary circumstances, the Secretary
shall prohibit the sponsor of a clinical in-
vestigation from continuing the investiga-
tion if—

“(I) the Secretary determines
that the investigation is intended to
support a biosimilar biological product
application; and

“(II) the sponsor has failed to
pay an initial or annual biosimilar bio-
logical product development fee for
the product as required under sub-
paragraph (A) or (B), or a reactiva-
tion fee for the product as required
under subparagraph (D).

“(iv) NO ACCEPTANCE OF BIOSIMILAR
BIOLOGICAL PRODUCT APPLICATIONS OR
SUPPLEMENTS.—If a person has failed to
pay an initial or annual biosimilar biologi-
cal product development fee as required under subparagraph (A) or (B), or a reactivation fee as required under subparagraph (D), any biosimilar biological product application or supplement submitted by that person shall be considered incomplete and shall not be accepted for filing by the Secretary until all such fees owed by such person have been paid.

“(F) LIMITS REGARDING BIOSIMILAR DEVELOPMENT PROGRAM FEES.—

“(i) No refunds.—The Secretary shall not refund any initial or annual biosimilar biological product development fee paid under subparagraph (A) or (B), or any reactivation fee paid under subparagraph (D).

“(ii) No waivers, exemptions, or reductions.—The Secretary shall not grant a waiver, exemption, or reduction of any initial or annual biosimilar biological product development fee due or payable under subparagraph (A) or (B), or any reactivation fee due or payable under subparagraph (D).
“(2) Biosimilar biological product application and supplement fee.—

“(A) In general.—Each person that submits, on or after October 1, 2012, a biosimilar biological product application or a supplement shall be subject to the following fees:

“(i) A fee for a biosimilar biological product application that is equal to—

“(I) the amount of the fee established under subsection (b)(1)(D) for a biosimilar biological product application; minus

“(II) the cumulative amount of fees paid, if any, under subparagraphs (A), (B), and (D) of paragraph (1) for the product that is the subject of the application.

“(ii) A fee for a biosimilar biological product application for which clinical data (other than comparative bioavailability studies) with respect to safety or effectiveness are not required, that is equal to—

“(I) half of the amount of the fee established under subsection (b)(1)(D)
for a biosimilar biological product application; minus

“(II) the cumulative amount of fees paid, if any, under subparagraphs (A), (B), and (D) of paragraph (1) for that product.

“(iii) A fee for a supplement for which clinical data (other than comparative bioavailability studies) with respect to safety or effectiveness are required, that is equal to half of the amount of the fee established under subsection (b)(1)(D) for a biosimilar biological product application.

“(B) REDUCTION IN FEES.—Notwithstanding section 404 of the Biosimilars User Fee Act of 2012, any person who pays a fee under subparagraph (A), (B), or (D) of paragraph (1) for a product before October 1, 2017, but submits a biosimilar biological product application for that product after such date, shall be entitled to the reduction of any biosimilar biological product application fees that may be assessed at the time when such biosimilar biological product application is submitted, by the cumulative amount of fees paid under subpara-
graphs (A), (B), and (D) of paragraph (1) for that product.

“(C) Payment due date.—Any fee required by subparagraph (A) shall be due upon submission of the application or supplement for which such fee applies.

“(D) Exception for previously filed application or supplement.—If a biosimilar biological product application or supplement was submitted by a person that paid the fee for such application or supplement, was accepted for filing, and was not approved or was withdrawn (without a waiver), the submission of a biosimilar biological product application or a supplement for the same product by the same person (or the person’s licensee, assignee, or successor) shall not be subject to a fee under subparagraph (A).

“(E) Refund of application fee if application refused for filing or withdrawn before filing.—The Secretary shall refund 75 percent of the fee paid under this paragraph for any application or supplement which is refused for filing or withdrawn without a waiver before filing.
“(F) Fees for applications previously refused for filing or withdrawn before filing.—A biosimilar biological product application or supplement that was submitted but was refused for filing, or was withdrawn before being accepted or refused for filing, shall be subject to the full fee under subparagraph (A) upon being resubmitted or filed over protest, unless the fee is waived under subsection (c).

“(3) Biosimilar biological product establishment fee.—

“(A) In general.—Except as provided in subparagraph (E), each person that is named as the applicant in a biosimilar biological product application shall be assessed an annual fee established under subsection (b)(1)(E) for each biosimilar biological product establishment that is listed in the approved biosimilar biological product application as an establishment that manufactures the biosimilar biological product named in such application.

“(B) Assessment in fiscal years.—The establishment fee shall be assessed in each fiscal year for which the biosimilar biological prod-
uct named in the application is assessed a fee under paragraph (4) unless the biosimilar biological product establishment listed in the application does not engage in the manufacture of the biosimilar biological product during such fiscal year.

“(C) DUE DATE.—The establishment fee for a fiscal year shall be due on the later of—

“(i) the first business day on or after October 1 of such fiscal year; or

“(ii) the first business day after the enactment of an appropriations Act providing for the collection and obligation of fees for such fiscal year under this section.

“(D) APPLICATION TO ESTABLISHMENT.—

“(i) Each biosimilar biological product establishment shall be assessed only one fee per biosimilar biological product establishment, notwithstanding the number of biosimilar biological products manufactured at the establishment, subject to clause (ii).

“(ii) In the event an establishment is listed in a biosimilar biological product application by more than one applicant, the
establishment fee for the fiscal year shall be divided equally and assessed among the applicants whose biosimilar biological products are manufactured by the establishment during the fiscal year and assessed biosimilar biological product fees under paragraph (4).

“(E) Exception for New Products.—

If, during the fiscal year, an applicant initiates or causes to be initiated the manufacture of a biosimilar biological product at an establishment listed in its biosimilar biological product application—

“(i) that did not manufacture the biosimilar biological product in the previous fiscal year; and

“(ii) for which the full biosimilar biological product establishment fee has been assessed in the fiscal year at a time before manufacture of the biosimilar biological product was begun,

the applicant shall not be assessed a share of the biosimilar biological product establishment fee for the fiscal year in which the manufacture of the product began.
“(4) Biosimilar biological product fee.—

“(A) In general.—Each person who is named as the applicant in a biosimilar biological product application shall pay for each such biosimilar biological product the annual fee established under subsection (b)(1)(F).

“(B) Due date.—The biosimilar biological product fee for a fiscal year shall be due on the later of—

“(i) the first business day on or after October 1 of each such year; or

“(ii) the first business day after the enactment of an appropriations Act providing for the collection and obligation of fees for such year under this section.

“(C) One fee per product per year.—The biosimilar biological product fee shall be paid only once for each product for each fiscal year.

“(b) Fee setting and amounts.—

“(1) In general.—Subject to paragraph (2), the Secretary shall, 60 days before the start of each fiscal year that begins after September 30, 2012, establish, for the next fiscal year, the fees under sub-
section (a). Except as provided in subsection (c), such fees shall be in the following amounts:

“(A) Initial biosimilar biological product development fee.—The initial biosimilar biological product development fee under subsection (a)(1)(A) for a fiscal year shall be equal to 10 percent of the amount established under section 736(c)(4) for a human drug application described in section 736(a)(1)(A)(i) for that fiscal year.

“(B) Annual biosimilar biological product development fee.—The annual biosimilar biological product development fee under subsection (a)(1)(B) for a fiscal year shall be equal to 10 percent of the amount established under section 736(c)(4) for a human drug application described in section 736(a)(1)(A)(i) for that fiscal year.

“(C) Reactivation fee.—The reactivation fee under subsection (a)(1)(D) for a fiscal year shall be equal to 20 percent of the amount of the fee established under section 736(c)(4) for a human drug application described in section 736(a)(1)(A)(i) for that fiscal year.
“(D) **Biosimilar biological product application fee.**—The biosimilar biological product application fee under subsection (a)(2) for a fiscal year shall be equal to the amount established under section 736(c)(4) for a human drug application described in section 736(a)(1)(A)(i) for that fiscal year.

“(E) **Biosimilar biological product establishment fee.**—The biosimilar biological product establishment fee under subsection (a)(3) for a fiscal year shall be equal to the amount established under section 736(c)(4) for a prescription drug establishment for that fiscal year.

“(F) **Biosimilar biological product fee.**—The biosimilar biological product fee under subsection (a)(4) for a fiscal year shall be equal to the amount established under section 736(c)(4) for a prescription drug product for that fiscal year.

“(2) **Limit.**—The total amount of fees charged for a fiscal year under this section may not exceed the total amount for such fiscal year of the costs of resources allocated for the process for the review of biosimilar biological product applications.
“(c) Application Fee Waiver for Small Business.—

“(1) Waiver of application fee.—The Secretary shall grant to a person who is named in a biosimilar biological product application a waiver from the application fee assessed to that person under subsection (a)(2)(A) for the first biosimilar biological product application that a small business or its affiliate submits to the Secretary for review. After a small business or its affiliate is granted such a waiver, the small business or its affiliate shall pay—

“(A) application fees for all subsequent biosimilar biological product applications submitted to the Secretary for review in the same manner as an entity that is not a small business; and

“(B) all supplement fees for all supplements to biosimilar biological product applications submitted to the Secretary for review in the same manner as an entity that is not a small business.

“(2) Considerations.—In determining whether to grant a waiver of a fee under paragraph (1), the Secretary shall consider only the circumstances
and assets of the applicant involved and any affiliate of the applicant.

“(3) SMALL BUSINESS DEFINED.—In this subsection, the term ‘small business’ means an entity that has fewer than 500 employees, including employees of affiliates, and does not have a drug product that has been approved under a human drug application (as defined in section 735) or a biosimilar biological product application (as defined in section 744G(4)) and introduced or delivered for introduction into interstate commerce.

“(d) EFFECT OF FAILURE TO PAY FEES.—A biosimilar biological product application or supplement submitted by a person subject to fees under subsection (a) shall be considered incomplete and shall not be accepted for filing by the Secretary until all fees owed by such person have been paid.

“(e) CREDITING AND AVAILABILITY OF FEES.—

“(1) IN GENERAL.—Subject to paragraph (2), fees authorized under subsection (a) shall be collected and available for obligation only to the extent and in the amount provided in advance in appropriations Acts. Such fees are authorized to remain available until expended. Such sums as may be necessary may be transferred from the Food and Drug Admin-
istration salaries and expenses appropriation account
without fiscal year limitation to such appropriation
account for salaries and expenses with such fiscal
year limitation. The sums transferred shall be available solely for the process for the review of bio-
similar biological product applications.

“(2) COLLECTIONS AND APPROPRIATION
ACTS.—

“(A) IN GENERAL.—Subject to subpara-
graphs (C) and (D), the fees authorized by this
section shall be collected and available in each
fiscal year in an amount not to exceed the
amount specified in appropriation Acts, or oth-
erwise made available for obligation for such
fiscal year.

“(B) USE OF FEES AND LIMITATION.—
The fees authorized by this section shall be available for a fiscal year beginning after fiscal
year 2012 to defray the costs of the process for the review of biosimilar biological product appli-
cations (including such costs for an additional
number of full-time equivalent positions in the
Department of Health and Human Services to be engaged in such process), only if the Sec-
retary allocates for such purpose an amount for
such fiscal year (excluding amounts from fees collected under this section) no less than $20,000,000, multiplied by the adjustment factor applicable to the fiscal year involved.

“(C) Fee Collection during First Program Year.—Until the date of enactment of an Act making appropriations through September 30, 2013, for the salaries and expenses account of the Food and Drug Administration, fees authorized by this section for fiscal year 2013 may be collected and shall be credited to such account and remain available until expended.

“(D) Provision for Early Payments in Subsequent Years.—Payment of fees authorized under this section for a fiscal year (after fiscal year 2013), prior to the due date for such fees, may be accepted by the Secretary in accordance with authority provided in advance in a prior year appropriations Act.

“(3) Authorization of Appropriations.—For each of fiscal years 2013 through 2017, there is authorized to be appropriated for fees under this section an amount equivalent to the total amount of fees assessed for such fiscal year under this section.
“(f) Collection of Unpaid Fees.—In any case where the Secretary does not receive payment of a fee assessed under subsection (a) within 30 days after it is due, such fee shall be treated as a claim of the United States Government subject to subchapter II of chapter 37 of title 31, United States Code.

“(g) Written Requests for Waivers and Refunds.—To qualify for consideration for a waiver under subsection (c), or for a refund of any fee collected in accordance with subsection (a)(2)(A), a person shall submit to the Secretary a written request for such waiver or refund not later than 180 days after such fee is due.

“(h) Construction.—This section may not be construed to require that the number of full-time equivalent positions in the Department of Health and Human Services, for officers, employers, and advisory committees not engaged in the process of the review of biosimilar biological product applications, be reduced to offset the number of officers, employees, and advisory committees so engaged.”.

SEC. 403. REAUTHORIZATION; REPORTING REQUIREMENTS.

Part 8 of subchapter C of chapter VII, as added by section 402, is further amended by inserting after section 744H the following:
SEC. 744I. REAUTHORIZATION; REPORTING REQUIREMENTS.

“(a) Performance Report.—Beginning with fiscal year 2013, not later than 120 days after the end of each fiscal year for which fees are collected under this part, the Secretary shall prepare and submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate a report concerning the progress of the Food and Drug Administration in achieving the goals identified in the letters described in section 401(b) of the Biosimilar User Fee Act of 2012 during such fiscal year and the future plans of the Food and Drug Administration for meeting such goals. The report for a fiscal year shall include information on all previous cohorts for which the Secretary has not given a complete response on all biosimilar biological product applications and supplements in the cohort.

“(b) Fiscal Report.—Not later than 120 days after the end of fiscal year 2013 and each subsequent fiscal year for which fees are collected under this part, the Secretary shall prepare and submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate a report on the implementation of the authority for such fees during such fiscal year and the use, by the
Food and Drug Administration, of the fees collected for such fiscal year.

"(c) Public Availability.—The Secretary shall make the reports required under subsections (a) and (b) available to the public on the Internet Web site of the Food and Drug Administration.

"(d) Study.—

"(1) In General.—The Secretary shall contract with an independent accounting or consulting firm to study the workload volume and full costs associated with the process for the review of biosimilar biological product applications.

"(2) Interim Results.—Not later than June 1, 2015, the Secretary shall publish, for public comment, interim results of the study described under paragraph (1).

"(3) Final Results.—Not later than September 30, 2016, the Secretary shall publish, for public comment, the final results of the study described under paragraph (1).

"(e) Reauthorization.—

"(1) Consultation.—In developing recommendations to present to the Congress with respect to the goals described in subsection (a), and plans for meeting the goals, for the process for the
review of biosimilar biological product applications for the first 5 fiscal years after fiscal year 2017, and for the reauthorization of this part for such fiscal years, the Secretary shall consult with—

“(A) the Committee on Energy and Commerce of the House of Representatives;

“(B) the Committee on Health, Education, Labor, and Pensions of the Senate;

“(C) scientific and academic experts;

“(D) health care professionals;

“(E) representatives of patient and consumer advocacy groups; and

“(F) the regulated industry.

“(2) PUBLIC REVIEW OF RECOMMENDATIONS.—After negotiations with the regulated industry, the Secretary shall—

“(A) present the recommendations developed under paragraph (1) to the congressional committees specified in such paragraph;

“(B) publish such recommendations in the Federal Register;

“(C) provide for a period of 30 days for the public to provide written comments on such recommendations;
“(D) hold a meeting at which the public may present its views on such recommendations; and

“(E) after consideration of such public views and comments, revise such recommendations as necessary.

“(3) TRANSMITTAL OF RECOMMENDATIONS.—Not later than January 15, 2017, the Secretary shall transmit to the Congress the revised recommendations under paragraph (2), a summary of the views and comments received under such paragraph, and any changes made to the recommendations in response to such views and comments.”.

SEC. 404. SUNSET DATES.

(a) AUTHORIZATION.—The amendment made by section 402 shall cease to be effective October 1, 2017.

(b) REPORTING REQUIREMENTS.—The amendment made by section 403 shall cease to be effective January 31, 2018.

SEC. 405. EFFECTIVE DATE.

(a) IN GENERAL.—Except as provided under subsection (b), the amendments made by this title shall take effect on the later of—

(1) October 1, 2012; or

(2) the date of the enactment of this title.
(b) EXCEPTION.—Fees under part 8 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act, as added by this title, shall be assessed for all biologic similar biological product applications received on or after October 1, 2012, regardless of the date of the enactment of this title.

SEC. 406. SAVINGS CLAUSE.

Notwithstanding the amendments made by this title, part 2 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act, as in effect on the day before the date of the enactment of this title, shall continue to be in effect with respect to human drug applications and supplements (as defined in such part as of such day) that were accepted by the Food and Drug Administration for filing on or after October 1, 2007, but before October 1, 2012, with respect to assessing and collecting any fee required by such part for a fiscal year prior to fiscal year 2013.

SEC. 407. CONFORMING AMENDMENT.

Section 735(1)(B) (21 U.S.C. 379g(1)(B)) is amended by striking “or (k)”.

S 2516 PCS
TITLE V—PEDIATRIC DRUGS AND DEVICES

SEC. 501. PERMANENCE.

(a) Pediatric Studies of Drugs.—Subsection (q) of section 505A (21 U.S.C. 355a) is amended—

(1) in the subsection heading, by striking “SUNSET” and inserting “PERMANENCE”;

(2) in paragraph (1), by striking “on or before October 1, 2012,”; and

(3) in paragraph (2), by striking “on or before October 1, 2012,“.

(b) Research Into Pediatric Uses for Drugs and Biological Products.—Section 505B (21 U.S.C. 355c) is amended—

(1) by striking subsection (m); and

(2) by redesignating subsection (n) as subsection (m).

SEC. 502. WRITTEN REQUESTS.

(a) Federal Food, Drug, and Cosmetic Act.—

Subsection (h) of section 505A (21 U.S.C. 355a) is amended to read as follows:

“(h) Relationship to Pediatric Research Requirements.—Exclusivity under this section shall only be granted for the completion of a study or studies that are the subject of a written request and for which reports are
submitted and accepted in accordance with subsection (d)(3). Written requests under this section may consist of a study or studies required under section 505B.”.

(b) Public Health Service Act.—Section 351(m)(1) of the Public Health Service Act (42 U.S.C. 262(m)(1)) is amended by striking “(f), (i), (j), (k), (l), (p), and (q)” and inserting “(f), (h), (i), (j), (k), (l), (n), and (p)”.

SEC. 503. COMMUNICATION WITH PEDIATRIC REVIEW COMMITTEE.

Not later than 1 year after the date of enactment of this Act, the Secretary of Health and Human Services (referred to in this title as the “Secretary”) shall issue internal standard operating procedures that provide for the review by the internal review committee established under section 505C of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355d) of any significant modifications to initial pediatric study plans, agreed initial pediatric study plans, and written requests under sections 505A and 505B of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355e). Such internal standard operating procedures shall be made publicly available on the Internet website of the Food and Drug Administration.
SEC. 504. ACCESS TO DATA.

Not later than 3 years after the date of enactment of this Act, the Secretary shall make available to the public, including through posting on the Internet website of the Food and Drug Administration, the medical, statistical, and clinical pharmacology reviews of, and corresponding written requests issued to an applicant, sponsor, or holder for, pediatric studies submitted between January 4, 2002 and September 27, 2007 under subsection (b) or (c) of section 505A of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355a) for which 6 months of market exclusivity was granted and that resulted in a labeling change. The Secretary shall make public the information described in the preceding sentence in a manner consistent with how the Secretary releases information under section 505A(k) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355a(k)).

SEC. 505. ENSURING THE COMPLETION OF PEDIATRIC STUDIES.

(a) EXTENSION OF DEADLINE FOR DEFERRED STUDIES.—Section 505B (21 U.S.C. 355c) is amended—

(1) in subsection (a)(3)—

(A) by redesignating subparagraph (B) as subparagraph (C);

(B) by inserting after subparagraph (A) the following:
“(B) DEFERRAL EXTENSION.—

“(i) IN GENERAL.—On the initiative of the Secretary or at the request of the applicant, the Secretary may grant an extension of a deferral approved under subparagraph (A) for submission of some or all assessments required under paragraph (1) if—

“(I) the Secretary determines that the conditions described in subclause (II) or (III) of subparagraph (A)(i) continue to be met; and

“(II) the applicant submits a new timeline under subparagraph (A)(ii)(IV) and any significant updates to the information required under subparagraph (A)(ii).

“(ii) TIMING AND INFORMATION.—If the deferral extension under this subparagraph is requested by the applicant, the applicant shall submit the deferral extension request containing the information described in this subparagraph not less than 90 days prior to the date that the deferral would expire. The Secretary shall respond
to such request not later than 45 days after the receipt of such letter. If the Secretary grants such an extension, the specified date shall be the extended date. The sponsor of the required assessment under paragraph (1) shall not be issued a letter described in subsection (d) unless the specified or extended date of submission for such required studies has passed or if the request for an extension is pending. For a deferral that has expired prior to the date of enactment of the Food and Drug Administration Safety and Innovation Act or that will expire prior to 270 days after the date of enactment of such Act, a deferral extension shall be requested by an applicant not later than 180 days after the date of enactment of such Act. The Secretary shall respond to any such request as soon as practicable, but not later than 1 year after the date of enactment of such Act. Nothing in this clause shall prevent the Secretary from updating the status of a study or studies publicly if components of
such study or studies are late or delayed.”;
and
(C) in subparagraph (C), as so redesignated—
(i) in clause (i), by adding at the end
the following:
“(III) Projected completion date
for pediatric studies.
“(IV) The reason or reasons why
a deferral or deferral extension con-
tinues to be necessary.”; and
(ii) in clause (ii)—
(I) by inserting “, as well as the
date of each deferral or deferral ex-
tension, as applicable,” after “clause
(i)”; and
(II) by inserting “not later than
90 days after submission to the Sec-
retary or with the next routine quar-
terly update” after “Administration”; 
and
(2) in subsection (f)—
(A) in the subsection heading, by inserting
“DEFERRAL EXTENSIONS,” after “DEFER-
RALS,”;
(B) in paragraph (1), by inserting “, deferral extension,” after “deferral”; and

(C) in paragraph (4)—

(i) in the paragraph heading, by inserting “DEFERRAL EXTENSIONS,” after “DEFERRALS,”; and

(ii) by inserting “, deferral extensions,” after “deferrals”.

(b) TRACKING OF EXTENSIONS; ANNUAL INFORMATION.—Section 505B(f)(6)(D) (21 U.S.C. 355c(f)(6)(D)) is amended to read as follows:

“(D) aggregated on an annual basis—

“(i) the total number of deferrals and deferral extensions requested and granted under this section and, if granted, the reasons for each such deferral or deferral extension;

“(ii) the timeline for completion of the assessments; and

“(iii) the number of assessments completed and pending;”.

(c) ACTION ON FAILURE TO COMPLETE STUDIES.—

(1) ISSUANCE OF LETTER.—Subsection (d) of section 505B (21 U.S.C. 355e) is amended to read as follows:
“(d) Submission of Assessments.—If a person fails to submit a required assessment described in subsection (a)(2), fails to meet the applicable requirements in subsection (a)(3), or fails to submit a request for approval of a pediatric formulation described in subsection (a) or (b), in accordance with applicable provisions of subsections (a) and (b), the following shall apply:

“(1) Beginning 270 days after the date of enactment of the Food and Drug Administration Safety and Innovation Act, the Secretary shall issue a non-compliance letter to such person informing them of such failure to submit or meet the requirements of the applicable subsection. Such letter shall require the person to respond in writing within 45 calendar days of issuance of such letter. Such response may include the person’s request for a deferral extension if applicable. Such letter and the person’s written response to such letter shall be made publicly available on the Internet Web site of the Food and Drug Administration 45 calendar days after issuance, with redactions for any trade secrets and confidential commercial information. If the Secretary determines that the letter was issued in error, the requirements of this paragraph shall not apply.
“(2) The drug or biological product that is the subject of an assessment described in subsection (a)(2), applicable requirements in subsection (a)(3), or request for approval of a pediatric formulation, may be considered misbranded solely because of that failure and subject to relevant enforcement action (except that the drug or biological product shall not be subject to action under section 303), but such failure shall not be the basis for a proceeding—

“(A) to withdraw approval for a drug under section 505(e); or

“(B) to revoke the license for a biological product under section 351 of the Public Health Service Act.”.

(2) TRACKING OF LETTERS ISSUED.—Subparagraph (D) of section 505B(f)(6) (21 U.S.C. 355c(f)(6)), as amended by subsection (b), is further amended—

(A) in clause (ii), by striking “; and” and inserting a semicolon;

(B) in clause (iii), by adding “and” at the end; and

(C) by adding at the end the following:

“(iv) the number of postmarket non-compliance letters issued pursuant to sub-
section (d), and the recipients of such letters.”.

SEC. 506. PEDIATRIC STUDY PLANS.

(a) In General.—Subsection (e) of section 505B (21 U.S.C. 355e) is amended to read as follows:

“(e) PEDIATRIC STUDY PLANS.—

“(1) In General.—An applicant subject to subsection (a) shall submit to the Secretary an initial pediatric study plan prior to the submission of the assessments described under subsection (a)(2).

“(2) Timing; content; meeting.—

“(A) Timing.—An applicant shall submit an initial pediatric study plan to the Secretary not later than 60 calendar days after the date of the end of phase II meeting or such other equivalent time agreed upon between the Secretary and the applicant. Nothing in this paragraph shall preclude the Secretary from accepting the submission of an initial pediatric study plan earlier than the date described under the preceding sentence.

“(B) Content of initial plan.—The initial pediatric study plan shall include—

“(i) an outline of the pediatric study or studies that the applicant plans to con-
duct (including, to the extent practicable
study objectives and design, age groups,
relevant endpoints, and statistical ap-
proach);

“(ii) any request for a deferral, partial
waiver, or waiver under this section, if ap-
licable, along with any supporting infor-
mination; and

“(iii) other information specified in
the regulations promulgated under para-
graph (4).

“(C) MEETING.—The Secretary—

“(i) shall meet with the applicant to
discuss the initial pediatric study plan as
soon as practicable, but not later than 90
calendar days after the receipt of such plan
under subparagraph (A);

“(ii) may determine that a written re-
sponse to the initial pediatric study plan is
sufficient to communicate comments on the
initial pediatric study plan, and that no
meeting is necessary; and

“(iii) if the Secretary determines that
no meeting is necessary, shall so notify the
applicant and provide written comments of
the Secretary as soon as practicable, but not later than 90 calendar days after the receipt of the initial pediatric study plan.

“(3) AGREED INITIAL PEDIATRIC STUDY PLAN.—Not later than 90 calendar days following the meeting under paragraph (2)(C)(i) or the receipt of a written response from the Secretary under paragraph (2)(C)(iii), the applicant shall document agreement on the initial pediatric study plan in a submission to the Secretary marked ‘Agreed Initial Pediatric Study Plan’, and the Secretary shall confirm such agreement to the applicant in writing not later than 30 calendar days of receipt of such agreed initial pediatric study plan.

“(4) DEFERRAL AND WAIVER.—If the agreed initial pediatric study plan contains a request from the applicant for a deferral, partial waiver, or waiver under this section, the written confirmation under paragraph (3) shall include a recommendation from the Secretary as to whether such request meets the standards under paragraphs (3) or (4) of subsection (a).

“(5) AMENDMENTS TO THE PLAN.—At the initiative of the Secretary or the applicant, the agreed initial pediatric study plan may be amended at any
time. The requirements of paragraph (2)(C) shall apply to any such proposed amendment in the same manner and to the same extent as such requirements apply to an initial pediatric study plan under paragraph (1). The requirements of paragraphs (3) and (4) shall apply to any agreement resulting from such proposed amendment in the same manner and to the same extent as such requirements apply to an agreed initial pediatric study plan.

“(6) INTERNAL COMMITTEE.—The Secretary shall consult the internal committee under section 505C on the review of the initial pediatric study plan, agreed initial pediatric plan, and any significant amendments to such plans.

“(7) REQUIRED RULEMAKING.—Not later than 1 year after the date of enactment of the Food and Drug Administration Safety and Innovation Act, the Secretary shall promulgate proposed regulations and issue proposed guidance to implement the provisions of this subsection.”.

(b) CONFORMING AMENDMENTS.—Section 505B (21 U.S.C. 355c) is amended—

(1) by amending subclause (II) of subsection (a)(3)(A)(ii) to read as follows:
“(II) a pediatric study plan as described in subsection (e);” and

(2) in subsection (f)—

(A) in the subsection heading, by striking “PEDIATRIC PLANS,” and inserting “PEDIATRIC STUDY PLANS,”;

(B) in paragraph (1), by striking “all pediatric plans” and inserting “initial pediatric study plans, agreed initial pediatric study plans,”; and

(C) in paragraph (4)—

(i) in the paragraph heading, by striking “PEDIATRIC PLANS,” and inserting “PEDIATRIC STUDY PLANS,”; and

(ii) by striking “pediatric plans” and inserting “initial pediatric study plans, agreed initial pediatric study plans,”.

(c) EFFECTIVE DATES.—

(1) PEDIATRIC STUDY PLANS.—Subsection (e) of section 505B of the Federal Food, Drug, and Cosmetic Act (other than paragraph (4) of such subsection), as amended by subsection (a), shall take effect 180 days after the date of enactment of this Act, without regard to whether the Secretary has
promulgated final regulations under paragraph (4) of such subsection by such date.

(2) CONFORMING AMENDMENTS.—The amendments made by subsection (b) shall take effect 180 days after the date of enactment of this Act.

SEC. 507. REAUTHORIZATIONS.

(a) PEDIATRIC ADVISORY COMMITTEE.—Section 14(d) of the Best Pharmaceuticals for Children Act (42 U.S.C. 284m note) is amended by striking “Notwithstanding section 14 of the Federal Advisory Committee Act, the advisory committee shall continue to operate during the five-year period beginning on the date of the enactment of the Best Pharmaceuticals for Children Act of 2007” and inserting “Section 14 of the Federal Advisory Committee Act shall not apply to the advisory committee”.

(b) PEDIATRIC SUBCOMMITTEE OF THE ONCOLOGIC DRUGS ADVISORY COMMITTEE.—Section 15(a)(3) of the Best Pharmaceuticals for Children Act (42 U.S.C. 284m note) is amended by striking “during the five-year period beginning on the date of the enactment of the Best Pharmaceuticals for Children Act of 2007” and inserting “for the duration of the operation of the Oncologic Drugs Advisory Committee”.

(c) HUMANITARIAN DEVICE EXEMPTION EXTENSION.—Section 520(m)(6)(A)(iv) of the Federal Food,

(d) **Demonstration Grants to Improve Pediatric Device Availability.**—Section 305(e) of Pediatric Medical Device Safety and Improvement Act (Public Law 110–85; 42 U.S.C. 282 note)) is amended by striking “$6,000,000 for each of fiscal years 2008 through 2012” and inserting “$4,500,000 for each of fiscal years 2013 through 2017”.

(e) **Program for Pediatric Study of Drugs in PHSA.**—Section 409I(e)(1)(B) of the Public Health Service Act (42 U.S.C. 284m((e)(1)(B)) is amended by striking “of the four succeeding fiscal years” and inserting “succeeding fiscal year”.

**SEC. 508. REPORT.**

(a) **In General.**—Not later than October 31, 2016, and at the end of each subsequent 5-year period, the Secretary shall submit to Congress a report that evaluates the effectiveness of sections 505A and 505B of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355a, 355e) and section 409I of the Public Health Service Act (42 U.S.C. 284m) in ensuring that medicines used by children are tested in pediatric populations and properly labeled for use in children.
(b) CONTENTS.—The report under subsection (a) shall include—

(1) the number and importance of drugs and biological products for children for which studies have been requested or required (as of the date of such report) under 505A and 505B of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355a, 355c) and section 409I of the Public Health Service Act (42 U.S.C. 284m), including—

(A) the number of labeling changes made to drugs and biological products pursuant to such sections since the date of enactment of this Act; and

(B) the importance of such drugs and biological products in the improvement of the health of children;

(2) the number of required studies under such section 505B that have not met the initial deadline provided under such section, including—

(A) the number of deferrals and deferral extensions granted and the reasons such extensions were granted;

(B) the number of waivers and partial waivers granted; and
(C) the number of letters issued under subsection (d) of such section 505B;

(3) the number of written requests issued, declined, and referred to the National Institutes of Health under such section 505A since the date of enactment of this Act (including the reasons for such declination), and a description and status of referrals made under subsection (n) of such section 505A;

(4) the number of proposed pediatric study plans submitted and agreed to as identified in the marketing application under such section 505B;

(5) any labeling changes recommended by the Pediatric Advisory Committee as a result of the review by such Committee of adverse events reports;

(6) the number and current status of pediatric postmarketing requirements;

(7) the number and importance of drugs and biological products for children that are not being tested for use in pediatric populations, notwithstanding the existence of the programs under such sections 505A and 505B and section 409I of the Public Health Service Act;

(8) the possible reasons for the lack of testing reported under paragraph (7);
(9) the number of drugs and biological products for which testing is being done (as of the date of the report) and for which a labeling change is required under the programs described in paragraph (7), including—

(A) the date labeling changes are made;

(B) which labeling changes required the use of the dispute resolution process; and

(C) for labeling changes that required such dispute resolution process, a description of—

(i) the disputes;

(ii) the recommendations of the Pediatric Advisory Committee; and

(iii) the outcomes of such process; and

(D) an assessment of the effectiveness in improving information about pediatric uses of drugs and biological products;

(10)(A) the efforts made by the Secretary to increase the number of studies conducted in the neonatal population (including efforts made to encourage the conduct of appropriate studies in neonates by companies with products that have sufficient safety and other information to make the conduct of the studies ethical and safe); and

(B) the results of such efforts;
(11)(A) the number and importance of drugs and biological products for children with cancer that are being tested as a result of the programs described in paragraph (7); and

(B) any recommendations for modifications to such programs that would lead to new and better therapies for children with cancer, including a detailed rationale for each recommendation;

(12) an assessment of progress made in addressing the recommendations and findings of any prior report issued by the Comptroller General, the Institute of Medicine, or the Secretary regarding the topics addressed in the report under this section, including with respect to—

(A) improving public access to information from pediatric studies conducted under such sections 505A and 505B; and

(B) improving the timeliness of pediatric studies and pediatric study planning under such sections 505A and 505B;

(13) any recommendations for modification to the programs that would improve pediatric drug research and increase pediatric labeling of drugs and biological products; and
(14) an assessment of the successes of and limitations to studying drugs for rare diseases under such sections 505A and 505B.

(c) Consultation on Recommendations.—At least 180 days before the report is due under subsection (a), and no sooner than 4 years after the date of enactment of this Act, the Secretary shall consult with representatives of patient groups, including pediatric patient groups, consumer groups, regulated industry, scientific and medical communities, academia, and other interested parties to obtain any recommendations or information relevant to the effectiveness of the programs described in subsection (b)(7), including suggestions for modifications to such programs.

SEC. 509. TECHNICAL AMENDMENTS.

(a) Pediatric Studies of Drugs in FFDCA.—Section 505A (21 U.S.C. 355a) is amended—

(1) in subsection (k)(2), by striking "subsection (f)(3)(F)" and inserting "subsection (f)(6)(F)";

(2) in subsection (n)—

(A) in the subsection heading, by striking "COMPLETED" and inserting "SUBMITTED";

and

(B) in paragraph (1)—
(i) in the matter preceding subparagraph (A), by striking “have not been completed” and inserting “have not been submitted by the date specified in the written request issued or if the applicant or holder does not agree to the request”;

(ii) in subparagraph (A)—

(I) in the first sentence, by inserting “, or for which a period of exclusivity eligible for extension under subsection (b)(1) or (c)(1) of this section or under subsection (m)(2) or (m)(3) of section 351 of the Public Health Service Act has not ended” after “expired”; and

(II) by striking “Prior to” and all that follows through the period at the end; and

(iii) in subparagraph (B), by striking “no listed patents or has 1 or more listed patents that have expired,” and inserting “no unexpired listed patents and for which no unexpired periods of exclusivity eligible for extension under subsection (b)(1) or (c)(1) of this section or under subsection
(m)(2) or (m)(3) of section 351 of the Public Health Service Act apply,”; and

(3) in subsection (o)(2), by amendment subparagraph (B) to read as follows:

“(B) a statement of any appropriate pediatric contraindications, warnings, precautions, or other information that the Secretary considers necessary to assure safe use.”.

(b) Research Into Pediatric Uses for Drugs and Biological Projects in FFDCA.—Section 505B (21 U.S.C. 355e) is amended—

(1) in subsection (a)—

(A) in paragraph (1)—

(i) in the matter preceding subparagraph (A), by inserting “for a drug” after “(or supplement to an application)”;

(ii) in subparagraph (A), by striking “for a” and inserting “, including, with respect to a drug, an application (or supplement to an application) for a”;

(iii) in subparagraph (B), by striking “for a” and inserting “, including, with respect to a drug, an application (or supplement to an application) for a”; and
(iv) in the matter following subpara-

graph (B), by inserting “(or supplement)”
after “application”; and

(B) in paragraph (4)(C)—

(i) in the first sentence, by inserting
“partial” before “waiver is granted”; and

(ii) in the second sentence, by striking
“either a full or” and inserting “such a”;

(2) in subsection (b)(1), in the matter pre-
ceeding subparagraph (A), by striking “After pro-
viding notice” and all that follows through “studies),
the” and inserting “The”;

(3) in subsection (g)—

(A) in paragraph (1)(A), by inserting
“that receives a priority review or 330 days
after the date of the submission of an applica-
tion or supplement that receives a standard re-
view” after “after the date of the submission of
the application or supplement”; and

(B) in paragraph (2), by striking “the
label of such product” and inserting “the label-
ing of such product”; and

(4) in subsection (h)(1)—
(A) by inserting “an application (or supplement to an application) that contains” after “date of submission of”; and

(B) by inserting “, if the application (or supplement) receives a priority review, or not later than 330 days after the date of submission of an application (or supplement to an application) that contains a pediatric assessment under this section, if the application (or supplement) receives a standard review,” after “under this section,”.

(c) INTERNAL REVIEW COMMITTEE.—The heading of section 505C (21 U.S.C. 355d) is amended by inserting “AND DEFERRAL EXTENSIONS” after “DEFERRALS”.

(d) PROGRAM FOR PEDIATRIC STUDIES OF DRUGS.—Section 409I(c) of the Public Health Service Act (42 U.S.C. 284m(c)) is amended—

(1) in paragraph (1)—

(A) in the matter preceding subparagraph (A), by inserting “or section 351(m) of this Act,” after “Cosmetic Act,”;

(B) in subparagraph (A)(i), by inserting “or section 351(k) of this Act” after “Cosmetic Act”; and
(C) by amending subparagraph (B) to read as follows:

“(B) there remains no patent listed pursuant to section 505(b)(1) of the Federal Food, Drug, and Cosmetic Act, and every three-year and five-year period referred to in subsection (c)(3)(E)(ii), (c)(3)(E)(iii), (c)(3)(E)(iv), (j)(5)(F)(ii), (j)(5)(F)(iii), or (j)(5)(F)(iv) of section 505 of the Federal Food, Drug, and Cosmetic Act, or applicable twelve-year period referred to in section 351(k)(7) of this Act, and any seven-year period referred to in section 527 of the Federal Food, Drug, and Cosmetic Act has ended for at least one form of the drug; and

(2) in paragraph (2)—

(A) in the paragraph heading, by striking “FOR DRUGS LACKING EXCLUSIVITY”; and

(B) by striking “under section 505 of the Federal Food, Drug, and Cosmetic Act”; and

(C) by striking “505A of such Act” and inserting “505A of the Federal Food, Drug, and Cosmetic Act or section 351(m) of this Act”.

(e) Pediatric Subcommittee of the Oncologic Advisory Committee.—Section 15(a) of the Best Pharmaceuticals for Children Act (Public Law 107–109), as amended by section 502(e) of the Food and Drug Administration Amendments Act of 2007 (Public Law 110–85), is amended in paragraph (1)(D), by striking “section 505B(f)” and inserting “‘section 505C’”.

(f) Foundation of National Institutes of Health.—Section 499(c)(1)(C) of the Public Health Service Act (42 U.S.C. 290b(c)(1)(C)) is amended by striking “for which the Secretary issues a certification in the affirmative under section 505A(n)(1)(A) of the Federal Food, Drug, and Cosmetic Act”.

(g) Application.—Notwithstanding any provision of section 505A and 505B of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355a, 355e) stating that a provision applies beginning on the date of the enactment of the Best Pharmaceuticals for Children Act of 2007 or the date of the enactment of the Pediatric Research Equity Act of 2007, any amendment made by this title to such a provision applies beginning on the date of the enactment of this Act.
SEC. 510. RELATIONSHIP BETWEEN PEDIATRIC LABELING
AND NEW CLINICAL INVESTIGATION EXCLUSIVITY.

(a) In General.—Section 505 (21 U.S.C. 351) is amended by adding at the end the following:

“(w) RELATIONSHIP BETWEEN PEDIATRIC LABELING AND NEW CLINICAL INVESTIGATION EXCLUSIVITY.—

The period of market exclusivity described in clauses (iii) and (iv) of subsection (c)(3)(E) and clauses (iii) and (iv) of subsection (j)(5)(F) shall not apply to a pediatric study conducted under section 505A or 505B that results, pursuant to section 505B(g)(2), in the inclusion in the labeling of the product a determination that the product is not indicated for use in pediatric populations or subpopulations or information indicating that the results of a study were inconclusive or did not demonstrate that the product is safe or effective in pediatric populations or subpopulations.”.

(b) Pediatric Studies of Drugs.—Section 505A(m) (21 U.S.C. 355a(m)) is amended—

(1) by striking ““(m) CLARIFICATION OF INTERACTION OF MARKET EXCLUSIVITY UNDER THIS SECTION AND MARKET EXCLUSIVITY AWARDED TO AN APPLICANT FOR APPROVAL OF A DRUG UNDER SECTION 505(j).—If a” and all that follows through
the end of the matter that precedes paragraph (1) and inserting the following:

“(m) Clarification of Interaction of Market Exclusivity Under This Section and Market Exclusivity Awarded to An Application or Supplement Under Subsection (c) or (J) of Section 505.—

“(1) 180-day exclusivity period.—If a 180-day period under section 505(j)(5)(B)(iv) overlaps with a 6-month exclusivity period under this section, so that the applicant for approval of a drug under section 505(j) entitled to the 180-day period under that section loses a portion of the 180-day period to which the applicant is entitled for the drug, the 180-day period shall be extended from—”;

(2) by redesignating paragraphs (1) and (2) as subparagraphs (A) and (B) and moving such subparagraphs, as so redesignated, 2 ems to the right; and

(3) by adding at the end the following:

“(2) 3-year exclusivity period.—The 3-year period of exclusivity under clauses (iii) and (iv) of subsection 505(c)(3)(E) and clauses (iii) and (iv) of subsection 505(j)(5)(F) are not available for approval of applications or supplements to applications based on reports of pediatric studies conducted
under sections 505A or 505B that resulted, pursuant to section 505A(j) or 505B(g)(2), in the inclusion in the labeling of the product a determination that the product is not indicated for use in pediatric populations or subpopulations or information indicating that the results of an assessment were inconclusive or did not demonstrate that the product is safe or effective in pediatric populations or subpopulation.”.

(c) PROMPT APPROVAL OF DRUGS.—Section 505A(o) (21 U.S.C. 355a(o)) is amended—

(1) in the heading, by striking “SECTION 505(J)” and inserting “SUBSECTIONS (C) AND (J) OF SECTION 505”;

(2) in paragraph (1), by striking “under section 505(j)” and inserting “under subsection (b)(2), (e), or (j) of section 505”;

(3) in paragraph (2), in the matter preceding subparagraph (A), by inserting “clauses (iii) and (iv) of section 505(e)(3)(E) or” after “Notwithstanding”; and

(4) in paragraph (3)—

(A) in subparagraph (B), by inserting “that differ from adult formulations” before the semicolon at the end; and
(B) in subparagraph (C)—

(i) by striking “under section 505(j)” and inserting “under subsection (c) or (j) of section 505”; and

(ii) by inserting “clauses (iii) or (iv) of section 505(c)(3)(E) or” after “exclusivity under”.

TITLE VI—MEDICAL DEVICE REGULATORY IMPROVEMENTS

SEC. 601. RECLASSIFICATION PROCEDURES.

(a) Classification Changes.—

(1) In general.—Section 513(e)(1) (21 U.S.C. 360e(e)(1)) is amended to read as follows:

“(e)(1)(A) Based on new information respecting a device, the Secretary may, upon the initiative of the Secretary or upon petition of an interested person, change the classification of such device, and revoke, on account of the change in classification, any regulation or requirement in effect under section 514 or 515 with respect to such device, by administrative order published in the Federal Register following publication of a proposed reclassification order in the Federal Register, a meeting of a device classification panel described in subsection (b), and consideration of comments to a public docket, notwith-
United States Code. An order under this subsection changing the classification of a device from class III to class II may provide that such classification shall not take effect until the effective date of a performance standard established under section 514 for such device.

“(B) Authority to issue such administrative order shall not be delegated below the Commissioner. The Commissioner shall issue such an order as proposed by the Director of the Center for Devices and Radiological Health unless the Commissioner, in consultation with the Office of the Secretary of Health and Human Services, concludes that the order exceeds the legal authority of the Food and Drug Administration or that the order would be lawful, but unlikely to advance the public health.”

(2) **TECHNICAL AND CONFORMING AMENDMENTS.**—

(A) Section 513(e)(2) (21 U.S.C. 360c(e)(2)) is amended by striking “regulation promulgated” and inserting “an order issued”.

(B) Section 514(a)(1) (21 U.S.C. 360d(a)(1)) is amended by striking “under a regulation under section 513(e) but such regulation” and inserting “under an administrative order under section 513(e) (or a regulation promulgated under such section prior to the date
of enactment of the Food and Drug Administration Safety and Innovation Act) but such order (or regulation)”;

(C) Section 517(a)(1) (21 U.S.C. 360g(a)(1)) is amended by striking “or changing the classification of a device to class I” and inserting “, an administrative order changing the classification of a device to class I,”.

(3) Devices reclassified prior to the date of enactment of this Act.—

(A) In general.—The amendments made by this subsection shall have no effect on a regulation promulgated with respect to the classification of a device under section 513(e) of the Federal Food, Drug, and Cosmetic Act prior to the date of enactment of this Act.

(B) Applicability of other provisions.—In the case of a device reclassified under section 513(e) of the Federal Food, Drug, and Cosmetic Act by regulation prior to the date of enactment of this Act, section 517(a)(1) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360g(a)(1)) shall apply to such regulation promulgated under section 513(e) of such Act with respect to such device.
in the same manner such section 517(a)(1) applies to an administrative order issued with respect to a device reclassified after the date of enactment of this Act.

(b) Devices Marketed Before May 28, 1976.—

(1) Premarket Approval.—Section 515 (21 U.S.C. 360e) is amended—

(A) in subsection (a), by striking “regulation promulgated under subsection (b)” and inserting “an order issued under subsection (b) (or a regulation promulgated under such subsection prior to the date of enactment of the Food and Drug Administration Safety and Innovation Act)”;

(B) in subsection (b)—

(i) in paragraph (1)—

(I) in the heading, by striking “Regulation” and inserting “Order”;

and

(II) in the matter following subparagraph (B)—

(aa) by striking “by regulation, promulgated in accordance with this subsection” and inserting “by administrative order fol-
lowing publication of a proposed
order in the Federal Register, a
meeting of a device classification
panel described in section 513(b),
and consideration of comments
from all affected stakeholders, in-
cluding patients, payors, and pro-
viders, notwithstanding sub-
chapter II of chapter 5 of title 5,
United States Code”; and

(bb) by adding at the end
the following:

“Authority to issue such administrative order shall not be
delegated below the Commissioner. Before publishing such
administrative order, the Commissioner shall consult with
the Office of the Secretary. The Commissioner shall issue
such an order as proposed by the Director of the Center
for Devices and Radiological Health unless the Commis-
sioner, in consultation with the Office of the Secretary,
concludes that the order exceeds the legal authority of the
Food and Drug Administration or that the order would
be lawful, but unlikely to advance the public health.”;

(ii) in paragraph (2)—
(I) by striking subparagraph (B); and

(II) in subparagraph (A)—

(aa) by striking “(2)(A) A proceeding for the promulgation of a regulation under paragraph (1) respecting a device shall be initiated by the publication in the Federal Register of a notice of proposed rulemaking. Such notice shall contain—” and inserting “(2) A proposed order required under paragraph (1) shall contain—”;

(bb) by redesignating clauses (i) through (iv) as subparagraphs (A) through (D), respectively;

(cc) in subparagraph (A), as so redesignated, by striking “regulation” and inserting “order”; and

(dd) in subparagraph (C), as so redesignated, by striking “regulation” and inserting “order”;
(iii) in paragraph (3)—

(I) by striking “proposed regulation” each place such term appears and inserting “proposed order”;

(II) by striking “paragraph (2) and after” and inserting “paragraph (2),”;

(III) by inserting “and a meeting of a device classification panel described in section 513(b),” after “such proposed regulation and findings,”;

(IV) by striking “(A) promulgate such regulation” and inserting “(A) issue an administrative order under paragraph (1)”;

(V) by striking “paragraph (2)(A)(ii)” and inserting “paragraph (2)(B)”;

(VI) by striking “promulgation of the regulation” and inserting “issuance of the administrative order”; and

(iv) by striking paragraph (4); and

(C) in subsection (i)—

(i) in paragraph (2)—
(I) in the matter preceding subparagraph (A)—

(aa) by striking “December 1, 1995” and inserting “the date that is 2 years after the date of enactment of the Food and Drug Administration Safety and Innovation Act”; and

(bb) by striking “publish a regulation in the Federal Register” and inserting “issue an administrative order following publication of a proposed order in the Federal Register, a meeting of a device classification panel described in section 513(b), and consideration of comments from all affected stakeholders, including patients, payors, and providers, notwithstanding subchapter II of chapter 5 of title 5, United States Code,”;

(II) in subparagraph (B), by striking “final regulation has been promulgated under section 515(b)”
and inserting “administrative order
has been issued under subsection (b)
(or no regulation has been promul-
gated under such subsection prior to
the date of enactment of the Food
and Drug Administration Safety and
Innovation Act)”;

(III) in the matter following sub-
paragraph (B), by striking “regula-
tion requires” and inserting “adminis-
trative order issued under this para-
graph requires”; and

(IV) by striking the third and
fourth sentences; and

(ii) in paragraph (3)—

(I) by striking “regulation requir-
ing” each place such term appears
and inserting “order requiring”; and

(II) by striking “promulgation of
a section 515(b) regulation” and in-
serting “issuance of an administrative
order under subsection (b)”.

(2) TECHNICAL AND CONFORMING AMEND-
MENTS.—Section 501(f) (21 U.S.C. 351(f)) is
amended—
(A) in subparagraph (1)(A)—

(i) in subclause (i), by striking “a regulation promulgated” and inserting “an order issued”; and

(ii) in subclause (ii), by striking “promulgation of such regulation” and inserting “issuance of such order”;

(B) in subparagraph (2)(B)—

(i) by striking “a regulation promulgated” and inserting “an order issued”; and

(ii) by striking “promulgation of such regulation” and inserting “issuance of such order”; and

(C) by adding at the end the following:

“(3) In the case of a device with respect to which a regulation was promulgated under section 515(b) prior to the date of enactment of the Food and Drug Administration Safety and Innovation Act, a reference in this subsection to an order issued under section 515(b) shall be deemed to include such regulation.”.

(3) APPROVAL BY REGULATION PRIOR TO THE DATE OF ENACTMENT OF THIS ACT.—The amendments made by this subsection shall have no effect on a regulation that was promulgated prior to the
date of enactment of this Act requiring that a device
have an approval under section 515 of the Federal
Food, Drug, and Cosmetic Act (21 U.S.C. 360e) of
an application for premarket approval.

(c) REPORTING.—The Secretary of Health and
Human Services shall annually post on the Internet web
site of the Food and Drug Administration—

(1) the number and type of class I and class II
devices reclassified as class II or class III in the pre-
vious calendar year under section 513(e)(1) of the
360e(e)(1));

(2) the number and type of class II and class
III devices reclassified as class I or class II in the
previous calendar year under such section 513(e)(1);
and

(3) the number and type of devices reclassified
in the previous calendar year under section 515 of
the Federal Food, Drug, and Cosmetic Act (21

SEC. 602. CONDITION OF APPROVAL STUDIES.

Section 515(d)(1)(B)(ii) (21 U.S.C.
360e(d)(1)(B)(ii)) is amended—

(1) by striking “(ii)” and inserting “(ii)(I)”;
and
(2) by adding at the end the following:

“(II) An order approving an application for a device may require as a condition to such approval that the applicant conduct a postmarket study regarding the device.”.

SEC. 603. POSTMARKET SURVEILLANCE.

Section 522 (21 U.S.C. 360l) is amended—

(1) in subsection (a)(1)(A), in the matter preceding clause (i), by inserting “, at the time of approval or clearance of a device or at any time thereafter,” after “by order”; and

(2) in subsection (b)(1), by inserting “The manufacturer shall commence surveillance under this section not later than 15 months after the day on which the Secretary issues an order under this section.” after the second sentence.

SEC. 604. SENTINEL.

Section 519 (21 U.S.C. 360i) is amended by adding at the end the following:

“(h) INCLUSION OF DEVICES IN THE POSTMARKET RISK IDENTIFICATION AND ANALYSIS SYSTEM.—

“(1) IN GENERAL.—

“(A) APPLICATION TO DEVICES.—The Secretary shall amend the procedures established and maintained under clauses (i), (ii), (iii), and (v) of section 505(k)(3)(C) in order to expand
the postmarket risk identification and analysis
system established under such section to include
and apply to devices.

“(B) EXCEPTION.—Subclause (II) of
clause (i) of section 505(k)(3)(C) shall not
apply to devices.

“(C) CLARIFICATION.—With respect to de-
vices, the private sector health-related electronic
data provided under section
505(k)(3)(C)(i)(III)(bb) may include medical
device utilization data, health insurance claims
data, and procedure and device registries.

“(2) DATA.—In expanding the system as de-
scribed in paragraph (1)(A), the Secretary shall use
relevant data with respect to devices cleared under
section 510(k) or approved under section 515, in-
cluding claims data, patient survey data, and any
other data deemed appropriate by the Secretary.

“(3) STAKEHOLDER INPUT.—To help ensure ef-
fective implementation of the system described in
paragraph (1)(A), the Secretary shall engage outside
stakeholders in development of the system through a
public hearing, advisory committee meeting, public
docket, or other like public measures, as appro-
priate.
“(4) VOLUNTARY SURVEYS.—Chapter 35 of title 44, United States Code, shall not apply to the collection of voluntary information from health care providers, such as voluntary surveys or questionnaires, initiated by the Secretary for purposes of postmarket risk identification for devices.”

SEC. 605. RECALLS.

(a) ASSESSMENT OF DEVICE RECALL INFORMATION.—

(1) IN GENERAL.—

(A) ASSESSMENT PROGRAM.—The Secretary of Health and Human Services (referred to in this section as the “Secretary”) shall enhance the Food and Drug Administration’s recall program to routinely and systematically assess—

(i) information submitted to the Secretary pursuant to a device recall order under section 518(e) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360h(e)); and

(ii) information required to be reported to the Secretary regarding a correction or removal of a device under section 519(g) of such Act (21 U.S.C. 360i(g)).
(B) Use.—The Secretary shall use the assessment of information described under sub-
paragraph (A) to proactively identify strategies for mitigating health risks presented by defec-
tive or unsafe devices.

(2) Design.—The program under paragraph (1) shall, at a minimum, identify—

(A) trends in the numbers and types of device recalls;

(B) the types of devices in each device class that are most frequently recalled;

(C) the causes of device recalls; and

(D) any other information as the Secretary determines appropriate.

(b) Audit Check Procedures.—The Secretary shall clarify procedures for conducting device recall audit checks to improve the ability of investigators to perform these checks in a consistent manner.

(c) Assessment Criteria.—The Secretary shall de-
velop explicit criteria for assessing whether a person sub-
ject to a recall order under section 518(e) of the Federal
Food, Drug, and Cosmetic Act (21 U.S.C. 360h(e)) or to a requirement under section 519(g) of such Act (21 U.S.C. 360i(g)) has performed an effective recall under
• such section 518(e) or an effective correction or removal action under such section 519(g), respectively.
(d) TERMINATION OF RECALLS.—The Secretary shall document the basis for the termination by the Food and Drug Administration of—

(1) an individual device recall ordered under section 518(e) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360h(e)); and

(2) any correction or removal action for which a report is required to be submitted to the Secretary under section 519(g) of such Act (21 U.S.C. 360i(g)).

SEC. 606. CLINICAL HOLDS ON INVESTIGATIONAL DEVICE EXEMPTIONS.

Section 520(g) (21 U.S.C. 360j(g)) is amended by adding at the end the following:

“(8)(A) At any time, the Secretary may prohibit the sponsor of an investigation from conducting the investigation (referred to in this paragraph as a ‘clinical hold’) if the Secretary makes a determination described in subparagraph (B). The Secretary shall specify the basis for the clinical hold, including the specific information available to the Secretary which served as the basis for such clinical hold, and confirm such determination in writing.
“(B) For purposes of subparagraph (A), a determination described in this subparagraph with respect to a clinical hold is a determination that—

“(i) the device involved represents an unreasonable risk to the safety of the persons who are the subjects of the clinical investigation, taking into account the qualifications of the clinical investigators, information about the device, the design of the clinical investigation, the condition for which the device is to be investigated, and the health status of the subjects involved; or

“(ii) the clinical hold should be issued for such other reasons as the Secretary may by regulation establish.

“(C) Any written request to the Secretary from the sponsor of an investigation that a clinical hold be removed shall receive a decision, in writing and specifying the reasons therefor, within 30 days after receipt of such request. Any such request shall include sufficient information to support the removal of such clinical hold.”.

SEC. 607. UNIQUE DEVICE IDENTIFIER.

Section 519(f) (21 U.S.C. 360i(f)) is amended—

(1) by striking “The Secretary shall promulgate” and inserting “Not later than December 31, 2012, the Secretary shall issue proposed”; and
(2) by adding at the end the following: “The Secretary shall finalize the proposed regulations not later than 6 months after the close of the comment period and shall implement the final regulations with respect to devices that are implantable, life-saving, and life sustaining not later than 2 years after the regulations are finalized.”.

SEC. 608. CLARIFICATION OF LEAST BURDENSOME STANDARD.


(1) by redesignating clause (iii) as clause (v); and

(2) by inserting after clause (ii) the following:

“(iii) For purposes of clause (ii), the term ‘necessary’ means the minimum required information that would support a determination by the Secretary that an application provides reasonable assurance of the effectiveness of the device.

“(iv) Nothing in this subparagraph shall alter the criteria for evaluating an application for premarket approval of a device.”.

(b) Premarket Notification Under Section 510(k).—Section 513(i)(1)(D) (21 U.S.C. 360e(i)(1)(D)) is amended—
(1) by striking “(D) Whenever” and inserting
“(D)(i) Whenever”; and
(2) by adding at the end the following:
“(ii) For purposes of clause (i), the term ‘necessary’
means the minimum required information that would sup-
port a determination of substantial equivalence between
a new device and a predicate device.
“(iii) Nothing in this subparagraph shall alter the
standard for determining substantial equivalence between
a new device and a predicate device.”.

SEC. 609. CUSTOM DEVICES.

Section 520(b) (21 U.S.C. 360j(b)) is amended to
read as follows:
“(b) CUSTOM DEVICES.—
“(1) IN GENERAL.—The requirements of sec-
tions 514 and 515 shall not apply to a device that—
“(A) is created or modified in order to
comply with the order of an individual physician
or dentist (or any other specially qualified per-
son designated under regulations promulgated
by the Secretary after an opportunity for an
oral hearing);
“(B) in order to comply with an order de-
scribed in subparagraph (A), necessarily devi-
ates from an otherwise applicable performance
standard under section 514 or requirement
under section 515;

“(C) is not generally available in the
United States in finished form through labeling
or advertising by the manufacturer, importer,
or distributor for commercial distribution;

“(D) is designed to treat a unique pathol-
ogy or physiological condition that no other de-
vice is domestically available to treat;

“(E)(i) is intended to meet the special
needs of such physician or dentist (or other spe-
cially qualified person so designated) in the
course of the professional practice of such phy-
sician or dentist (or other specially qualified
person so designated); or

“(ii) is intended for use by an individual
patient named in such order of such physician
or dentist (or other specially qualified person so
designated);

“(F) is assembled from components or
manufactured and finished on a case-by-case
basis to accommodate the unique needs de-
scribed in clause (i) or (ii) of subparagraph (E); and
“(G) may have common, standardized design characteristics, chemical and material compositions, and manufacturing processes as commercially distributed devices.

“(2) LIMITATIONS.—Paragraph (1) shall apply to a device only if—

“(A) such device is for the purpose of treating a sufficiently rare condition, such that conducting clinical investigations on such device would be impractical; and

“(B) production of such device under paragraph (1) is limited to no more than 5 units per year of a particular device type, provided that such replication otherwise complies with this section.

“(3) EXCEPTION.—Paragraph (1) shall not apply to oral facial devices.

“(4) GUIDANCE.—Not later than 2 years after the date of enactment of this section, the Secretary shall issue final guidance on replication of multiple devices described in paragraph (2)(B).

“(5) NOTIFICATION TO THE SECRETARY.—The manufacturer of a device created or modified as described in paragraph (1) shall notify the Secretary,
in a manner prescribed by the Secretary, of the
manufacture of such device.”.

SEC. 610. AGENCY DOCUMENTATION AND REVIEW OF CERTAIN DECISIONS REGARDING DEVICES.

Chapter V (21 U.S.C. 351 et seq.) is amended by inserting after section 517 the following:

“SEC. 517A. AGENCY DOCUMENTATION AND REVIEW OF CERTAIN DECISIONS REGARDING DEVICES.

“(a) DOCUMENTATION OF RATIONALE FOR DENIAL.—If the Secretary renders a final decision to deny clearance of a premarket notification under section 510(k) or approval of a premarket application under section 515, or when the Secretary disapproves an application for an investigational exemption under 520(g), the written correspondence to the applicant communicating that decision shall provide a substantive summary of the scientific and regulatory rationale for the decision.

“(b) REVIEW OF DENIAL.—

“(1) IN GENERAL.—A person who has submitted a report under section 510(k), an application under section 515, or an application for an exemption under section 520(g) and for whom clearance of the report or approval of the application is denied may request a supervisory review of the decision to deny such clearance or approval. Such review shall
be conducted by an individual at the organizational level above the organization level at which the decision to deny the clearance of the report or approval of the application is made.

“(2) Submission of request.—A person requesting a supervisory review under paragraph (1) shall submit such request to the Secretary not later than 30 days after such denial and shall indicate in the request whether such person seeks an in-person meeting or a teleconference review.

“(3) Timeframe.—

“(A) In general.—Except as provided in subparagraph (B), the Secretary shall schedule an in-person or teleconference review, if so requested, not later than 30 days after such request is made. The Secretary shall issue a decision to the person requesting a review under this subsection not later than 45 days after the request is made under paragraph (1), or, in the case of a person who requests an in-person meeting or teleconference, 30 days after such meeting or teleconference.

“(B) Exception.—Subparagraph (A) shall not apply in cases that involve consultation with experts outside of the Food and Drug
Administration, or in cases in which the sponsor seeks to introduce evidence not already in the administrative record at the time the denial decision was made.”.

SEC. 611. GOOD GUIDANCE PRACTICES RELATING TO DEVICES.

Subparagraph (C) of section 701(h)(1) (21 U.S.C. 371(h)(1)) is amended—

(1) by striking “(C) For guidance documents” and inserting “(C)(i) For guidance documents”; and

(2) by adding at the end the following:

“(ii) With respect to devices, if a notice to industry guidance letter, a notice to industry advisory letter, or any similar notice sets forth initial interpretations of a regulation or policy or sets forth changes in interpretation or policy, such notice shall be treated as a guidance document for purposes of this subparagraph.”.

SEC. 612. MODIFICATION OF DE NOVO APPLICATION PROCESS.

(a) In general.—Section 513(f)(2) (21 U.S.C. 360c(f)(2)) is amended—

(1) by redesignating subparagraphs (B) and (C) as subparagraphs (C) and (D), respectively;
(2) by amending subparagraph (A) to read as follows:

“(A) In the case of a type of device that has not previously been classified under this Act, a person may do one of the following:

“(i) Submit a report under section 510(k), and, if the device is classified into class III under paragraph (1), such person may request, not later than 30 days after receiving written notice of such a classification, the Secretary to classify the device under the criteria set forth in subparagraphs (A) through (C) of subsection (a)(1). The person may, in the request, recommend to the Secretary a classification for the device. Any such request shall describe the device and provide detailed information and reasons for the recommended classification.

“(ii) Submit a request for initial classification of the device under this subparagraph, if the person declares that there is no legally marketed device upon which to base a substantial equivalence determination as that term is defined in subsection (i). Subject to subparagraph (B), the Secretary shall classify the device under the criteria set forth in subparagraphs (A) through (C) of subsection (a)(1). The person submitting the request for classification
under this subparagraph may recommend to the Secretary a classification for the device and shall, if recommending classification in class II, include in the request an initial draft proposal for applicable special controls, as described in subsection (a)(1)(B), that are necessary, in conjunction with general controls, to provide reasonable assurance of safety and effectiveness and a description of how the special controls provide such assurance. Requests under this clause shall be subject to the electronic copy requirements of section 745A(b).”;

(3) by inserting after subparagraph (A) the following:

“(B) The Secretary may decline to undertake a classification request submitted under clause (2)(A)(ii) if the Secretary identifies a legally marketed device that could provide a reasonable basis for review of substantial equivalence under paragraph (1), or when the Secretary determines that the device submitted is not of low-moderate risk or that general controls would be inadequate to control the risks and special controls to mitigate the risks cannot be developed.”; and

(4) in subparagraph (C), as so redesignated—

(A) in clause (i), by striking “Not later than 60 days after the date of the submission
of the request under subparagraph (A),’’ and inserting ‘‘Not later than 120 days after the date of the submission of the request under subparagraph (A)(i) or 150 days after the date of the submission of the request under subparagraph (A)(ii),’’; and

(B) in clause (ii), by inserting ‘‘or is classified in’’ after ‘‘remains in’’.

(b) GAO REPORT.—Not later than 2 years after the date of enactment of this Act, the Comptroller General of the United States shall complete a study and submit to Congress a report on the effectiveness of the review pathway under section 513(f)(2)(A) of the Federal Food, Drug, and Cosmetic Act, as amended by this Act.

(c) CONFORMING AMENDMENT.—Section 513(f)(1)(B) (21 U.S.C. 360c(f)(1)(B)) is amended by inserting ‘‘a request under paragraph (2) or’’ after ‘‘response to’’.

SEC. 613. HUMANITARIAN DEVICE EXEMPTIONS.

(a) IN GENERAL.—Section 520(m) (21 U.S.C. 360j(m)) is amended—

(1) in paragraph (6)—

(A) in subparagraph (A)—
(i) in the matter preceding clause (i),
by striking “subparagraph (D)” and insert-
ing “subparagraph (C)”;

(ii) by striking clause (i) and inserting
the following:

“(i) The device with respect to which the ex-
emption is granted—

“(I) is intended for the treatment or diag-
nosis of a disease or condition that occurs in
pediatric patients or in a pediatric subpopu-
lation, and such device is labeled for use in pedi-
atriic patients or in a pediatric subpopulation in
which the disease or condition occurs; or

“(II) is intended for the treatment or diag-
nosis of a disease or condition that does not
occur in pediatric patients or that occurs in pe-
diatric patients in such numbers that the devel-
opment of the device for such patients is impos-
sible, highly impracticable, or unsafe.”; and

(iii) by striking clause (ii) and insert-
ing the following:

“(ii) During any calendar year, the number of
such devices distributed during that year under each
exemption granted under this subsection does not
exceed the number of such devices needed to treat,
diagnose, or cure a population of 4,000 individuals in the United States (referred to in this paragraph as the ‘annual distribution number’).”;

(B) by striking subparagraph (C);

(C) by redesignating subparagraphs (D) and (E) as subparagraphs (C) and (D), respectively; and

(D) in subparagraph (C), as so redesignated, by striking “and modified under subparagraph (C), if applicable,”;

(2) in paragraph (7), by striking “regarding a device” and inserting “regarding a device described in paragraph (6)(A)(i)(I)”;

(3) in paragraph (8), by striking “of all devices described in paragraph (6)” and inserting “of all devices described in paragraph (6)(A)(i)(I)”.

(b) APPLICABILITY TO EXISTING DEVICES.—A sponsor of a device for which an exemption was approved under paragraph (2) of section 520(m) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360j(m)) before the date of enactment of this Act may seek a determination under subclause (I) or (II) of section 520(m)(6)(A)(i) (as amended by subsection (a)). If the Secretary determines that such subclause (I) or (II) applies with respect to a device, clauses (ii), (iii), and (iv) of subparagraph (A) and
subparagraphs (B), (C), and (D) of paragraph (6) of such section 520(m) shall apply to such device.

(c) REPORT.—Not later than January 1, 2017, the Comptroller General of the United States shall submit to Congress a report that evaluates and describes—

(1) the effectiveness of the amendments made by subsection (a) in stimulating innovation with respect to medical devices, including any favorable or adverse impact on pediatric device development;

(2) the impact of such amendments on pediatric device approvals for devices that received a humanitarian use designation under section 520(m) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360j(m)) prior to the date of enactment of this Act;

(3) the status of public and private insurance coverage of devices granted an exemption under paragraph (2) of such section 520(m) (as amended by subsection (a)) and costs to patients of such devices;

(4) the impact that paragraph (4) of such section 520(m) has had on access to and insurance coverage of devices granted an exemption under paragraph (2) of such section 520(m); and
(5) the effect of the amendments made by sub-
section (a) on patients described in such section 520(m).

SEC. 614. REAUTHORIZATION OF THIRD-PARTY REVIEW AND INSPECTIONS.

(a) THIRD PARTY REVIEW.—Section 523(c) (21 U.S.C. 360m(c)) is amended by striking “2012” and inser-
ting “2017”.

(b) THIRD PARTY INSPECTIONS.—Section 704(g)(11) (21 U.S.C. 374(g)(11)) is amended by striking “2012” and inser-
ting “2017”.

SEC. 615. 510(K) DEVICE MODIFICATIONS.

Having acknowledged to Congress potential unin-
tended consequences that may result from the implemen-
tation of the Food and Drug Administration guidance ent-
titled “Guidance for Industry and FDA Staff—510(k) De-
vice Modifications: Deciding When to Submit a 510(k) for a Change to an Existing Device”, the Secretary of Health and Human Services shall withdraw such guidance promptly and ensure that, before any future guidance doc-
ument on this issue is made final, affected stakeholders are provided with an opportunity to comment.
TITLE VII—DRUG SUPPLY CHAIN

SEC. 701. REGISTRATION OF DOMESTIC DRUG ESTABLISHMENTS.

Section 510 (21 U.S.C. 360) is amended—

(1) in subsection (b)—

(A) in paragraph (1), by striking “On or before” and all that follows through the period at the end and inserting the following: “During the period beginning on October 1 and ending on December 31 of each year, every person who owns or operates any establishment in any State engaged in the manufacture, preparation, propagation, compounding, or processing of a drug or drugs shall register with the Secretary—

“(A) the name of such person, places of business of such person, all such establishments, the unique facility identifier of each such establishment, and a point of contact e-mail address; and

“(B) the name and place of business of each drug importer that takes physical possession of a drug (other than an excipient), with which the person conducts business, including all establishments of each such drug importer, the unique facility identifier of each such establishment, and a point of con-
tact e-mail address for each such drug importer.”;

and

(B) by adding at the end the following:

“(3) The Secretary may specify the unique facility
identifier system that shall be used by registrants under
paragraph (1).”; and

(2) in subsection (e), by striking “with the Sec-
retary his name, place of business, and such estab-
lishment” and inserting “with the Secretary—

“(1) with respect to drugs, the information de-
scribed under subsection (b)(1); and

“(2) with respect to devices, the information de-
scribed under subsection (b)(2).”.

SEC. 702. REGISTRATION OF FOREIGN ESTABLISHMENTS.

(a) Enforcement of Registration of Foreign
Estabiliements.—Section 502(o) (21 U.S.C. 352(o)) is
amended by striking “in any State”.

(b) Registration of Foreign Drug Estabiliements.—Section 510(i) (U.S.C. 360(i)) is amended—

(1) in paragraph (1)—

(A) by amending the matter preceding sub-
paragraph (A) to read as follows: “Every per-
son who owns or operates any establishment
within any foreign country engaged in the man-
ufacture, preparation, propagation,
compounding, or processing of a drug or device
that is imported or offered for import into the
United States shall, through electronic means
in accordance with the criteria of the Sec-
retary—'';

(B) by amending subparagraph (A) to read
as follows:

"(A) upon first engaging in any such activity,
immediately submit a registration to the Secretary
that includes—

"(i) with respect to drugs, the name and
place of business of such person, all such estab-
ishments, the unique facility identifier of each
such establishment, a point of contact e-mail
address, the name of the United States agent of
each such establishment, the name and place of
business of each drug importer with which such
person conducts business, including all estab-
ishments of each such drug importer, the
unique facility identifier of each such establish-
ment, and a point of contact e-mail address for
each such drug importer; and

"(ii) with respect to devices, the name and
place of business of the establishment, the name
of the United States agent for the establish-
ment, the name of each importer of such device
in the United States that is known to the estab-
lishment, and the name of each person who im-
ports or offers for import such device to the
United States for purposes of importation;
and”; and

(C) by amending subparagraph (B) to read
as follows:
“(B) each establishment subject to the require-
ments of subparagraph (A) shall thereafter register
with the Secretary during the period beginning on
October 1 and ending on December 31 of each
year.”; and

(2) by adding at the end the following:
“(4) The Secretary may specify the unique facility
identifier system that shall be used by registrants under
paragraph (1) with respect to drugs.”.

SEC. 703. IDENTIFICATION OF DRUG EXCIPIENT INFORMA-
TION WITH PRODUCT LISTING.

Section 510(j)(1) (21 U.S.C. 360(j)(1)) is amend-
ed—

(1) in subparagraph (C), by striking “; and”
and inserting a semicolon;

(2) in subparagraph (D), by striking the period
at the end and inserting “; and”; and
(3) by adding at the end the following:

“(E) in the case of a drug contained in the applicable list and subject to section 505 or 512, the name and place of business of each manufacturer of an excipient of the listed drug with which the person listing the drug conducts business, including all establishments used in the production of such excipient, the unique facility identifier of each such establishment, and a point of contact e-mail address for each such excipient manufacturer.”.

SEC. 704. ELECTRONIC SYSTEM FOR REGISTRATION AND LISTING.

Section 510(p) (21 U.S.C. 360(p)) is amended—

(1) by striking “(p) Registrations and listings” and inserting the following:

“(p) ELECTRONIC REGISTRATION AND LISTING.—

“(1) IN GENERAL.—Registration and listing”;

and

(2) by adding at the end the following:

“(2) ELECTRONIC DATABASE.—Not later than 2 years after the Secretary specifies a unique facility identifier system under subsections (b) and (i), the Secretary shall maintain an electronic database, which shall not be subject to inspection under sub-
section (f), populated with the information submitted as described under paragraph (1) that—

“(A) enables personnel of the Food and Drug Administration to search the database by any field of information submitted in a registration described under paragraph (1), or combination of such fields; and

“(B) uses the unique facility identifier system to link with other relevant databases within the Food and Drug Administration, including the database for submission of information under section 801(r).

“(3) Risk-based information and coordination.—The Secretary shall ensure the accuracy and coordination of relevant Food and Drug Administration databases in order to identify and inform risk-based inspections under section 510(h).”.

SEC. 705. RISK-BASED INSPECTION FREQUENCY.

Section 510(h) (21 U.S.C. 360(h)) is amended to read as follows:

“(h) Inspections.—

“(1) In general.—Every establishment that is required to be registered with the Secretary under this section shall be subject to inspection pursuant to section 704.
“(2) Biennial inspections for devices.— Every establishment described in paragraph (1) that is engaged in the manufacture, propagation, compounding, or processing of a device or devices classified in class II or III shall be so inspected by one or more officers or employees duly designated by the Secretary, or by persons accredited to conduct inspections under section 704(g), at least once in the 2-year period beginning with the date of registration of such establishment pursuant to this section and at least once in every successive 2-year period thereafter.

“(3) Risk-based schedule for drugs.—The Secretary, acting through one or more officers or employees duly designated by the Secretary, shall inspect establishments described in paragraph (1) that are engaged in the manufacture, preparation, propagation, compounding, or processing of a drug or drugs (referred to in this subsection as ‘drug establishments’) in accordance with a risk-based schedule established by the Secretary.

“(4) Risk factors.—In establishing the risk-based schedule under paragraph (3), the Secretary shall inspect establishments according to the known
safety risks of such establishments, which shall be based on the following factors:

“(A) The compliance history of the establishment.

“(B) The record, history, and nature of recalls linked to the establishment.

“(C) The inherent risk of the drug manufactured, prepared, propagated, compounded, or processed at the establishment.

“(D) The certifications described under sections 801(r) and 809 for the establishment.

“(E) Whether the establishment has been inspected in the preceding 4-year period.

“(F) Any other criteria deemed necessary and appropriate by the Secretary for purposes of allocating inspection resources.

“(5) Effect of Status.—In determining the risk associated with an establishment for purposes of establishing a risk-based schedule under paragraph (3), the Secretary shall not consider whether the drugs manufactured, prepared, propagated, compounded, or processed by such establishment are drugs described in section 503(b).

“(6) Annual Report on Inspections of Establishments.—Not later than February 1 of each
year, the Secretary shall submit a report to Congress regarding—

“(A)(i) the number of domestic and foreign establishments registered pursuant to this section in the previous fiscal year; and

“(ii) the number of such domestic establishments and the number of such foreign establishments that the Secretary inspected in the previous fiscal year;

“(B) with respect to establishments that manufacture, prepare, propagate, compound, or process an active ingredient of a drug, a finished drug product, or an excipient of a drug, the number of each such type of establishment; and

“(C) the percentage of the budget of the Food and Drug Administration used to fund the inspections described under subparagraph (A).

“(7) PUBLIC AVAILABILITY OF ANNUAL REPORTS.—The Secretary shall make the report required under paragraph (6) available to the public on the Internet Web site of the Food and Drug Administration.”.
SEC. 706. RECORDS FOR INSPECTION.

Section 704(a) (21 U.S.C. 374(a)) is amended by adding at the end the following:

“(4)(A) Any records or other information that the Secretary is entitled to request under this section from a person that owns or operates an establishment that is engaged in the manufacture, preparation, propagation, compounding, or processing of a drug shall, upon the request of the Secretary, be provided to the Secretary by such person within a reasonable time frame, within reasonable limits and in a reasonable manner, and in electronic form, at the expense of such person. The Secretary’s request shall include a clear description of the records requested.

“(B) Upon receipt of the records requested under subparagraph (A), the Secretary shall provide to the person confirmation of the receipt of such records.

“(C) Nothing in this paragraph supplants the authority of the Secretary to conduct inspections otherwise permitted under this Act in order to ensure compliance by an establishment with this Act.”.

SEC. 707. FAILURE TO ALLOW FOREIGN INSPECTION.

Section 801(a) (21 U.S.C. 381(a)) is amended by adding at the end the following: “Notwithstanding any other provision of this subsection, the Secretary of Homeland Security shall, upon request from the Secretary of
Health and Human Services refuse to admit into the United States any article if the article was manufactured, prepared, propagated, compounded, processed, or held at an establishment that has refused to permit the Secretary of Health and Human Services to enter or inspect the establishment in the same manner and to the same extent as the Secretary may inspect establishments under section 704.”.

SEC. 708. EXCHANGE OF INFORMATION.

Section 708 (21 U.S.C. 379) is amended—

(1) by striking “CONFIDENTIAL INFORMATION” and all that follows through “The Secretary” and inserting “CONFIDENTIAL INFORMATION.

“(a) CONTRACTORS.—The Secretary”; and

(2) by adding at the end the following:

“(b) ABILITY TO RECEIVE AND PROTECT CONFIDENTIAL INFORMATION.—The Secretary shall not be required to disclose under section 552 of title 5, United States Code, or any other provision of law, any information relating to drugs obtained from a Federal, State or local government agency, or from a foreign government agency, if the agency has requested that the information be kept confidential, except pursuant to an order of a court of the United States. For purposes of section 552 of title 5,
United States Code, this subsection shall be considered a statute described in section 552(b)(3)(B).

“(c) Authority to Enter Into Memoranda of Understanding for Purposes of Information Exchange.—The Secretary may enter into written agreements regarding the exchange of information referenced in section 301(j) subject to the following criteria:

“(1) Certification.—The Secretary may only enter into written agreements under this subsection with foreign governments that the Secretary has certified as having the authority and demonstrated ability to protect trade secret information from disclosure. Responsibility for this certification shall not be delegated to any officer or employee other than the Commissioner.

“(2) Written Agreement.—The written agreement under this subsection shall include a commitment by the foreign government to protect information exchanged under this subsection from disclosure unless and until the sponsor gives written permission for disclosure or the Secretary makes a declaration of a public health emergency pursuant to section 319 of the Public Health Service Act that is relevant to the information.
“(3) INFORMATION EXCHANGE.—The Secretary may provide to a foreign government that has been certified under paragraph (1) and that has executed a written agreement under paragraph (2) information referenced in section 301(j) in the following circumstances:

“(A) Information concerning the inspection of a facility may be provided if—

“(i) the Secretary reasonably believes, or that the written agreement described in paragraph (2) establishes, that the government has authority to otherwise obtain such information; and

“(ii) the written agreement executed under paragraph (2) limits the recipient’s use of the information to the recipient’s civil regulatory purposes.

“(B) Information not described in subparagraph (A) may be provided as part of an investigation, or to alert the foreign government to the potential need for an investigation, if the Secretary has reasonable grounds to believe that a drug has a reasonable probability of causing serious adverse health consequences or death to humans or animals.
“(4) Effect of subsection.—Nothing in this subsection affects the ability of the Secretary to enter into any written agreement authorized by other provisions of law to share confidential information.”.

SEC. 709. ENHANCING THE SAFETY AND QUALITY OF THE DRUG SUPPLY.

Section 501 (21 U.S.C. 351) is amended by adding at the end the following flush text:

“For purposes of subsection (a)(2)(B), the term ‘current good manufacturing practice’ includes the implementation of oversight and controls over the manufacture of drugs to ensure quality, including managing the risk of and establishing the safety of raw materials, materials used in the manufacturing of drugs, and finished drug products.”.

SEC. 710. ACCREDITATION OF THIRD-PARTY AUDITORS FOR DRUG ESTABLISHMENTS.

(a) In General.—Chapter VIII (21 U.S.C. 381 et seq.) is amended by adding at the end the following:

“SEC. 809. ACCREDITATION OF THIRD-PARTY AUDITORS FOR DRUG ESTABLISHMENTS.

“(a) Definitions.—In this section:

“(1) Accreditation body.—The term ‘accreditation body’ means an authority that performs accreditation of third-party auditors.
“(2) ACCREDITED THIRD-PARTY AUDITOR.—
The term ‘accredited third-party auditor’ means a third-party auditor (which may be an individual) accredited by an accreditation body to conduct drug safety and quality audits.

“(3) AUDIT AGENT.—The term ‘audit agent’ means an individual who is an employee or agent of an accredited third-party auditor and, although not individually accredited, is qualified to conduct drug safety and quality audits on behalf of an accredited third-party auditor.

“(4) CONSULTATIVE AUDIT.—The term ‘consultative audit’ means an audit of an eligible entity intended for internal purposes only to determine whether an establishment is in compliance with the provisions of this Act and applicable industry practices, or any other such service.

“(5) DRUG SAFETY AND QUALITY AUDIT.—The term ‘drug safety and quality audit’—

“(A) means an audit of an eligible entity to certify that the eligible entity meets the requirements of this Act applicable to drugs, including the requirements of section 501 with respect to drugs; and

“(B) is not a consultative audit.
“(6) ELIGIBLE ENTITY.—The term ‘eligible entity’ means an entity, including a foreign drug establishment registered under section 510(c), in the drug supply chain that chooses to be audited by an accredited third-party auditor or the audit agent of such accredited third-party auditor.

“(7) THIRD-PARTY AUDITOR.—The term ‘third-party auditor’ means a foreign government, agency of a foreign government or any other third party (which may be an individual), as the Secretary determines appropriate in accordance with the criteria described in subsection (c)(1), that is eligible to be considered for accreditation to conduct drug safety and quality audits.

“(b) ACCREDITATION SYSTEM.—

“(1) RECOGNITION OF ACCREDITATION BODIES.—

“(A) IN GENERAL.—Not later than 2 years after date of enactment of the Food and Drug Administration Safety and Innovation Act, the Secretary shall establish a system for the recognition of accreditation bodies that accredit third-party auditors to conduct drug safety and quality audits.

“(B) DIRECT ACCREDITATION.—
“(i) In general.—If, by the date that is 2 years after the date of establishment of the system described in subparagraph (A), the Secretary has not identified and recognized an accreditation body to meet the requirements of this section, the Secretary may directly accredit third-party auditors.

“(ii) Certain direct accreditations.—Notwithstanding subparagraph (A) or clause (i), the Secretary may directly accredit any foreign government or any agency of a foreign government as a third-party auditor at any time after the date of enactment of the Food and Drug Administration Safety and Innovation Act.

“(2) Notification.—Each accreditation body recognized by the Secretary shall submit to the Secretary—

“(A) a list of all accredited third-party auditors accredited by such body (including the name, contact information, and scope and duration of accreditation for each such auditor), and the audit agents of such auditors; and
“(B) updated lists as needed to ensure the list held by the Secretary is accurate.

“(3) Revocation of recognition as an accreditation body.—The Secretary shall promptly revoke, after the opportunity for an informal hearing, the recognition of any accreditation body found not to be in compliance with the requirements of this section.

“(4) Reinstatement.—The Secretary shall establish procedures to reinstate recognition of an accreditation body if the Secretary determines, based on evidence presented by such accreditation body, that revocation was inappropriate or that the body meets the requirements for recognition under this section.

“(5) Model accreditation standards.—

“(A) In general.—Not later than 18 months after the date of enactment of the Food and Drug Administration Safety and Innovation Act, the Secretary shall develop model standards, including standards for drug safety and quality audit results, reports, and certifications, and each recognized accreditation body shall ensure that third-party auditors and audit agents of such auditors meet such standards in
order to qualify such third-party auditors as accredited third-party auditors under this section.

“(B) CONTENT.—The standards developed under subparagraph (A) may—

“(i) include a description of required standards relating to the training procedures, competency, management responsibilities, quality control, and conflict of interest requirements of accredited third-party auditors; and

“(ii) set forth procedures for the periodic renewal of the accreditation of accredited third-party auditors.

“(C) REQUIREMENT TO PROVIDE RESULTS AND REPORTS TO THE SECRETARY.—An accreditation body (or, in the case of direct accreditation under subsection (b)(1)(B), the Secretary) may not accredit a third-party auditor unless such third-party auditor agrees to provide to the Secretary, upon request, the results and reports of any drug safety and quality audit conducted pursuant to the accreditation provided under this section.

“(6) DISCLOSURE.—The Secretary shall maintain on the Internet Web site of the Food and Drug
Administration a list of recognized accreditation bodies and accredited third-party auditors under this section.

“(c) ACCREDITED THIRD-PARTY AUDITORS.—

“(1) REQUIREMENTS FOR ACCREDITATION AS A THIRD-PARTY AUDITOR.—

“(A) FOREIGN GOVERNMENTS.—Prior to accrediting a foreign government or an agency of a foreign government as an accredited third-party auditor, the accreditation body (or, in the case of direct accreditation under subsection (b)(1)(B), the Secretary) shall perform such reviews and audits of drug safety programs, systems, and standards of the government or agency of the government as the Secretary deems necessary, including requirements under the standards developed under subsection (b)(5), to determine that the foreign government or agency of the foreign government is capable of adequately ensuring that eligible entities or drugs certified by such government or agency meet the requirements of this Act.

“(B) OTHER THIRD PARTIES.—Prior to accrediting any other third party to be an accredited third-party auditor, the accreditation
body (or, in the case of direct accreditation under subsection (b)(1)(B), the Secretary) shall perform such reviews and audits of the training and qualifications of audit agents used by that party and conduct such reviews of internal systems and such other investigation of the party as the Secretary deems necessary, including requirements under the standards developed under subsection (b)(5), to determine that the third-party auditor is capable of adequately ensuring that an eligible entity or drug certified by such third-party auditor meets the requirements of this Act.

“(2) USE OF AUDIT AGENTS.—An accredited third-party auditor may conduct drug safety and quality audits and may employ or use audit agents to conduct drug safety and quality audits, but must ensure that such audit agents comply with all requirements the Secretary deems necessary, including requirements under paragraph (1) and subsection (b)(5).

“(3) REVOCATION OF ACCREDITATION.—

“(A) IN GENERAL.—The Secretary shall promptly revoke, after the opportunity for an
informal hearing, the accreditation of an accredited third-party auditor—

“(i) if, following an evaluation, the Secretary finds that the accredited third-party auditor is not in compliance with the requirements of this section; or

“(ii) following a refusal to allow United States officials to conduct such audits and investigations as may be necessary to determine compliance with the requirements set forth in this section.

“(B) ADDITIONAL BASIS FOR REVOCATION OF ACCREDITATION.—The Secretary may revoke accreditation from an accredited third-party auditor in the case that such third-party auditor is accredited by an accreditation body for which recognition as an accreditation body under subsection (b)(3) is revoked, if the Secretary determines that there is good cause for the revocation of accreditation.

“(4) REACCREDITATION.—The Secretary shall establish procedures to reinstate the accreditation of a third-party auditor for which accreditation has been revoked under paragraph (3)—
“(A) if the Secretary determines, based on evidence presented, that—

“(i) the third-party auditor satisfies the requirements of this section; and

“(ii) adequate grounds for revocation no longer exist; and

“(B) in the case of a third-party auditor accredited by an accreditation body for which recognition as an accreditation body is revoked under subsection (b)(3)—

“(i) if the third-party auditor becomes accredited not later than 1 year after revocation of accreditation under paragraph (3), through direct accreditation under subsection (b)(1)(B), or by an accreditation body in good standing; or

“(ii) under such other conditions as the Secretary may require.

“(5) REQUIREMENT TO ISSUE CERTIFICATION OF ELIGIBLE ENTITIES FOR COMPLIANCE WITH CURRENT GOOD MANUFACTURING PRACTICE.—

“(A) IN GENERAL.—An accreditation body (or, in the case of direct accreditation under subsection (b)(1)(B), the Secretary) may not accredit a third-party auditor unless such third-
party auditor agrees to issue a written and, as
appropriate, electronic, document or certifi-
cation, as the Secretary may require under this
Act, regarding compliance with section 501.
The Secretary may consider any such document
or certification to satisfy requirements under
section 801(r) and to target inspection re-
sources under section 510(h).

“(B) REQUIREMENTS FOR ISSUING CER-
TIFICATION.—

“(i) IN GENERAL.—An accredited
third-party auditor shall issue a drug cer-
tification described in subparagraph (A)
only after conducting a drug safety and
quality audit and such other activities that
may be necessary to establish compliance
with the provisions of section 501.

“(ii) PROVISION OF CERTIFICATION.—
Only an accredited third-party auditor or
the Secretary may provide a drug certifi-
cation described in subparagraph (A).

“(C) RECORDS.—Following any accredita-
tion of a third-party auditor, the Secretary
may, at any time, require the accredited third-
party auditor or any audit agent of such audi-
tor to submit to the Secretary a drug safety and quality audit report and such other reports or documents required as part of the drug safety and quality audit process, for any eligible entity for which the accredited third-party auditor or audit agent of such auditor performed a drug safety and quality audit. The Secretary may require documentation that the eligible entity is in compliance with any applicable registration requirements.

“(D) LIMITATION.—The requirement under subparagraph (C) shall not include any report or other documents resulting from a consultative audit, except that the Secretary may access the results of a consultative audit in accordance with section 704.

“(E) DECLARATION OF AUDIT TYPE.—Before an accredited third-party auditor begins any audit or provides any consultative service to an eligible entity, both the accredited third-party auditor and eligible entity shall establish in writing whether the audit is intended to be a drug safety and quality audit. Any audit, inspection, or consultative service of any type provided by an accredited third-party auditor on
behalf of an eligible entity shall be presumed to
be a drug safety and quality audit in the ab-
sence of such a written agreement. Once a drug
safety and quality audit is initiated, it shall be
subject to the requirements of this section, and
no person may withhold from the Secretary any
document subject to subparagraph (C) on the
grounds that the audit was a consultative audit
or otherwise not a drug safety and quality
audit.

“(F) RULE OF CONSTRUCTION.—Nothing
in this section shall be construed to limit the
authority of the Secretary under section 704.

“(6) REQUIREMENTS REGARDING SERIOUS
RISKS TO THE PUBLIC HEALTH.—If, at any time
during a drug safety and quality audit, an accredited
third-party auditor or an audit agent of such auditor
discovers a condition that could cause or contribute
to a serious risk to the public health, such auditor
shall immediately notify the Secretary of—

“(A) the identity and location of the eligi-
ble entity subject to the drug safety and quality
audit; and

“(B) such condition.

“(7) LIMITATIONS.—
“(A) IN GENERAL.—An audit agent of an accredited third-party auditor may not perform a drug safety and quality audit of an eligible entity if such audit agent has performed a drug safety and quality audit or consultative audit of such eligible entity during the previous 13-month period.

“(B) WAIVER.—The Secretary may waive the application of subparagraph (A) if the Secretary determines that there is insufficient access to accredited third-party auditors in a country or region or that the use of the same audit agent or accredited third-party auditor is otherwise necessary.

“(C) CONFLICTS OF INTEREST.—

“(A) ACCREDITATION BODIES.—A recognized accreditation body shall—

“(i) not be owned, managed, or controlled by any person that owns or operates a third-party auditor to be accredited by such body;

“(ii) in carrying out accreditation of third-party auditors under this section, have procedures to ensure against the use of any officer or employee of such body
that has a financial conflict of interest re-
garding a third-party auditor to be accred-
ited by such body; and

“(iii) annually make available to the
Secretary disclosures of the extent to
which such body and the officers and em-
ployees of such body have maintained com-
pliance with clauses (i) and (ii) relating to
financial conflicts of interest.

“(B) ACCREDITED THIRD-PARTY AUDI-
TORS.—An accredited third-party auditor
shall—

“(i) not be owned, managed, or con-
trolled by any person that owns or operates
an eligible entity to be certified by such
auditor;

“(ii) in carrying out drug safety and
quality audits of eligible entities under this
section, have procedures to ensure against
the use of any officer or employee of such
auditor that has a financial conflict of in-
terest regarding an eligible entity to be
certified by such auditor; and

“(iii) annually make available to the
Secretary disclosures of the extent to
which such auditor and the officers and
employees of such auditor have maintained
compliance with clauses (i) and (ii) relating
to financial conflicts of interest.

“(C) AUDIT AGENTS.—An audit agent
shall—

“(i) not own or operate an eligible en-
tity to be audited by such agent;

“(ii) in carrying out audits of eligible
entities under this section, have procedures
to ensure that such agent does not have a
financial conflict of interest regarding an
eligible entity to be audited by such agent;
and

“(iii) annually make available to the
Secretary disclosures of the extent to
which such agent has maintained compli-
ance with clauses (i) and (ii) relating to fi-
nancial conflicts of interest.

“(d) FALSE STATEMENTS.—Any statement or rep-
resentation made—

“(1) by an employee or agent of an eligible enti-
ty to an accredited third-party auditor or audit
agent; or
“(2) by an accreditation body, accredited third-party auditor, or audit agent of such auditor to the Secretary, shall be subject to section 1001 of title 18, United States Code.

“(e) MONITORING.—To ensure compliance with the requirements of this section, the Secretary—

“(1) shall periodically, or at least once every 4 years, reevaluate the accreditation bodies described in subsection (b)(1);

“(2) shall periodically, or at least once every 4 years, evaluate the performance of each accredited third-party auditor, through the review of regulatory audit reports by such auditors, the compliance history as available of eligible entities certified by such auditors, and any other measures deemed necessary by the Secretary;

“(3) may at any time, conduct an onsite audit of any eligible entity certified by an accredited third-party auditor, with or without the auditor present; and

“(4) shall take any other measures deemed necessary by the Secretary.

“(f) EFFECT OF AUDIT.—The results of a drug safety and quality audit by an accredited third-party auditor under this section—
“(1) may be used by the eligible entity—

“(A) as documentation of compliance with section 501(a)(2)(B) or section 801(r); and

“(B) for other purposes as determined appropriate by the Secretary; and

“(2) shall be used by the Secretary in establishing the risk-based inspection schedules under section 510(h).

“(g) Costs.—

“(1) Authorized fees of Secretary.—The Secretary may assess fees on accreditation bodies and accredited third-party auditors in such an amount necessary to establish and administer the recognition and accreditation program under this section. The Secretary may require accredited third-party auditors and audit agents to reimburse the Food and Drug Administration for the work performed to carry out this section. The Secretary shall not generate surplus revenue from such a reimbursement mechanism. Fees authorized under this paragraph shall be collected and available for obligation only to the extent and in the amount provided in advance in appropriation Acts. Such fees are authorized to remain available until expended.
“(2) AUTHORIZED FEES FOR RECOGNIZED ACCREDITATION BODIES.—An accreditation body recognized by the Secretary under subsection (b) may assess a reasonable fee to accredit third-party auditors.

“(h) LIMITATIONS.—

“(1) NO EFFECT ON SECTION 704 INSPECTIONS.—The drug safety and quality audits performed under this section shall not be considered inspections under section 704.

“(2) NO EFFECT ON INSPECTION AUTHORITY.—Nothing in this section affects the authority of the Secretary to inspect any eligible entity pursuant to this Act.

“(i) REGULATIONS.—

“(1) IN GENERAL.—Not later than 18 months after the date of enactment of the Food and Drug Administration Safety and Innovation Act, the Secretary shall adopt final regulations implementing this section.

“(2) PROCEDURE.—In promulgating the regulations implementing this section, the Secretary shall—

“(A) issue a notice of proposed rulemaking that includes the proposed regulation;
“(B) provide a period of not less than 60 days for comments on the proposed regulation; and

“(C) publish the final regulation not less than 30 days before the effective date of the regulation.

“(3) CONTENT.—Such regulations shall include—

“(A) requirements that, to the extent practicable, drug safety and quality audits performed under this section be unannounced;

“(B) a structure to decrease the potential for conflicts of interest, including timing and public disclosure, for fees paid by eligible entities to accredited third-party auditors; and

“(C) appropriate limits on financial affiliations between an accredited third-party auditor or audit agents of such auditor and any person that owns or operates an eligible entity to be audited by such auditor, as described in subparagraphs (A) and (B).

“(4) RESTRICTIONS.—Notwithstanding any other provision of law, the Secretary shall promulgate regulations implementing this section only as described in paragraph (2).”.

"
(b) **Report on Accredited Third-party Auditors.**—Not later than January 20, 2017, the Comptroller General of the United States shall submit to Congress a report that addresses the following, with respect to the period beginning on the date of implementation of section 809 of the Federal Food, Drug, and Cosmetic Act (as added by subsection (a)) and ending on the date of such report:

1. The extent to which drug safety and quality audits completed by accredited third-party auditors under such section 809 are being used by the Secretary of Health and Human Services (referred to in this subsection as the “Secretary”) in establishing or applying the risk-based inspection schedules under section 510(h) of such Act (as amended by section 705).

2. The extent to which drug safety and quality audits completed by accredited third-party auditors or agents are assisting the Food and Drug Administration in evaluating compliance with sections 501(a)(2)(B) of such Act (21 U.S.C. 351(a)(2)(B)) and 801(r) of such Act (as added by section 711).

3. Whether the Secretary has been able to access drug safety and quality audit reports completed
by accredited third-party auditors under such section 809.

(4) Whether accredited third-party auditors accredited under such section 809 have adhered to the conflict of interest provisions set forth in such section.

(5) The extent to which the Secretary has audited recognized accreditation bodies or accredited third-party auditors to ensure compliance with the requirements of such section 809.

(6) The number of waivers under subsection (c)(7)(B) of such section 809 issued during the most recent 12-month period and the official justification by the Secretary for each determination that there was insufficient access to an accredited third-party auditor.

(7) The number of times a manufacturer has used the same accredited third-party auditor for 2 or more consecutive drug safety and quality audits under such section 809.

(8) Recommendations to Congress regarding the accreditation program under such section 809, including whether Congress should continue, modify, or terminate the program.
SEC. 711. STANDARDS FOR ADMISSION OF IMPORTED DRUGS.

Section 801 (21 U.S.C. 381) is amended—

(1) in subsection (o), by striking “drug or”;

and

(2) by adding at the end the following:

“(r)(1) The Secretary may require, as a condition of granting admission to a drug imported or offered for import into the United States, that the importer electronically submit information demonstrating that the drug complies with applicable requirements of this Act.

“(2) The information described under paragraph (1) may include—

“(A) information demonstrating the regulatory status of the drug, such as the new drug application, abbreviated new drug application, or investigational new drug or drug master file number;

“(B) facility information, such as proof of registration and the unique facility identifier;

“(C) indication of compliance with current good manufacturing practice, testing results, certifications relating to satisfactory inspections, and compliance with the country of export regulations; and

“(D) any other information deemed necessary and appropriate by the Secretary to assess compliance of the article being offered for import.
“(3) Information requirements referred to in paragraph (2)(C) may, at the discretion of the Secretary, be satisfied—

“(A) by certifications from accredited third parties, as described under section 809;

“(B) through representation by a foreign government, if such inspection is conducted using standards and practices as agreed to by the Secretary; or

“(C) other appropriate documentation or evidence as described by the Secretary.

“(4)(A) Not later than 18 months after the date of enactment of the Food and Drug Administration Safety and Innovation Act, the Secretary shall adopt final regulations implementing this subsection. Such requirements shall be appropriate for the type of import, such as whether the drug is for import into the United States for use in preclinical research or in a clinical investigation under an investigational new drug exemption under 505(i).

“(B) In promulgating the regulations implementing this subsection, the Secretary shall—

“(i) issue a notice of proposed rulemaking that includes the proposed regulation;

“(ii) provide a period of not less than 60 days for comments on the proposed regulation; and
“(iii) publish the final regulation not less than 30 days before the effective date of the regulation.

“(C) Notwithstanding any other provision of law, the Secretary shall promulgate regulations implementing this subsection only as described in subparagraph (B).”.

SEC. 712. NOTIFICATION.

(a) Prohibited Acts.—Section 301 (21 U.S.C. 331) is amended by adding at the end the following:

“(aaa) The failure to notify the Secretary in violation of section 568.”.

(b) Notification.—

(1) In general.—Subchapter E of chapter V (21 U.S.C. 360bbb et seq.) is amended by adding at the end the following:

SEC. 568. NOTIFICATION.

“(a) Notification to Secretary.—With respect to a drug, the Secretary may require notification to the Secretary by a covered person if the covered person knows—

“(1) of a substantial loss or theft of such drug;

or

“(2) that such drug—

“(A) has been or is being counterfeited; and
“(B)(i) is the counterfeit product in commerce in the United States; or

“(ii) is offered for import into the United States.

“(b) MANNER OF NOTIFICATION.—Notification under this section shall be made in a reasonable time, in such reasonable manner, and by such reasonable means as the Secretary may require by regulation or specify in guidance.

“(c) DEFINITION.—In this section, the term ‘covered person’ means—

“(1) a person who is required to register under section 510 with respect to an establishment engaged in the manufacture, preparation, propagation, compounding, or processing of a drug; or

“(2) a person engaged in the wholesale distribution (as defined in section 503(e)(3)(B)) of a drug.”.

(2) APPLICABILITY.—Notifications under section 568 of the Federal Food, Drug, and Cosmetic Act (as added by paragraph (1)) apply to losses, thefts, or counterfeiting, as described in subsection (a) of such section 568, that occur on or after the date of enactment of this Act.
SEC. 713. PROTECTION AGAINST INTENTIONAL ADULTERATION.

Section 303(b) (21 U.S.C. 333(b)) is amended by adding at the end the following:

“(7) Notwithstanding subsection (a)(2), any person that knowingly and intentionally adulterates a drug such that the drug is adulterated under subsection (a)(1), (b), (c), or (d) of section 501 and has a reasonable probability of causing serious adverse health consequences or death to humans or animals shall be imprisoned for not more than 20 years or fined not more than $1,000,000, or both.”.

SEC. 714. ENHANCED CRIMINAL PENALTY FOR COUNTERFEITING DRUGS.

Section 303(b) (21 U.S.C. 333(b)), as amended by section 713, is further amended by adding at the end the following:

“(8) Notwithstanding subsection (a)(2), any person who knowingly and intentionally violates section 301(i) shall be imprisoned for not more than 20 years or fined not more than $4,000,000 or both.”.

SEC. 715. EXTRATERRITORIAL JURISDICTION.

Chapter III (21 U.S.C. 331 et seq.) is amended by adding at the end the following:
SEC. 311. EXTRATERRITORIAL JURISDICTION.

“There is extraterritorial jurisdiction over any violation of this Act relating to any article regulated under this Act if such article was intended for import into the United States or if any act in furtherance of the violation was committed in the United States.”

SEC. 716. COMPLIANCE WITH INTERNATIONAL AGREEMENTS.

The provisions of this title (and the amendments made by this title) shall be applied in a manner that the Secretary of Health and Human Services, in consultation with the United States Trade Representative, considers necessary to comply with the obligations of the United States under international agreements.

TITLE VIII—GENERATING ANTIBIOTIC INCENTIVES NOW

SEC. 801. EXTENSION OF EXCLUSIVITY PERIOD FOR DRUGS.

(a) In General.—Chapter V (21 U.S.C. 351 et seq.) is amended by inserting after section 505D the following:

“SEC. 505E. EXTENSION OF EXCLUSIVITY PERIOD FOR NEW QUALIFIED INFECTIOUS DISEASE PRODUCTS.

“(a) Extension.—If the Secretary approves an application pursuant to section 505 for a drug that has been designated as a qualified infectious disease product under subsection (d), the 4- and 5-year periods described in subsections (e)(3)(E)(ii) and (j)(5)(F)(ii) of section 505, the
3-year periods described in clauses (iii) and (iv) of subsection (e)(3)(E) and clauses (iii) and (iv) of subsection (j)(5)(F) of section 505, or the 7-year period described in section 527, as applicable, shall be extended by 5 years.

“(b) Relation to Pediatric Exclusivity.—Any extension under subsection (a) of a period shall be in addition to any extension of the period under section 505A with respect to the drug.

“(c) Limitations.—Subsection (a) does not apply to the approval of—

“(1) a supplement to an application under section 505(b) for any qualified infectious disease product for which an extension described in subsection (a) is in effect or has expired;

“(2) a subsequent application filed with respect to a product approved under section 505 for a change that results in a new indication, route of administration, dosing schedule, dosage form, delivery system, delivery device, or strength; or

“(3) an application for a product that is not approved for the use for which it received a designation under subsection (d).

“(d) Designation.—

“(1) In General.—The manufacturer or sponsor of a drug may request the Secretary to designate
a drug as a qualified infectious disease product at
any time before the submission of an application
under section 505(b) for such drug. The Secretary
shall, not later than 60 days after the submission of
such a request, determine whether the drug is a
qualified infectious disease product.

“(2) LIMITATION.—Except as provided in para-
graph (3), a designation under this subsection shall
not be withdrawn for any reason, including modifica-
tions to the list of qualifying pathogens under sub-
section (f)(2)(C).

“(3) REVOCATION OF DESIGNATION.—The Sec-
retary may revoke a designation of a drug as a
qualified infectious disease product if the Secretary
finds that the request for such designation contained
an untrue statement of material fact.

“(e) REGULATIONS.—

“(1) IN GENERAL.—Not later than 2 years
after the date of enactment of the Food and Drug
Administration Safety and Innovation Act, the Sec-
retary shall adopt final regulations implementing
this section.

“(2) PROCEDURE.—In promulgating a regu-
lation implementing this section, the Secretary shall—
“(A) issue a notice of proposed rulemaking that includes the proposed regulation;

“(B) provide a period of not less than 60 days for comments on the proposed regulation; and

“(C) publish the final regulation not less than 30 days before the effective date of the regulation.

“(3) RESTRICTIONS.—Notwithstanding any other provision of law, the Secretary shall promulgate regulations implementing this section only as described in paragraph (2), except that the Secretary may issue interim guidance for sponsors seeking designation under subsection (d) prior to the promulgation of such regulations.

“(4) DESIGNATION PRIOR TO REGULATIONS.—The Secretary may designate drugs as qualified infectious disease products under subsection (d) prior to the promulgation of regulations under this subsection.

“(f) QUALIFYING PATHOGEN.—

“(1) DEFINITION.—In this section, the term ‘qualifying pathogen’ means a pathogen identified and listed by the Secretary under paragraph (2) that
has the potential to pose a serious threat to public health, such as—

“(A) resistant gram positive pathogens, including methicillin-resistant Staphylococcus aureus, vancomycin-resistant Staphylococcus aureus, and vancomycin-resistant enterococcus;

“(B) multi-drug resistant gram negative bacteria, including Acinetobacter, Klebsiella, Pseudomonas, and E. coli species;

“(C) multi-drug resistant tuberculosis; and

“(D) Clostridium difficile.

“(2) LIST OF QUALIFYING PATHOGENS.—

“(A) IN GENERAL.—The Secretary shall establish and maintain a list of qualifying pathogens, and shall make public the methodology for developing such list.

“(B) CONSIDERATIONS.—In establishing and maintaining the list of pathogens described under this section the Secretary shall—

“(i) consider—

“(I) the impact on the public health due to drug-resistant organisms in humans;

“(II) the rate of growth of drug-resistant organisms in humans;
“(III) the increase in resistance rates in humans; and

“(IV) the morbidity and mortality in humans; and

“(ii) consult with experts in infectious diseases and antibiotic resistance, including the Centers for Disease Control and Prevention, the Food and Drug Administration, medical professionals, and the clinical research community.

“(C) Review.—Every 5 years, or more often as needed, the Secretary shall review, provide modifications to, and publish the list of qualifying pathogens under subparagraph (A) and shall by regulation revise the list as necessary, in accordance with subsection (e).

“(g) Qualified Infectious Disease Product.—The term ‘qualified infectious disease product’ means an antibacterial or antifungal drug for human use intended to treat serious or life-threatening infections, including those caused by—

“(1) an antibacterial or antifungal resistant pathogen, including novel or emerging infectious pathogens; or
“(2) qualifying pathogens listed by the Secretary under subsection (f).”.

(b) APPLICATION.—Section 505E of the Federal Food, Drug, and Cosmetic Act, as added by subsection (a), applies only with respect to a drug that is first approved under section 505(c) of such Act (21 U.S.C. 355(c)) on or after the date of the enactment of this Act.

SEC. 802. PRIORITY REVIEW.

(a) AMENDMENT.—Chapter V (21 U.S.C. 351 et seq.) is amended by inserting after section 524 the following:

“SEC. 524A. PRIORITY REVIEW FOR QUALIFIED INFECTIOUS DISEASE PRODUCTS.

“If the Secretary designates a drug under section 505E(d) as a qualified infectious disease product, then the Secretary shall give priority review to any application submitted for approval for such drug under section 505(b).”.

(b) APPLICATION.—Section 524A of the Federal Food, Drug, and Cosmetic Act, as added by subsection (a), applies only with respect to an application that is submitted under section 505(b) of such Act (21 U.S.C. 355(b)) on or after the date of the enactment of this Act.

SEC. 803. FAST TRACK PRODUCT.

Section 506(a)(1) (21 U.S.C. 356(a)(1)), as amended by section 901(b), is amended by inserting “, or if the

*S 2516 PCS
Secretary designates the drug as a qualified infectious disease product under section 505E(d)” before the period at the end of the first sentence.

**SEC. 804. GAO STUDY.**

(a) **IN GENERAL.**—The Comptroller General of the United States shall—

(1) conduct a study—

(A) on the need for, and public health impact of, incentives to encourage the research, development, and marketing of qualified infectious disease biological products and antifungal products; and

(B) consistent with trade and confidentiality data protections, assessing, for all antibacterial and antifungal drugs, including biological products, the average or aggregate—

(i) costs of all clinical trials for each phase;

(ii) percentage of success or failure at each phase of clinical trials; and

(iii) public versus private funding levels of the trials for each phase; and

(2) not later than 1 year after the date of enactment of this Act, submit a report to Congress on the results of such study, including any rec-
ommendations of the Comptroller General on appropriate incentives for addressing such need.

(b) CONTENTS.—The part of the study described in subsection (a)(1)(A) shall include—

(1) an assessment of any underlying regulatory issues related to qualified infectious disease products, including qualified infectious disease biological products;

(2) an assessment of the management by the Food and Drug Administration of the review of qualified infectious disease products, including qualified infectious disease biological products and the regulatory certainty of related regulatory pathways for such products;

(3) a description of any regulatory impediments to the clinical development of new qualified infectious disease products, including qualified infectious disease biological products, and the efforts of the Food and Drug Administration to address such impediments; and

(4) recommendations with respect to—

(A) improving the review and predictability of regulatory pathways for such products; and

(B) overcoming any regulatory impediments identified in paragraph (3).
(c) DEFINITIONS.—In this section:

(1) The term “biological product” has the meaning given to such term in section 351 of the Public Health Service Act (42 U.S.C. 262).

(2) The term “qualified infectious disease biological product” means a biological product intended to treat a serious or life-threatening infection described in section 505E(g) of the Federal Food, Drug, and Cosmetic Act, as added by section 801.

(3) The term “qualified infectious disease product” has the meaning given such term in section 505E(g) of the Federal Food, Drug, and Cosmetic Act, as added by section 801.

SEC. 805. CLINICAL TRIALS.

(a) REVIEW AND REVISION OF GUIDANCE DOCUMENTS.—

(1) IN GENERAL.—The Secretary of Health and Human Services (referred to in this section as the “Secretary”) shall review and, as appropriate, revise not fewer than 3 guidance documents per year, which shall include—

(A) reviewing the guidance documents of the Food and Drug Administration for the conduct of clinical trials with respect to antibacterial and antifungal drugs; and
(B) as appropriate, revising such guidance
documents to reflect developments in scientific
and medical information and technology and to
ensure clarity regarding the procedures and re-
quirements for approval of antibacterial and
antifungal drugs under chapter V of the Fed-
eral Food, Drug, and Cosmetic Act (21 U.S.C.
351 et seq.).

(2) Issues for review.—At a minimum, the
review under paragraph (1) shall address the appro-
priate animal models of infection, in vitro tech-
niques, valid micro-biological surrogate markers, the
use of non-inferiority versus superiority trials, trial
enrollment, data requirements, and appropriate delta
values for non-inferiority trials.

(3) Rule of construction.—Except to the
extent to which the Secretary makes revisions under
paragraph (1)(B), nothing in this section shall be
construed to repeal or otherwise effect the guidance
documents of the Food and Drug Administration.

(b) Recommendations for investigations.—

(1) Request.—The sponsor of a drug intended
to be designated as a qualified infectious disease
product may request that the Secretary provide writ-
ten recommendations for nonclinical and clinical in-
vestigations which the Secretary believes may be
necessary to be conducted with the drug before such
drug may be approved under section 505 of the Fed-
for use in treating, detecting, preventing, or identi-
fying a qualifying pathogen, as defined in section
505E of such Act.

(2) RECOMMENDATIONS.—If the Secretary has
reason to believe that a drug for which a request is
made under this subsection is a qualified infectious
disease product, the Secretary shall provide the per-
son making the request written recommendations for
the nonclinical and clinical investigations which the
Secretary believes, on the basis of information avail-
able to the Secretary at the time of the request,
would be necessary for approval under section 505
of the Federal Food, Drug, and Cosmetic Act (21
U.S.C. 355) of such drug for the use described in
paragraph (1).

(c) GAO STUDY.—Not later than January 1, 2016,
the Comptroller General of the United States shall submit
to Congress a report—

(1) regarding the review and revision of the
clinical trial guidance documents required under
subsection (a) and the impact such review and revi-
sion has had on the review and approval of qualified infectious disease products;

(2) assessing—

(A) the effectiveness of the results-oriented metrics managers employ to ensure that reviewers of such products are familiar with, and consistently applying, clinical trial guidance documents; and

(B) the predictability of related regulatory pathways and review;

(3) identifying any outstanding regulatory impediments to the clinical development of qualified infectious disease products;

(4) reporting on the progress the Food and Drug Administration has made in addressing the impediments identified under paragraph (3); and

(5) containing recommendations regarding how to improve the review of, and regulatory pathway for, such products.

(d) QUALIFIED INFECTIOUS DISEASE PRODUCT.—For purposes of this section, the term “qualified infectious disease product” has the meaning given such term in section 505E(g) of the Federal Food, Drug, and Cosmetic Act, as added by section 801.
SEC. 806. REGULATORY CERTAINTY AND PREDICTABILITY.

(a) Initial Strategy and Implementation Plan.—Not later than 1 year after the date of enactment of this Act, the Secretary of Health and Human Services (referred to in this section as the “Secretary”) shall submit to Congress a strategy and implementation plan with respect to the requirements of this Act. The strategy and implementation plan shall include—

(1) a description of the regulatory challenges to clinical development, approval, and licensure of qualified infectious disease products;

(2) the regulatory and scientific priorities of the Secretary with respect to such challenges; and

(3) the steps the Secretary will take to ensure regulatory certainty and predictability with respect to qualified infectious disease products, including steps the Secretary will take to ensure managers and reviewers are familiar with related regulatory pathways, requirements of the Food and Drug Administration, guidance documents related to such products, and applying such requirements consistently.

(b) Subsequent Report.—Not later than 3 years after the date of enactment of this Act, the Secretary shall submit to Congress a report on—

(1) the progress made toward the priorities identified under subsection (a)(2);
(2) the number of qualified infectious disease products that have been submitted for approval or licensure on or after the date of enactment of this Act;

(3) a list of qualified infectious disease products with information on the types of exclusivity granted for each product, consistent with the information published under section 505(j)(7)(A)(iii) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(j)(7)(A)(iii));

(4) the number of such qualified infectious disease products and that have been approved or licensed on or after the date of enactment of this Act; and

(5) the number of calendar days it took for the approval or licensure of the qualified infectious disease products approved or licensed on or after the date of enactment of this Act.

(c) QUALIFIED INFECTIOUS DISEASE PRODUCT.—For purposes of this section, the term “qualified infectious disease product” has the meaning given such term in section 505E(g) of the Federal Food, Drug, and Cosmetic Act, as added by section 801.
TITLE IX—DRUG APPROVAL AND PATIENT ACCESS

SEC. 901. ENHANCEMENT OF ACCELERATED PATIENT ACCESS TO NEW MEDICAL TREATMENTS.

(a) Findings; Sense of Congress.—

(1) Findings.—Congress finds as follows:

(A) The Food and Drug Administration (referred to in this section as the “FDA”) serves a critical role in helping to assure that new medicines are safe and effective. Regulatory innovation is 1 element of the Nation’s strategy to address serious and life-threatening diseases or conditions by promoting investment in and development of innovative treatments for unmet medical needs.

(B) During the 2 decades following the establishment of the accelerated approval mechanism, advances in medical sciences, including genomics, molecular biology, and bioinformatics, have provided an unprecedented understanding of the underlying biological mechanism and pathogenesis of disease. A new generation of modern, targeted medicines is under development to treat serious and life-threatening diseases, some applying drug development strate-
gies based on biomarkers or pharmacogenomics, predictive toxicology, clinical trial enrichment techniques, and novel clinical trial designs, such as adaptive clinical trials.

(C) As a result of these remarkable scientific and medical advances, the FDA should be encouraged to implement more broadly effective processes for the expedited development and review of innovative new medicines intended to address unmet medical needs for serious or life-threatening diseases or conditions, including those for rare diseases or conditions, using a broad range of surrogate or clinical endpoints and modern scientific tools earlier in the drug development cycle when appropriate. This may result in fewer, smaller, or shorter clinical trials for the intended patient population or targeted subpopulation without compromising or altering the high standards of the FDA for the approval of drugs.

(D) Patients benefit from expedited access to safe and effective innovative therapies to treat unmet medical needs for serious or life-threatening diseases or conditions.
(E) For these reasons, the statutory author-
ity in effect on the day before the date of
enactment of this Act governing expedited ap-
proval of drugs for serious or life-threatening
diseases or conditions should be amended in
order to enhance the authority of the FDA to
consider appropriate scientific data, methods,
and tools, and to expedite development and ac-
cess to novel treatments for patients with a
broad range of serious or life-threatening dis-

cases or conditions.

(2) Sense of Congress.—It is the sense of
Congress that the Food and Drug Administration
should apply the accelerated approval and fast track
provisions set forth in section 506 of the Federal
Food, Drug, and Cosmetic Act (21 U.S.C. 356), as
amended by this section, to help expedite the devel-
opment and availability to patients of treatments for
serious or life-threatening diseases or conditions
while maintaining safety and effectiveness standards
for such treatments.

(b) Expedited Approval of Drugs for Serious
or Life-Threatening Diseases or Conditions.—Sec-
tion 506 (21 U.S.C. 356) is amended to read as follows:
“SEC. 506. EXPEDITED APPROVAL OF DRUGS FOR SERIOUS OR LIFE-THREATENING DISEASES OR CONDITIONS.

“(a) Designation of Drug as Fast Track Product.—

“(1) In general.—The Secretary shall, at the request of the sponsor of a new drug, facilitate the development and expedite the review of such drug if it is intended, whether alone or in combination with one or more other drugs, for the treatment of a serious or life-threatening disease or condition, and it demonstrates the potential to address unmet medical needs for such a disease or condition. (In this section, such a drug is referred to as a ‘fast track product’.)

“(2) Request for designation.—The sponsor of a new drug may request the Secretary to designate the drug as a fast track product. A request for the designation may be made concurrently with, or at any time after, submission of an application for the investigation of the drug under section 505(i) or section 351(a)(3) of the Public Health Service Act.

“(3) Designation.—Within 60 calendar days after the receipt of a request under paragraph (2), the Secretary shall determine whether the drug that
is the subject of the request meets the criteria described in paragraph (1). If the Secretary finds that the drug meets the criteria, the Secretary shall designate the drug as a fast track product and shall take such actions as are appropriate to expedite the development and review of the application for approval of such product.

“(b) ACCELERATED APPROVAL OF A DRUG FOR A SERIOUS OR LIFE-THREATENING DISEASE OR CONDITION, INCLUDING A FAST TRACK PRODUCT.—

“(1) IN GENERAL.—

“(A) ACCELERATED APPROVAL.—The Secretary may approve an application for approval of a product for a serious or life-threatening disease or condition, including a fast track product, under section 505(c) or section 351(a) of the Public Health Service Act upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the
condition and the availability or lack of alternative treatments. The approval described in the preceding sentence is referred to in this section as ‘accelerated approval’.

“(B) Evidence.—The evidence to support that an endpoint is reasonably likely to predict clinical benefit under subparagraph (A) may include epidemiological, pathophysiological, therapeutic, pharmacologic, or other evidence developed using biomarkers, for example, or other scientific methods or tools.

“(2) Limitation.—Approval of a product under this subsection may be subject to 1 or both of the following requirements:

“(A) That the sponsor conduct appropriate post-approval studies to verify and describe the predicted effect on irreversible morbidity or mortality or other clinical benefit.

“(B) That the sponsor submit copies of all promotional materials related to the product during the preapproval review period and, following approval and for such period thereafter as the Secretary determines to be appropriate, at least 30 days prior to dissemination of the materials.
“(3) Expedited Withdrawal of Approval.—The Secretary may withdraw approval of a product approved under accelerated approval using expedited procedures (as prescribed by the Secretary in regulations which shall include an opportunity for an informal hearing) if—

“(A) the sponsor fails to conduct any required post-approval study of the drug with due diligence;

“(B) a study required to verify and describe the predicted effect on irreversible morbidity or mortality or other clinical benefit of the product fails to verify and describe such effect or benefit;

“(C) other evidence demonstrates that the product is not safe or effective under the conditions of use; or

“(D) the sponsor disseminates false or misleading promotional materials with respect to the product.

“(c) Review of Incomplete Applications for Approval of a Fast Track Product.—

“(1) In General.—If the Secretary determines, after preliminary evaluation of clinical data submitted by the sponsor, that a fast track product...
may be effective, the Secretary shall evaluate for filing, and may commence review of portions of, an application for the approval of the product before the sponsor submits a complete application. The Secretary shall commence such review only if the applicant—

“(A) provides a schedule for submission of information necessary to make the application complete; and

“(B) pays any fee that may be required under section 736.

“(2) EXCEPTION.—Any time period for review of human drug applications that has been agreed to by the Secretary and that has been set forth in goals identified in letters of the Secretary (relating to the use of fees collected under section 736 to expedite the drug development process and the review of human drug applications) shall not apply to an application submitted under paragraph (1) until the date on which the application is complete.

“(d) AWARENESS EFFORTS.—The Secretary shall—

“(1) develop and disseminate to physicians, patient organizations, pharmaceutical and biotechnology companies, and other appropriate persons a description of the provisions of this section appli-
cable to accelerated approval and fast track products; and

“(2) establish a program to encourage the development of surrogate and clinical endpoints, including biomarkers, and other scientific methods and tools that can assist the Secretary in determining whether the evidence submitted in an application is reasonably likely to predict clinical benefit for serious or life-threatening conditions for which significant unmet medical needs exist.

“(e) CONSTRUCTION.—

“(1) PURPOSE.—The amendments made by the Food and Drug Administration Safety and Innovation Act to this section are intended to encourage the Secretary to utilize innovative and flexible approaches to the assessment of products under accelerated approval for treatments for patients with serious or life-threatening diseases or conditions and unmet medical needs.

“(2) CONSTRUCTION.—Nothing in this section shall be construed to alter the standards of evidence under subsection (c) or (d) of section 505 (including the substantial evidence standard in section 505(d)) of this Act or under section 351(a) of the Public Health Service Act. Such sections and standards of
evidence apply to the review and approval of products under this section, including whether a product is safe and effective. Nothing in this section alters the ability of the Secretary to rely on evidence that does not come from adequate and well-controlled investigations for the purpose of determining whether an endpoint is reasonably likely to predict clinical benefit as described in subsection (b)(1)(B).”.

(c) GUIDANCE; AMENDED REGULATIONS.—

(1) DRAFT GUIDANCE.—Not later than 1 year after the date of enactment of this Act, the Secretary of Health and Human Services (referred to in this section as the “Secretary”) shall issue draft guidance to implement the amendments made by this section. In developing such guidance, the Secretary shall specifically consider issues arising under the accelerated approval and fast track processes under section 506 of the Federal Food, Drug, and Cosmetic Act, as amended by subsection (b), for drugs designated for a rare disease or condition under section 526 of such Act (21 U.S.C. 360bb) and shall also consider any unique issues associated with very rare diseases.

(2) FINAL GUIDANCE.—Not later than 1 year after the issuance of draft guidance under para-
graph (1), and after an opportunity for public com-
ment, the Secretary shall issue final guidance.

(3) CONFORMING CHANGES.—The Secretary
shall issue, as necessary, conforming amendments to
the applicable regulations under title 21, Code of
Federal Regulations, governing accelerated approval.

(4) NO EFFECT OF INACTION ON REQUESTS.—
If the Secretary fails to issue final guidance or
amended regulations as required by this subsection,
such failure shall not preclude the review of, or ac-
tion on, a request for designation or an application
for approval submitted pursuant to section 506 of
the Federal Food, Drug, and Cosmetic Act, as
amended by subsection (b).

(d) INDEPENDENT REVIEW.—The Secretary may, in
conjunction with other planned reviews, contract with an
independent entity with expertise in assessing the quality
and efficiency of biopharmaceutical development and regu-
latory review programs to evaluate the Food and Drug Ad-
ministration’s application of the processes described in
section 506 of the Federal Food, Drug, and Cosmetic Act,
as amended by subsection (b), and the impact of such
processes on the development and timely availability of in-
novative treatments for patients suffering from serious or
life-threatening conditions. Any such evaluation shall in-
clude consultation with regulated industries, patient advocacy and disease research foundations, and relevant academic medical centers.

SEC. 902. BREAKTHROUGH THERAPIES.

(a) In General.—Section 506 (21 U.S.C. 356), as amended by section 901, is further amended—

(1) by redesignating subsections (a) through (c) as subsections (b) through (d), respectively;

(2) by redesignating subsection (d) as subsection (f);

(3) by inserting before subsection (b), as so redesignated, the following:

“(a) Designation of a Drug as a Breakthrough Therapy.—

“(1) In General.—The Secretary shall, at the request of the sponsor of a drug, expedite the development and review of such drug if the drug is intended, alone or in combination with 1 or more other drugs, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on 1 or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development.
(In this section, such a drug is referred to as a ‘breakthrough therapy’.)

“(2) Request for designation.—The sponsor of a drug may request the Secretary to designate the drug as a breakthrough therapy. A request for the designation may be made concurrently with, or at any time after, the submission of an application for the investigation of the drug under section 505(i) or section 351(a)(3) of the Public Health Service Act.

“(3) Designation.—

“(A) In general.—Not later than 60 calendar days after the receipt of a request under paragraph (2), the Secretary shall determine whether the drug that is the subject of the request meets the criteria described in paragraph (1). If the Secretary finds that the drug meets the criteria, the Secretary shall designate the drug as a breakthrough therapy and shall take such actions as are appropriate to expedite the development and review of the application for approval of such drug.

“(B) Actions.—The actions to expedite the development and review of an application
under subparagraph (A) may include, as appropriate—

“(i) holding meetings with the sponsor and the review team throughout the development of the drug;

“(ii) providing timely advice to, and interactive communication with, the sponsor regarding the development of the drug to ensure that the development program to gather the non-clinical and clinical data necessary for approval is as efficient as practicable;

“(iii) involving senior managers and experienced review staff, as appropriate, in a collaborative, cross-disciplinary review;

“(iv) assigning a cross-disciplinary project lead for the Food and Drug Administration review team to facilitate an efficient review of the development program and to serve as a scientific liaison between the review team and the sponsor; and

“(v) taking steps to ensure that the design of the clinical trials is as efficient as practicable, when scientifically appropriate,
such as by minimizing the number of patients exposed to a potentially less efficacious treatment.”;

(4) in subsection (f)(1), as so redesignated, by striking “applicable to accelerated approval” and inserting “applicable to breakthrough therapies, accelerated approval, and”; and

(5) by adding at the end the following:

“(g) REPORT.—Beginning in fiscal year 2013, the Secretary shall annually prepare and submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives, and make publicly available, with respect to this section for the previous fiscal year—

“(1) the number of drugs for which a sponsor requested designation as a breakthrough therapy;

“(2) the number of products designated as a breakthrough therapy; and

“(3) for each product designated as a breakthrough therapy, a summary of the actions taken under subsection (a)(3).”.

(b) GUIDANCE; AMENDED REGULATIONS.—

(1) IN GENERAL.—

(A) GUIDANCE.—Not later than 18 months after the date of enactment of this Act,
the Secretary of Health and Human Services (referred to in this section as the “Secretary’’) shall issue draft guidance on implementing the requirements with respect to breakthrough therapies, as set forth in section 506(a) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 356(a)), as amended by this section. The Secretary shall issue final guidance not later than 1 year after the close of the comment period for the draft guidance.

(B) Amended regulations.—

(i) In general.—If the Secretary determines that it is necessary to amend the regulations under title 21, Code of Federal Regulations in order to implement the amendments made by this section to section 506(a) of the Federal Food, Drug, and Cosmetic Act, the Secretary shall amend such regulations not later than 2 years after the date of enactment of this Act.

(ii) Procedure.—In amending regulations under clause (i), the Secretary shall—
(I) issue a notice of proposed rulemaking that includes the proposed regulation;

(II) provide a period of not less than 60 days for comments on the proposed regulation; and

(III) publish the final regulation not less than 30 days before the effective date of the regulation.

(iii) RESTRICTIONS.—Notwithstanding any other provision of law, the Secretary shall promulgate regulations implementing the amendments made by section only as described in clause (ii).

(2) REQUIREMENTS.—Guidance issued under this section shall—

(A) specify the process and criteria by which the Secretary makes a designation under section 506(a)(3) of the Federal Food, Drug, and Cosmetic Act; and

(B) specify the actions the Secretary shall take to expedite the development and review of a breakthrough therapy pursuant to such designation under such section 506(a)(3), includ-
ing updating good review management practices
to reflect breakthrough therapies.

(c) INDEPENDENT REVIEW.—Not later than 3 years
after the date of enactment of this Act, the Comptroller
General of the United States, in consultation with appro-
priate experts, shall assess the manner by which the Food
and Drug Administration has applied the processes de-
scribed in section 506(a) of the Federal Food, Drug, and
Cosmetic Act, as amended by this section, and the impact
of such processes on the development and timely avail-
ability of innovative treatments for patients affected by se-
rious or life-threatening conditions. Such assessment shall
be made publicly available upon completion.

(d) CONFORMING AMENDMENTS.—Section 506B(e)
(21 U.S.C. 356b) is amended by striking “section
506(b)(2)(A)” each place such term appears and inserting
“section 506(c)(2)(A)”.

SEC. 903. CONSULTATION WITH EXTERNAL EXPERTS ON
RARE DISEASES, TARGETED THERAPIES, AND
GENETIC TARGETING OF TREATMENTS.

Subchapter E of chapter V (21 U.S.C. 360bbb et
seq.), as amended by section 712, is further amended by
adding at the end the following:
“SEC. 569. CONSULTATION WITH EXTERNAL EXPERTS ON RARE DISEASES, TARGETED THERAPIES, AND GENETIC TARGETING OF TREATMENTS.

“(a) IN GENERAL.—For the purpose of promoting the efficiency of and informing the review by the Food and Drug Administration of new drugs and biological products for rare diseases and drugs and biological products that are genetically targeted, the following shall apply:

“(1) CONSULTATION WITH STAKEHOLDERS.—Consistent with sections X.C and IX.E.4 of the PDUFA Reauthorization Performance Goals and Procedures Fiscal Years 2013 through 2017, as referenced in the letters described in section 101(b) of the Prescription Drug User Fee Amendments of 2012, the Secretary shall ensure that opportunities exist, at a time the Secretary determines appropriate, for consultations with stakeholders on the topics described in subsection (c).

“(2) CONSULTATION WITH EXTERNAL EXPERTS.—The Secretary shall develop and maintain a list of external experts who, because of their special expertise, are qualified to provide advice on rare disease issues, including topics described in subsection (c). The Secretary may, when appropriate to address a specific regulatory question, consult such external
experts on issues related to the review of new drugs
and biological products for rare diseases and drugs
and biological products that are genetically targeted,
including the topics described in subsection (c),
when such consultation is necessary because the Sec-
retary lacks specific scientific, medical, or technical
expertise necessary for the performance of its regu-
latory responsibilities and the necessary expertise
can be provided by the external experts.

“(b) EXTERNAL EXPERTS.—For purposes of sub-
section (a)(2), external experts are those who possess sci-
entific or medical training that the Secretary lacks with
respect to one or more rare diseases.

“(c) TOPICS FOR CONSULTATION.—Topics for con-
sultation pursuant to this section may include—

“(1) rare diseases;
“(2) the severity of rare diseases;
“(3) the unmet medical need associated with
rare diseases;
“(4) the willingness and ability of individuals
with a rare disease to participate in clinical trials;
“(5) an assessment of the benefits and risks of
therapies to treat rare diseases;
“(6) the general design of clinical trials for rare
disease populations and subpopulations; and
“(7) demographics and the clinical description
of patient populations.

“(d) Classification as Special Government Em-
ployees.—The external experts who are consulted under
this section may be considered special government employ-
ees, as defined under section 202 of title 18, United States
Code.

“(e) Protection of Proprietary Information.—Nothing in this section shall be construed to alter
the protections offered by laws, regulations, and policies
governing disclosure of confidential commercial or trade
secret information, and any other information exempt
from disclosure pursuant to section 552(b) of title 5,
United States Code, as such provisions would be applied
to consultation with individuals and organizations prior to
the date of enactment of this section.

“(f) Other Consultation.—Nothing in this sec-
tion shall be construed to limit the ability of the Secretary
to consult with individuals and organizations as authorized
prior to the date of enactment of this section.

“(g) No Right or Obligation.—Nothing in this
section shall be construed to create a legal right for a con-
sultation on any matter or require the Secretary to meet
with any particular expert or stakeholder. Nothing in this
section shall be construed to alter agreed upon goals and
procedures identified in the letters described in section 101(b) of the Prescription Drug User Fee Amendments of 2012. Nothing in this section is intended to increase the number of review cycles as in effect before the date of enactment of this section.”.

SEC. 904. ACCESSIBILITY OF INFORMATION ON PRESCRIPTION DRUG CONTAINER LABELS BY VISUALLY-IMPAIRED AND BLIND CONSUMERS.

(a) Establishment of Working Group.—

(1) In general.—The Architectural and Transportation Barriers Compliance Board (referred to in this section as the “Access Board”) shall convene a stakeholder working group (referred to in this section as the “working group”) to develop best practices on access to information on prescription drug container labels for individuals who are blind or visually impaired.

(2) Members.—The working group shall be comprised of representatives of national organizations representing blind and visually-impaired individuals, national organizations representing the elderly, and industry groups representing stakeholders, including retail, mail order, and independent community pharmacies, who would be impacted by such best practices. Representation within the work-
ing group shall be divided equally between consumer
and industry advocates.

(3) Best practices.—

(A) In general.—The working group
shall develop, not later than 1 year after the
date of the enactment of this Act, best practices
for pharmacies to ensure that blind and vis-
ually-impaired individuals have safe, consistent,
reliable, and independent access to the informa-
tion on prescription drug container labels.

(B) Public availability.—The best
practices developed under subparagraph (A)
may be made publicly available, including
through the Internet Web sites of the working
group participant organizations, and through
other means, in a manner that provides access
to interested individuals, including individuals
with disabilities.

(C) Limitations.—The best practices de-
developed under subparagraph (A) shall not be
construed as accessibility guidelines or stand-
ards of the Access Board, and shall not confer
any rights or impose any obligations on working
group participants or other persons. Nothing in
this section shall be construed to limit or condi-
tion any right, obligation, or remedy available under the Americans with Disabilities Act of 1990 (42 U.S.C. 12101 et seq.) or any other Federal or State law requiring effective communication, barrier removal, or nondiscrimination on the basis of disability.

(4) CONSIDERATIONS.—In developing and issuing the best practices under paragraph (3)(A), the working group shall consider—

(A) the use of—

(i) Braille;

(ii) auditory means, such as—

(I) “talking bottles” that provide audible container label information;

(II) digital voice recorders attached to the prescription drug container; and

(III) radio frequency identification tags;

(iii) enhanced visual means, such as—

(I) large font labels or large font “duplicate” labels that are affixed or matched to a prescription drug container;

(II) high-contrast printing; and
(III) sans-serif font; and

(iv) other relevant alternatives as determined by the working group;

(B) whether there are technical, financial, manpower, or other factors unique to pharmacies with 20 or fewer retail locations which may pose significant challenges to the adoption of the best practices; and

(C) such other factors as the working group determines to be appropriate.

(5) INFORMATION CAMPAIGN.—Upon completion of development of the best practices under subsection (a)(3), the National Council on Disability, in consultation with the working group, shall conduct an informational and educational campaign designed to inform individuals with disabilities, pharmacists, and the public about such best practices.

(6) FACA WAIVER.—The Federal Advisory Committee Act (5 U.S.C. App.) shall not apply to the working group.

(b) GAO STUDY.—

(1) IN GENERAL.—Beginning 18 months after the completion of the development of best practices under subsection (a)(3)(A), the Comptroller General of the United States shall conduct a review of the
extent to which pharmacies are utilizing such best practices, and the extent to which barriers to accessible information on prescription drug container labels for blind and visually-impaired individuals continue.

(2) REPORT.—Not later than September 30, 2016, the Comptroller General of the United States shall submit to Congress a report on the review conducted under paragraph (1). Such report shall include recommendations about how best to reduce the barriers experienced by blind and visually-impaired individuals to independently accessing information on prescription drug container labels.

(e) DEFINITIONS.—In this section—

(1) the term “pharmacy” includes a pharmacy that receives prescriptions and dispenses prescription drugs through an Internet Web site or by mail;

(2) the term “prescription drug” means a drug subject to section 503(b)(1) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 353(b)(1)); and

(3) the term “prescription drug container label” means the label with the directions for use that is affixed to the prescription drug container by the pharmacist and dispensed to the consumer.
SEC. 905. RISK-BENEFIT FRAMEWORK.

Section 505(d) (21 U.S.C. 355(d)) is amended by adding at the end the following: “The Secretary shall implement a structured risk-benefit assessment framework in the new drug approval process to facilitate the balanced consideration of benefits and risks, a consistent and systematic approach to the discussion and regulatory decisionmaking, and the communication of the benefits and risks of new drugs. Nothing in the preceding sentence shall alter the criteria for evaluating an application for premarket approval of a drug.”.

SEC. 906. INDEPENDENT STUDY ON MEDICAL INNOVATION INDUCEMENT MODEL.

(a) In General.—The Secretary of Health and Human Services shall enter into an agreement with the National Academies to provide expert consultation and conduct a study that evaluates the feasibility and possible consequences of the use of innovation inducement prizes to reward successful medical innovations. Under the agreement, the National Academies shall submit to the Secretary a report on such study not later than 15 months after the date of enactment of this Act.

(b) Requirements.—

(1) In General.—The study conducted under subsection (a) shall model at least 3 separate segments on the medical technologies market as can-
didate targets for the new incentive system and consider different medical innovation inducement prize design issues, including the challenges presented in the implementation of prizes for end products, open source dividend prizes, and prizes for upstream research.

(2) **MARKET SEGMENTS.**—The segments on the medical technologies market that shall be considered under paragraph (1) include—

(A) all pharmaceutical and biologic drugs and vaccines;

(B) drugs and vaccines used solely for the treatment of HIV/AIDS; and

(C) antibiotics.

(c) **ELEMENTS.**—The study conducted under subsection (a) shall include consideration of each of the following:

(1) Whether a system of large innovation inducement prizes could work as a replacement for the existing product monopoly/patent-based system, as in effect on the date of enactment of this Act.

(2) How large the innovation prize funds would have to be in order to induce at least as much research and development investment in innovation as is induced under the current system of time-limited
market exclusivity, as in effect on the date of enact-
ment of this Act.

(3) Whether a system of large innovation in-
ducement prizes would be more or less expensive
than the current system of time-limited market ex-
clusivity, as in effect on the date of enactment of
this Act, calculated over different time periods.

(4) Whether a system of large innovation in-
ducement prizes would expand access to new prod-
ucts and improve health outcomes.

(5) The type of information and decisionmaking
skills that would be necessary to manage end prod-
uct prizes.

(6) Whether there would there be major advan-
tages in rewarding the incremental impact of innova-
tions, as benchmarked against existing products.

(7) How open-source dividend prizes could be
managed, and whether such prizes would increase
access to knowledge, materials, data and tech-
nologies.

(8) Whether a system of competitive inter-
mediaries for interim research prizes would provide
an acceptable solution to the valuation challenges for
interim prizes.
TITLE X—DRUG SHORTAGES

SEC. 1001. DRUG SHORTAGES.

(a) In General.—Section 506C (21 U.S.C. 356c) is amended to read as follows:

"SEC. 506C. DISCONTINUANCE OR INTERRUPTION IN THE PRODUCTION OF LIFE-SAVING DRUGS.

“(a) In General.—A manufacturer of a drug—

“(1) that is—

“(A) life-supporting;

“(B) life-sustaining;

“(C) intended for use in the prevention of a debilitating disease or condition;

“(D) a sterile injectable product; or

“(E) used in emergency medical care or during surgery; and

“(2) that is not a radio pharmaceutical drug product, a human tissue replaced by a recombinant product, a product derived from human plasma protein, or any other product as designated by the Secretary,

shall notify the Secretary, in accordance with subsection (b), of a permanent discontinuance in the manufacture of the drug or an interruption of the manufacture of the drug that could lead to a meaningful disruption in the supply of that drug in the United States."
“(b) TIMING.—A notice required under subsection (a) shall be submitted to the Secretary—

“(1) at least 6 months prior to the date of the discontinuance or interruption; or

“(2) if compliance with paragraph (1) is not possible, as soon as practicable.

“(c) EXPEDITED INSPECTIONS AND REVIEWS.—If, based on notifications described in subsection (a) or any other relevant information, the Secretary concludes that there is, or is likely to be, a drug shortage of a drug described in subsection (a), the Secretary may—

“(1) expedite the review of a supplement to a new drug application submitted under section 505(b), an abbreviated new drug application submitted under section 505(j), or a supplement to such an application submitted under section 505(j) that could help mitigate or prevent such shortage; or

“(2) expedite an inspection or reinspection of an establishment that could help mitigate or prevent such drug shortage.

“(d) COORDINATION.—

“(1) TASK FORCE AND STRATEGIC PLAN.—

“(A) IN GENERAL.—

“(i) TASK FORCE.—As soon as practicable after the date of enactment of the
Food and Drug Administration Safety and Innovation Act, the Secretary shall establish a Task Force to develop and implement a strategic plan for enhancing the Secretary’s response to preventing and mitigating drug shortages.

“(ii) STRATEGIC PLAN.—The strategic plan described in clause (i) shall include—

“(I) plans for enhanced interagency and intraagency coordination, communication, and decisionmaking;

“(II) plans for ensuring that drug shortages are considered when the Secretary initiates a regulatory action that could precipitate a drug shortage or exacerbate an existing drug shortage;

“(III) plans for effective communication with outside stakeholders, including who the Secretary should alert about potential or actual drug shortages, how the communication should occur, and what types of information should be shared; and
“(IV) plans for considering the impact of drug shortages on research and clinical trials.

“(iii) CONSULTATION.—In carrying out this subparagraph, the Task Force shall ensure consultation with the appropriate offices within the Food and Drug Administration, including the Office of the Commissioner, the Center for Drug Evaluation and Research, the Office of Regulatory Affairs, and employees within the Department of Health and Human Services with expertise regarding drug shortages. The Secretary shall engage external stakeholders and experts as appropriate.

“(B) TIMING.—Not later than 1 year after the date of enactment Food and Drug Administration Safety and Innovation Act, the Task Force shall—

“(i) publish the strategic plan described in subparagraph (A); and

“(ii) submit such plan to Congress.

“(2) COMMUNICATION.—The Secretary shall ensure that, prior to any enforcement action or issuance of a warning letter that the Secretary de-
terms could reasonably be anticipated to lead to a meaningful disruption in the supply in the United States of a drug described under subsection (a), there is communication with the appropriate office of the Food and Drug Administration with expertise regarding drug shortages regarding whether the action or letter could cause, or exacerbate, a shortage of the drug.

“(3) Action.—If the Secretary determines, after the communication described in paragraph (2), that an enforcement action or a warning letter could reasonably cause or exacerbate a shortage of a drug described under subsection (a), then the Secretary shall evaluate the risks associated with the impact of such shortage upon patients and those risks associated with the violation involved before taking such action or issuing such letter, unless there is imminent risk of serious adverse health consequences or death to humans.

“(4) Reporting by other entities.—The Secretary shall identify or establish a mechanism by which healthcare providers and other third-party organizations may report to the Secretary evidence of a drug shortage.
“(5) Review and Construction.—No determination, finding, action, or omission of the Secretary under this subsection shall—

“(A) be subject to judicial review; or

“(B) be construed to establish a defense to an enforcement action by the Secretary.

“(e) Recordkeeping and Reporting.—

“(1) Recordkeeping.—The Secretary shall maintain records related to drug shortages, including with respect to each of the following:

“(A) The number of manufacturers that submitted a notification to the Secretary under subsection (a) in each calendar year.

“(B) The number of drug shortages that occurred in each calendar year and a list of drug names, drug types, and classes that were the subject of such shortages.

“(C) A list of the known factors contributing to the drug shortages described in subparagraph (B).

“(D)(i) A list of major actions taken by the Secretary to prevent or mitigate the drug shortages described in subparagraph (B).

“(ii) The Secretary shall include in the list under clause (i) the following:
“(I) The number of applications for which the Secretary expedited review under subsection (c)(1) in each calendar year.

“(II) The number of establishment inspections or reinspections that the Secretary expedited under subsection (c)(2) in each calendar year.

“(E) The number of notifications submitted to the Secretary under subsection (a) in each calendar year.

“(F) The names of manufacturers that the Secretary has learned did not comply with the notification requirement under subsection (a) in each calendar year.

“(G) The number of times in each calendar year that the Secretary determined under subsection (d)(3) that an enforcement action or a warning letter could reasonably cause or exacerbate a shortage of a drug described under subsection (a), but did not evaluate the risks associated with the impact of such shortage upon patients and those risks associated with the violation involved before taking such action or issuing such letter on the grounds that there was imminent risk of serious adverse health
consequences or death to humans, and a sum-
mary of the determinations.

“(II) A summary of the communications
made and actions taken under subsection (d) in
each calendar year.

“(I) Any other information the Secretary
deems appropriate to better prevent and mitig-
gate drug shortages.

“(2) Trend Analysis.—The Secretary is au-
thorized to retain a third party to conduct a study,
if the Secretary believes such a study would help
clarify the causes, trends, or solutions related to
drug shortages.

“(3) Annual Summary.—Not later than 18
months after the date of enactment of the Food and
Drug Administration Safety and Innovation Act, and
annually thereafter, the Secretary shall submit to
the Committee on Health, Education, Labor, and
Pensions of the Senate and the Committee on En-
ergy and Commerce of the House of Representatives
a report summarizing, with respect to the 1-year pe-
period preceding such report, the information de-
scribed in paragraph (1). Such report shall not in-
clude any information that is exempt from disclosure
under subsection (a) of section 552 of title 5, United
States Code, by reason of subsection (b)(4) of such section.

“(f) DEFINITIONS.—For purposes of this section—

“(1) the term ‘drug’—

“(A) means a drug (as defined in section 201(g)) that is intended for human use; and

“(B) does not include biological products (as defined in section 351 of the Public Health Service Act), unless otherwise provided by the Secretary in the regulations promulgated under subsection (h);

“(2) the term ‘drug shortage’ or ‘shortage’, with respect to a drug, means a period of time when the demand or projected demand for the drug within the United States exceeds the supply of the drug; and

“(3) the term ‘meaningful disruption’—

“(A) means a change in production that is reasonably likely to lead to a reduction in the supply of a drug by a manufacturer that is more than negligible and impacts the ability of the manufacturer to fill orders or meet expected demand for its product; and

“(B) does not include interruptions in manufacturing due to matters such as routine
maintenance or insignificant changes in manufac-
turing so long as the manufacturer expects
to resume operations in a short period of time.

“(g) DISTRIBUTION.—To the maximum extent prac-
ticable, the Secretary may distribute information on drug
shortages and on the permanent discontinuation of the
drugs described in this section to appropriate provider and
patient organizations, except that any such distribution
shall not include any information that is exempt from dis-
closure under section 552 of title 5, United States Code,
by reason of subsection (b)(4) of such section.

“(h) REGULATIONS.—

“(1) IN GENERAL.—Not later than 18 months
after the date of enactment of the Food and Drug
Administration Safety and Innovation Act, the Sec-
retary shall adopt a final regulation implementing
this section.

“(2) INCLUSION OF BIOLOGICAL PRODUCTS.—

“(A) IN GENERAL.—The Secretary may by
regulation apply this section to biological prod-
ucts (as defined in section 351 of the Public
Health Service Act) if the Secretary determines
such inclusion would benefit the public health.
“(B) Rule for Vaccines.—If the Secretary applies this section to vaccines pursuant to subparagraph (A), the Secretary shall—

“(i) consider whether the notification requirement under subsection (a) may be satisfied by submitting a notification to the Centers for Disease Control and Prevention under the vaccine shortage notification program of such Centers; and

“(ii) explain the determination made by the Secretary under clause (i) in the regulation.

“(3) Procedure.—In promulgating a regulation implementing this section, the Secretary shall—

“(A) issue a notice of proposed rulemaking that includes the proposed regulation;

“(B) provide a period of not less than 60 days for comments on the proposed regulation; and

“(C) publish the final regulation not less than 30 days before the regulation’s effective date.

“(4) Restrictions.—Notwithstanding any other provision of Federal law, in implementing this
section, the Secretary shall only promulgate regulations as described in paragraph (3).”.

(b) Effect of Notification.—The submission of a notification to the Secretary of Health and Human Services (referred to in this section as the “Secretary”) for purposes of complying with the requirement in section 506C(a) of the Federal Food, Drug, and Cosmetic Act (as amended by subsection (a)) shall not be construed—

(1) as an admission that any product that is the subject of such notification violates any provision of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.); or

(2) as evidence of an intention to promote or market the product for an indication or use for which the product has not been approved by the Secretary.

(c) Internal Review.—Not later than 2 years after the date of enactment of this Act, the Secretary shall—

(1) analyze and review the regulations promulgated under the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.), the guidances or policies issued under such Act related to drugs intended for human use, and the practices of the Food and Drug Administration regarding enforcing such Act related to manufacturing of such drugs, to identify
any such regulations, guidances, policies, or practices that cause, exacerbate, prevent, or mitigate drug shortages (as defined in section 506C of the Federal Food, Drug, and Cosmetic Act (as amended by subsection (a)); and

(2) determine how regulations, guidances, policies, or practices identified under paragraph (1) should be modified, streamlined, expanded, or discontinued in order to reduce or prevent such drug shortages, taking into consideration the effect of any changes on the public health.

(d) Study on Market Factors Contributing to Drug Shortages and Stockpiling.—

(1) In general.—Not later than 1 year after the date of enactment of this Act, the Comptroller General of the United States, in consultation with the Secretary, the Department of Health and Human Services Office of the Inspector General, the Attorney General, and Chairman of the Federal Trade Commission, shall publish a report reviewing any findings that drug shortages (as so defined) have led market participants to stockpile affected drugs or sell them at significantly increased prices, the impact of such activities on Federal revenue, and
any economic factors that have exacerbated or created a market for such actions.

(2) CONTENT.—The report under paragraph (1) shall include—

(A) an analysis of the incidence of any of the activities described in paragraph (1) and the effect of such activities on the public health;

(B) an evaluation of whether in such cases there is a correlation between drugs in shortage and—

(i) the number of manufacturers producing such drugs;

(ii) the pricing structure, including Federal reimbursements, for such drugs before such drugs were in shortage, and to the extent possible, revenue received by each such manufacturer of such drugs;

(iii) pricing structure and revenue, to the extent possible, for the same drugs when sold under the conditions described in paragraph (1); and

(iv) the impact of contracting practices by market participants (including manufacturers, distributors, group purchasing organizations, and providers) on
competition, access to drugs, and pricing
of drugs;

(C) whether the activities described in
paragraph (1) are consistent with applicable
law; and

(D) recommendations to Congress on what,
if any, additional reporting or enforcement ac-
tions are necessary.

(3) TRADE SECRET AND CONFIDENTIAL INFOR-
MATION.—Nothing in this subsection alters or
amends section 1905 of title 18, United States Code,
or section 552(b)(4) of title 5, United States Code.

(e) GUIDANCE REGARDING REPACKAGING.—Not
later than 1 year after the date of enactment of this Act,
the Secretary shall issue guidance that clarifies the policy
of the Food and Drug Administration regarding hospital
pharmacies repackaging and safely transferring repack-
aged drugs among hospitals within a common health sys-
tem during a drug shortage, as identified by the Secretary.
TITLE XI—OTHER PROVISIONS

Subtitle A—Reauthorizations

SEC. 1101. REAUTHORIZATION OF PROVISION RELATING TO EXCLUSIVITY OF CERTAIN DRUGS CONTAINING SINGLE ENANTIOMERS.

Section 505(u)(4) (21 U.S.C. 355(u)(4)) is amended by striking “2012” and inserting “2017”.

SEC. 1102. REAUTHORIZATION OF THE CRITICAL PATH PUBLIC-PRIVATE PARTNERSHIPS.

Section 566(f) (21 U.S.C. 360bbb–5(f)) is amended by striking “2012” and inserting “2017”.

Subtitle B—Medical Gas Product Regulation

SEC. 1111. REGULATION OF MEDICAL GAS PRODUCTS.

(a) Regulation.—Chapter V (21 U.S.C. 351 et seq.) is amended by adding at the end the following:

“Subchapter G—Medical Gas Products

“SEC. 575. DEFINITIONS.

“In this subchapter:

“(1) The term ‘designated medical gas product’ means any of the following:

“(A) Oxygen, that meets the standards set forth in an official compendium.

“(B) Nitrogen, that meets the standards set forth in an official compendium.
“(C) Nitrous oxide, that meets the standards set forth in an official compendium.

“(D) Carbon dioxide, that meets the standards set forth in an official compendium.

“(E) Helium, that meets the standards set forth in an official compendium.

“(F) Carbon monoxide, that meets the standards set forth in an official compendium.

“(G) Medical air, that meets the standards set forth in an official compendium.

“(H) Any other medical gas product deemed appropriate by the Secretary, unless any period of exclusivity under section 505(c)(3)(E)(ii) or 505(j)(5)(F)(ii), or the extension of any such period under section 505A, applicable to such medical gas product has not expired.

“(2) The term ‘medical gas product’ means a drug that—

“(A) is manufactured or stored in a liquefied, nonliquefied, or cryogenic state; and

“(B) is administered as a gas.

“SEC. 576. REGULATION OF MEDICAL GAS PRODUCTS.

“(a) Certification of Designated Medical Gas Products.—
“(1) Submission.—

“(A) In general.—Beginning on the date of enactment of this section, any person may file with the Secretary a request for a certification of a designated medical gas product.

“(B) Content.—A request under subparagraph (A) shall contain—

“(i) a description of the medical gas product;

“(ii) the name and address of the sponsor;

“(iii) the name and address of the facility or facilities where the gas product is or will be manufactured; and

“(iv) any other information deemed appropriate by the Secretary to determine whether the medical gas product is a designated medical gas product.

“(2) Grant of certification.—A certification described under paragraph (1)(A) shall be determined to have been granted unless, not later than 60 days after the filing of a request under paragraph (1), the Secretary finds that—
“(A) the medical gas product subject to the certification is not a designated medical gas product;

“(B) the request does not contain the information required under paragraph (1) or otherwise lacks sufficient information to permit the Secretary to determine that the gas product is a designated medical gas product; or

“(C) granting the request would be contrary to public health.

“(3) EFFECT OF CERTIFICATION.—

“(A) IN GENERAL.—

“(i) APPROVED USES.—A designated medical gas product for which a certification is granted under paragraph (2) is deemed, alone or in combination with another designated gas product or products as medically appropriate, to have in effect an approved application under section 505 or 512, subject to all applicable post-approval requirements, for the following indications for use:

“(I) Oxygen for the treatment or prevention of hypoxemia or hypoxia.
“(II) Nitrogen for use in hypoxic challenge testing.

“(III) Nitrous oxide for analgesia.

“(IV) Carbon dioxide for use in extracorporeal membrane oxygenation therapy or respiratory stimulation.

“(V) Helium for the treatment of upper airway obstruction or increased airway resistance.

“(VI) Medical air to reduce the risk of hyperoxia.

“(VII) Carbon monoxide for use in lung diffusion testing.

“(VIII) Any other indication for use for a designated medical gas product or combination of designated medical gas products deemed appropriate by the Secretary, unless any period of exclusivity under clause (iii) or (iv) of section 505(c)(3)(E), under clause (iii) or (iv) of section 505(j)(5)(F), or under section 527, or the extension of any such period under section 505A, applicable to such indication for use
for such gas product or combination of products has not expired.

“(ii) Labeling.—The requirements established in sections 503(b)(4) and 502(f) shall be deemed to have been met for a designated medical gas product if the labeling on final use containers of such gas product bears the information required by section 503(b)(4) and a warning statement concerning the use of the gas product, as determined by the Secretary by regulation, as well as appropriate directions and warnings concerning storage and handling.

“(B) Inapplicability of exclusivity provisions.—

“(i) Effect on ineligibility.—No designated medical gas product deemed under paragraph (3)(A)(i) to have in effect an approved application shall be eligible for any periods of exclusivity under sections 505(c), 505(j), or 527, or the extension of any such period under section 505A, on the basis of such deemed approval.

“(ii) Effect on certification.—No period of exclusivity under sections
505(c), 505(j), or section 527, or the exten-
tion of any such period under section
505A, with respect to an application for a
drug shall prohibit, limit, or otherwise af-
flect the submission, grant, or effect of a
certification under this section, except as
provided in paragraph (3)(A)(i)(VIII).

“(4) Withd
W ITHDRAWAL, SUSPENSION, OR REVOCATION OF APPROVAL.—

“(A) I N GENERAL.—Nothing in this sub-
chapter limits the authority of the Secretary to
withdraw or suspend approval of a drug, includ-
ing a designated medical gas product deemed
under this section to have in effect an approved
application, under section 505 or section 512.

“(B) R EVOCATION.—The Secretary may
revoke the grant of a certification under this
section if the Secretary determines that the re-
quest for certification contains any material
omission or falsification.

“(b) PRESCRIPTION REQUIREMENT.—

“(1) I N GENERAL.—A designated medical gas
product shall be subject to section 503(b)(1) unless
the Secretary exercises the authority provided in sec-
section 503(b)(3) to remove such gas product from the
requirements of section 503(b)(1) or the use in question is authorized pursuant to another provision of this Act relating to use of medical products in emergencies.

“(2) EXCEPTION FOR OXYGEN.—

“(A) IN GENERAL.—Notwithstanding paragraph (1), oxygen may be provided without a prescription for the following uses:

“(i) The use in the event of depressurization or other environmental oxygen deficiency.

“(ii) The use in the event of oxygen deficiency or use in emergency resuscitation, when administered by properly trained personnel.

“(B) LABELING.—For oxygen provided pursuant to subparagraph (A), the requirements established in section 503(b)(4) shall be deemed to have been met if the labeling of the oxygen bears a warning that the medical gas product can be used for emergency use only and for all other medical applications a prescription is required.

“(c) INAPPLICABILITY OF DRUGS FEES TO DESIGNATED MEDICAL GAS PRODUCTS.—A designated med-

S 2516 PCS
Sec. 1112. Regulations.

(a) Review of Regulations.—Not later than 18 months after the date of enactment of this Act, the Secretary of Health and Human Services (referred to in this section as the "Secretary") shall, after obtaining input from medical gas product manufacturers, and any other interested members of the public, submit a report to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives regarding any changes to the Federal drug regulations in title 21, Code of Federal Regulations that the Secretary determines to be necessary.

(b) Amended Regulations.—If the Secretary determines that changes to the Federal drug regulations in title 21, Code of Federal Regulations are necessary under subsection (a), the Secretary shall issue final regulations implementing such changes not later than 4 years after the date of enactment of this Act.

Sec. 1113. Applicability.

Nothing in this subtitle or the amendments made by this subtitle shall apply to—
(1) a drug that is covered by an application under section 505 or 512 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355, 360b) approved prior to May 1, 2012; or

(2) any of the gases listed in subparagraphs (A) through (G) of section 575(1) of such Act (as added by section 1111), or any mixture of any such gases, for an indication that—

(A) is not included in, or is different from, those specified in subclauses (I) through (VII) of section 576(a)(3)(i) of such Act (as added by section 1111); and

(B) is approved on or after May 1, 2012, pursuant to an application submitted under section 505 or 512 of such Act.

Subtitle C—Miscellaneous Provisions

SEC. 1121. ADVISORY COMMITTEE CONFLICTS OF INTEREST.

Section 712 (21 U.S.C. 379d–1) is amended—

(1) in subsection (b)—

(A) by striking paragraph (2); and

(B) in paragraph (1)—

(i) by redesignating subparagraph (B) as paragraph (2) and moving such para-
graph, as so redesignated, 2 ems to the left;

(ii) in subparagraph (A), by redesignating clauses (i) through (iii) as subpar-
graphs (A) through (C), respectively, and moving such subparagraphs, as so redesign-
ated, 2 ems to the left;

(iii) in subparagraph (A), as so redesignated, by inserting “, including strategies to
increase the number of special Government employees across medical and sci-
entific specialties in areas where the Secretary would benefit from specific sci-
entific, medical, or technical expertise necessary for the performance of its regu-
latory responsibilities” before the semicolon at the end;

(iv) by striking “(1) RECRUITMENT.—
” and inserting “(1) RECRUITMENT IN
GENERAL.—The Secretary shall—”;

(v) by striking “(A) IN GENERAL.—
The Secretary shall—”;

(vi) by redesignating clauses (i)
through (iii) of paragraph (2) (as so redesign-
ated) as subparagraphs (A) through
(C), respectively, and moving such sub-
paragraphs, as so redesignated, 2 ems to
the left;

(vii) in paragraph (2) (as so redesign-
ated), in the matter before subparagraph
(A) (as so redesignated), by striking “sub-
paragraph (A)” and inserting “paragraph
(1)”;

(viii) by adding at the end the fol-
lowing:

“(3) Recruitment through referrals.—In
carrying out paragraph (1), the Secretary shall, in
order to further the goal of including in advisory
committees the most qualified and specialized ex-
perts in the specific diseases to be considered by
such advisory committees, at least every 180 days,
request referrals from a variety of stakeholders, in-
cluding the Institute of Medicine, the National Insti-
tutes of Health, product developers, patient groups,
disease advocacy organizations, professional soci-
eties, medical societies, including the American
Academy of Medical Colleges, and other govern-
mental organizations.”;

(2) by amending subsection (c)(2)(C) to read as
follows:
“(C) CONSIDERATION BY SECRETARY.—

The Secretary shall ensure that each determination made under subparagraph (B) considers the type, nature, and magnitude of the financial interests at issue and the public health interest in having the expertise of the member with respect to the particular matter before the advisory committee.”;

(3) in subsection (e), by inserting “, and shall make publicly available,” after “House of Representatives”; and

(4) by adding at the end the following:

“(g) GUIDANCE ON REPORTED FINANCIAL INTEREST OR INVOLVEMENT.—The Secretary shall issue guidance that describes how the Secretary reviews the financial interests and involvement of advisory committee members that are reported under subsection (e)(1) but that the Secretary determines not to meet the definition of a disqualifying interest under section 208 of title 18, United States Code for the purposes of participating in a particular matter.”.

SEC. 1122. GUIDANCE DOCUMENT REGARDING PRODUCT PROMOTION USING THE INTERNET.

Not later than 2 years after the date of enactment this Act, the Secretary of Health and Human Services
shall issue guidance that describes Food and Drug Admin-
istration policy regarding the promotion, using the Inter-
net (including social media), of medical products that are reguated by such Administration.

SEC. 1123. ELECTRONIC SUBMISSION OF APPLICATIONS.

Subchapter D of chapter VII (21 U.S.C. 379k et seq.) is amended by inserting after section 745 the fol-
lowing:

“SEC. 745A. ELECTRONIC FORMAT FOR SUBMISSIONS.

“(a) DRUGS AND BIOLOGICS.—

“(1) IN GENERAL.—Beginning no earlier than

24 months after the issuance of a final guidance

issued after public notice and opportunity for com-

ment, submissions under subsection (b), (i), or (j) of

section 505 of this Act or subsection (a) or (k) of

section 351 of the Public Health Service Act shall

be submitted in such electronic format as specified

by the Secretary in such guidance.

“(2) GUIDANCE CONTENTS.—In the guidance

under paragraph (1), the Secretary may—

“(A) provide a timetable for establishment

by the Secretary of further standards for elec-

tronic submission as required by such para-

graph; and
“(B) set forth criteria for waivers of and exemptions from the requirements of this subsection.

“(3) EXCEPTION.—This subsection shall not apply to submissions described in section 561.

“(b) DEVICES.—

“(1) IN GENERAL.—Beginning after the issuance of final guidance implementing this paragraph, pre-submissions and submissions for devices under section 510(k), 513(f)(2)(A), 515(c), 515(d), 515(f), 520(g), 520(m), or 564 of this Act or section 351 of the Public Health Service Act, and any supplements to such pre-submissions or submissions, shall include an electronic copy of such pre-submissions or submissions.

“(2) GUIDANCE CONTENTS.—In the guidance under paragraph (1), the Secretary may—

“(A) provide standards for the electronic copy required under such paragraph; and

“(B) set forth criteria for waivers of and exemptions from the requirements of this subsection.”.

SEC. 1124. COMBATING PRESCRIPTION DRUG ABUSE.

(a) IN GENERAL.—To combat the significant rise in prescription drug abuse and the consequences of such
abuse, the Secretary of Health and Human Services (referred to in this section as the “Secretary”), acting through the Commissioner of Food and Drugs (referred to in this section as the “Commissioner”) and in coordination with other Federal agencies, as appropriate, shall review current Federal initiatives and identify gaps and opportunities with respect to ensuring the safe use of prescription drugs with the potential for abuse.

(b) REPORT.—Not later than 1 year after the date of enactment of this Act, the Secretary shall issue a report to Congress on the findings of the review under subsection (a). Such report shall include recommendations on—

(1) how best to leverage and build upon existing Federal and federally funded data sources, such as prescription drug monitoring program data and the sentinel initiative of the Food and Drug Administration under section 505(k)(3) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 351(k)(3)), as it relates to collection of information relevant to adverse events, patient safety, and patient outcomes, to create a centralized data clearinghouse and early warning tool;

(2) how best to develop and disseminate widely best practices models and suggested standard requirements to States for achieving greater interoper-
ability and effectiveness of prescription drug moni-
toring programs, especially with respect to producing
standardized data on adverse events, patient safety,
and patient outcomes; and

(3) how best to develop provider and patient
education tools and a strategy to widely disseminate
such tools and assess the efficacy of such tools.

(c) **GUIDANCE ON TAMPER-DETERRENT PRODUCTS.**—Not later than 6 months after the date of enact-
ment of this Act, the Secretary, acting through the Com-
missioner, shall promulgate guidance on the development
of tamper-deterrent drug products.

**SEC. 1125. TANNING BED LABELING.**

Not later than 18 months after the date of enactment
of this Act, the Secretary of Health and Human Services
shall determine whether to amend the warning label re-
quirements for sunlamp products to include specific re-
quirements to more clearly and effectively convey the risks
that such products pose for the development of irreversible
damage to the eyes and skin, including skin cancer.

**SEC. 1126. OPTIMIZING GLOBAL CLINICAL TRIALS.**

Subchapter E of chapter V (21 U.S.C. 360bbb et
seq.), as amended by section 903, is further amended by
adding at the end the following:
“SEC. 569A. OPTIMIZING GLOBAL CLINICAL TRIALS.

“(a) IN GENERAL.—The Secretary shall—

“(1) work with other regulatory authorities of similar standing, medical research companies, and international organizations to foster and encourage uniform, scientifically-driven clinical trial standards with respect to medical products around the world; and

“(2) enhance the commitment to provide consistent parallel scientific advice to manufacturers seeking simultaneous global development of new medical products in order to—

“(A) enhance medical product development;

“(B) facilitate the use of foreign data; and

“(C) minimize the need to conduct duplicative clinical studies, preclinical studies, or non-clinical studies.

“(b) MEDICAL PRODUCT.—In this section, the term ‘medical product’ means a drug, as defined in subsection (g) of section 201, a device, as defined in subsection (h) of such section, or a biological product, as defined in section 351(i) of the Public Health Service Act.

“(c) SAVINGS CLAUSE.—Nothing in this section shall alter the criteria for evaluating the safety or effectiveness of a medical product under this Act.”.
SEC. 1127. ADVANCING REGULATORY SCIENCE TO PROMOTE PUBLIC HEALTH INNOVATION.

(a) In General.—Not later than 1 year after the date of enactment of this Act, the Secretary of Health and Human Services (referred to in this section as the “Secretary”) shall develop a strategy and implementation plan for advancing regulatory science for medical products in order to promote the public health and advance innovation in regulatory decisionmaking.

(b) Requirements.—The strategy and implementation plan developed under subsection (a) shall be consistent with the user fee performance goals in the Prescription Drug User Fee Agreement commitment letter, the Generic Drug User Fee Agreement commitment letter, and the Biosimilar User Fee Agreement commitment letter transmitted by the Secretary to Congress on January 13, 2012, and the Medical Device User Fee Agreement commitment letter transmitted by the Secretary to Congress on April 20, 2012, and shall—

(1) identify a clear vision of the fundamental role of efficient, consistent, and predictable, science-based decisions throughout regulatory decision-making of the Food and Drug Administration with respect to medical products;

(2) identify the regulatory science priorities of the Food and Drug Administration directly related
to fulfilling the mission of the agency with respect
to decisionmaking concerning medical products and
allocation of resources towards such regulatory
science priorities;

(3) identify regulatory and scientific gaps that
impede the timely development and review of, and
regulatory certainty with respect to, the approval, li-
censure, or clearance of medical products, including
with respect to companion products and new tech-
nologies, and facilitating the timely introduction and
adoption of new technologies and methodologies in a
safe and effective manner;

(4) identify clear, measurable metrics by which
progress on the priorities identified under paragraph
(2) and gaps identified under paragraph (3) will be
measured by the Food and Drug Administration, in-
cluding metrics specific to the integration and adop-
tion of advances in regulatory science described in
paragraph (5) and improving medical product deci-
sionmaking, in a predictable and science-based man-
ner; and

(5) set forth how the Food and Drug Adminis-
tration will ensure that advances in regulatory
science for medical products are adopted, as appro-
priate, on an ongoing basis and in an manner inte-
grated across centers, divisions, and branches of the Food and Drug Administration, including by senior managers and reviewers, including through the—

(A) development, updating, and consistent application of guidance documents that support medical product decisionmaking; and

(B) the adoption of the tools, methods, and processes under section 566 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bbb–5).

(c) ANNUAL PERFORMANCE REPORTS.—As part of the annual performance reports submitted to Congress under sections 736B(a) (as amended by section 104), 738A(a) (as amended by section 204), 744C(a) (as added by section 303), and 744I(a) (as added by section 403) of the Federal Food, Drug, and Cosmetic Act for each of fiscal years 2013 through 2017, the Secretary shall annually report on the progress made with respect to—

(1) advancing the regulatory science priorities identified under paragraph (2) of subsection (b) and resolving the gaps identified under paragraph (3) of such subsection, including reporting on specific metrics identified under paragraph (4) of such subsection;
(2) the integration and adoption of advances in regulatory science as set forth in paragraph (5) of such subsection; and

(3) the progress made in advancing the regulatory science goals outlined in the Prescription Drug User Fee Agreement commitment letter, the Generic Drug User Fee Agreement commitment letter, and the Biosimilar User Fee Agreement commitment letter transmitted by the Secretary to Congress on January 13, 2012, and the Medical Device User Fee Agreement transmitted by the Secretary to Congress on April 20, 2012.

(d) INDEPENDENT ASSESSMENT.—Not later than January 1, 2016, the Comptroller General of the United States shall submit to Congress a report—

(1) detailing the progress made by the Food and Drug Administration in meeting the priorities and addressing the gaps identified in subsection (b), including any outstanding gaps; and

(2) containing recommendations, as appropriate, on how regulatory science initiatives for medical products can be strengthened and improved to promote the public health and advance innovation in regulatory decisionmaking.
(c) Medical Product.—In this section, the term “medical product” means a drug, as defined in subsection (g) of section 201 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321), a device, as defined in subsection (h) of such section, or a biological product, as defined in section 351(i) of the Public Health Service Act.

SEC. 1128. INFORMATION TECHNOLOGY.

(a) HHS Report.—Not later than 1 year after the date of enactment of this Act, the Secretary of Health and Human Services shall—

(1) report to Congress on—

(A) the milestones and a completion date for developing and implementing a comprehensive information technology strategic plan to align the information technology systems modernization projects with the strategic goals of the Food and Drug Administration, including results-oriented goals, strategies, milestones, performance measures;

(B) efforts to finalize and approve a comprehensive inventory of the information technology systems of the Food and Drug Administration that includes information describing each system, such as costs, system function or purpose, and status information, and incor-
porate use of the system portfolio into the in-
formation investment management process of the Food and Drug Administration;

(C) the ways in which the Food and Drug Administration uses the plan described in sub-
paragraph (A) to guide and coordinate the modernization projects and activities of the
Food and Drug Administration, including the interdependencies among projects and activities;
and

(D) the extent to which the Food and Drug Administration has fulfilled or is imple-
menting recommendations of the Government Accountability Office with respect to the Food and Drug Administration and information tech-
nology; and

(2) develop—

(A) a documented enterprise architecture program management plan that includes the tasks, activities, and timeframes associated with developing and using the architecture and ad-
dresses how the enterprise architecture program management will be performed in coordination with other management disciplines, such as or-
organizational strategic planning, capital planning
and investment control, and performance manage- 
ment; and 

(B) a skills inventory, needs assessment, gap analysis, and initiatives to address skills gaps as part of a strategic approach to informa-
tion technology human capital planning.

(b) GAO REPORT.—Not later than January 1, 2016, the Comptroller General of the United States shall issue a report regarding the strategic plan described in sub-
section (a)(1)(A) and related actions carried out by the Food and Drug Administration. Such report shall assess the progress the Food and Drug Administration has made on—

(1) the development and implementation of a comprehensive information technology strategic plan, including the results-oriented goals, strategies, mile-
stones, and performance measures identified in sub-
section (a)(1)(A); 

(2) the effectiveness of the comprehensive information technology strategic plan described in sub-
section (a)(1)(A), including the results-oriented goals and performance measures; and 

(3) the extent to which the Food and Drug Ad-
ministration has fulfilled recommendations of the
Government Accountability Office with respect to such agency and information technology.

SEC. 1129. REPORTING REQUIREMENTS.

Subchapter A of chapter VII (21 U.S.C. 371 et seq.), as amended by section 208, is further amended by adding at the end the following:

"SEC. 715. REPORTING REQUIREMENTS.

“(a) NEW DRUGS.—Beginning with fiscal year 2013 and ending with fiscal year 2017, not later than 120 days after the end of each fiscal year for which fees are collected under part 2 of subchapter C, the Secretary shall prepare and submit to the Committee on Health Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives a report concerning, for all applications for approval of a new drug under section 505(b) of this Act or a new biological product under section 351(a) of the Public Health Service Act filed in the previous fiscal year—

“(1) the number of such applications that met the goals identified for purposes of part 2 of subchapter C in the letters from the Secretary of Health and Human Services to the Chairman of the Committee on Health, Education, Labor, and Pensions of the Senate and the Chairman of the Com-
mittee on Energy and Commerce of the House of Representatives, as set forth in the Congressional Record;

“(2) the percentage of such applications that were approved;

“(3) the percentage of such applications that were issued complete response letters;

“(4) the percentage of such applications that were subject to a refuse-to-file action;

“(5) the percentage of such applications that were withdrawn; and

“(6) the average total time to decision by the Secretary for all applications for approval of a new drug under section 505(b) of this Act or a new biological product under section 351(a) of the Public Health Service Act filed in the previous fiscal year, including the number of calendar days spent during the review by the Food and Drug Administration and the number of calendar days spent by the sponsor responding to a complete response letter or relevant legal, scientific, or medical questions raised by the Secretary.”.

“(b) GENERIC DRUGS.—Beginning with fiscal year 2013 and ending after fiscal year 2017, not later than 120 days after the end of each fiscal year for which fees
are collected under part 7 of subchapter C, the Secretary shall prepare and submit to the Committee on Health Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives a report concerning, for all applications for approval of a generic drug under section 505(j), amendments to such applications, and prior approval supplements with respect to such applications filed in the previous fiscal year—

“(1) the number of such applications that met the goals identified for purposes of part 7 of subchapter C, in the letters from the Secretary of Health and Human Services to the Chairman of the Committee on Health, Education, Labor, and Pensions of the Senate and the Chairman of the Committee on Energy and Commerce of the House of Representatives, as set forth in the Congressional Record;

“(2) the average total time to decision by the Secretary for applications for approval of a generic drug under section 505(j), amendments to such applications, and prior approval supplements with respect to such applications filed in the previous fiscal year, including the number of calendar days spent during the review by the Food and Drug Adminis-
tration and the number of calendar days spent by
the sponsor responding to a complete response letter
or relevant legal, scientific, or medical questions
raised by the Secretary;

“(3) the total number of applications under sec-
tion 505(j), amendments to such applications, and
prior approval supplements with respect to such ap-
plications that were pending with the Secretary for
more than 10 months on the date of enactment of
the Food and Drug Administration Safety and Inno-
vation Act; and

“(4) the number of applications described in
paragraph (3) on which the Food and Drug Admin-
istration took final regulatory action in the previous
fiscal year.

“(c) BIOSIMILAR BIOLOGICAL PRODUCTS.—

“(1) IN GENERAL.—Beginning with fiscal year
2014, not later than 120 days after the end of each
fiscal year for which fees are collected under part 8
of subchapter C, the Secretary shall prepare and
submit to the Committee on Health Education,
Labor, and Pensions of the Senate and the Com-
mittee on Energy and Commerce of the House of
Representatives a report concerning—
“(A) the number of applications for approval filed under section 351(k) of the Public Health Service Act; and

“(B) the percentage of applications described in subparagraph (A) that were approved by the Secretary.

“(2) ADDITIONAL INFORMATION.—As part of the performance report described in paragraph (1), the Secretary shall include an explanation of how the Food and Drug Administration is managing the biological product review program to ensure that the user fees collected under part 2 are not used to review an application under section 351(k) of the Public Health Service Act.”.

SEC. 1130. STRATEGIC INTEGRATED MANAGEMENT PLAN.

(a) STRATEGIC INTEGRATED MANAGEMENT PLAN.—Not later than 1 year after the date of enactment of this Act, the Secretary of Health and Human Services (referred to in this section as the “Secretary”) shall submit to Congress a strategic integrated management plan for the Center for Drug Evaluation and Research, the Center for Biologics Evaluation and Research, and the Center for Devices and Radiological Health. Such strategic management plan shall—
(1) identify strategic institutional goals and priorities for the Center for Drug Evaluation and Research, the Center for Biologics Evaluation and Research, and the Center for Devices and Radiological Health;

(2) describe the actions the Secretary will take to recruit, retain, train, and continue to develop the workforce at the Center for Drug Evaluation and Research, the Center for Biologics Evaluation and Research, and the Center for Devices and Radiological Health to fulfill the public health mission of the Food and Drug Administration; and

(3) identify results-oriented, outcome-based measures that the Secretary will use to measure the progress of achieving the strategic goals and priorities identified under paragraph (1) and the effectiveness of the actions identified under paragraph (2), including metrics to ensure that managers and reviewers of the Center for Drug Evaluation and Research, the Center for Biologics Evaluation and Research, and the Center for Devices and Radiological Health are familiar with and appropriately and consistently apply the requirements under the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.), including new requirements under parts 2, 3,

(b) REPORT.—Not later than January 1, 2016, the Comptroller General of the United States shall issue a report regarding the strategic management plan described in subsection (a) and related actions carried out by the Food and Drug Administration. Such report shall—

(1) assess the effectiveness of the actions described in subsection (a)(2) in recruiting, retaining, training, and developing the workforce at the Center for Drug Evaluation and Research, the Center for Biologics Evaluation and Research, and the Center for Devices and Radiological Health in fulfilling the public health mission of the Food and Drug Administration;

(2) assess the effectiveness of the measures identified under subsection (a)(3) in gauging progress against the strategic goals and priorities identified under subsection (a)(1);

(3) assess the extent to which the Center for Drug Evaluation and Research, the Center for Biologics Evaluation and Research, and the Center for Devices and Radiological Health are using the identified results-oriented set of performance measures
in tracking their workload by strategic goals and the
effectiveness of such measures;

(4) assess the extent to which performance in-
formation is collected, analyzed, and acted on by
managers; and

(5) make recommendations, as appropriate, re-
garding how the strategic management plan and re-
lated actions of the Center for Drug Evaluation and
Research, the Center for Biologies Evaluation and
Research, and the Center for Devices and Radi-
ological Health could be improved to fulfill the public
health mission of the Food and Drug Administration
in an efficient and effective manner as possible.

SEC. 1131. DRUG DEVELOPMENT AND BIOEQUIVALENCE
TESTING.

(a) In General.—Section 505–1 (21 U.S.C. 355–
1) is amended by adding at the end the following:

“(k) Drug Development and Bioequivalence
Testing.—

“(1) In General.—Notwithstanding any other
provision of law, if a drug is a covered drug, no ele-
ments to ensure safe use shall prohibit, or be con-
strued or applied to prohibit, supply of such drug to
any eligible drug developer for the purpose of devel-
oping, or conducting bioequivalence testing necessary
to support, an application under subsection (b)(2) or (j) of section 505 of this Act or section 351(k) of the Public Health Service Act, if the Secretary has issued a written notice described in paragraph (2), and the eligible drug developer has agreed to comply with the terms of the notice.

“(2) Written notice.—For purposes of this subsection, the Secretary shall issue a written notice to an eligible drug developer and the holder of an application for a covered drug authorizing the supply of a drug to such eligible drug developer for purposes of bioequivalence testing if—

“(A) the eligible drug developer has agreed to comply with any conditions the Secretary considers necessary; and

“(B) the eligible drug developer has submitted and the Secretary has approved a protocol for bioequivalence testing that includes protections that the Secretary finds will provide assurance of safety comparable to the assurance of safety provided by the elements to ensure safe use in the risk evaluation and mitigation strategy for the covered drug.

“(3) Additional required element.—The Secretary shall require as an element of each risk
evaluation and mitigation strategy approved by the Secretary that the holder of an application for a covered drug shall not restrict the resale of the covered drug to an eligible drug developer that receives a written notice from the Secretary under paragraph (2).

“(4) PENALTIES.—For purposes of subsection (f)(8) and sections 301, 303(f)(4), 502(y), and 505(p), it shall be a violation of the risk evaluation and mitigation strategy for the holder of the application for a covered drug to restrict the sale of the drug to an eligible drug developer. The Secretary shall provide written notice to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives of any penalty assessed under this subsection within 7 days of such assessment.

“(5) LIABILITY.—The holder of an application for a covered drug shall not be liable for any claim arising out of the eligible drug developer’s provision or testing of a drug obtained under this subsection, including a claim arising out of failure of the eligible drug developer to follow adequate safeguards to ensure safe use of the drug.
“(6) Definitions.—

“(A) Covered drug.—Notwithstanding subsection (b)(2), for purposes of this subsection, the term ‘covered drug’ means a drug subject to a risk evaluation and mitigation strategy with elements to ensure safe use under subsection (f), or that is deemed under section 909(b) of the Food and Drug Administration Amendments Act of 2007 to be a drug, including a biological product licensed under section 351(a) of the Public Health Service Act, subject to a risk evaluation and mitigation strategy with elements to ensure safe use.

“(B) Eligible drug developer.—For purposes of this subsection, the term ‘eligible drug developer’ means a sponsor seeking to develop an application for submission under subsection (b)(2) or (j) of section 505 of this Act or section 351(k) of the Public Health Service Act.”.

(b) Technical and Conforming Amendment.—Section 505–1(c)(2) (21 U.S.C. 355–1(c)(2)) is amended by striking “(e) and (f)” and inserting “(e), (f), and (k)(3)”.
A BILL

To amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user-fee programs for prescription drugs and medical devices, to establish user-fee programs for generic drugs and biosimilars, and for other purposes.

May 7, 2012

Read twice and placed on the calendar.